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SUMMARIES 
 
 
English 
 
Endothelial cells play a central role in vascular diseases and represent therefore a clinically 
relevant cell type for gene therapeutic approaches. However, the endothelium is difficult to 
transduce with wtAAV vectors at feasible levels. The potential of random peptide libraries 
displayed on AAV2 to select for AAV2 vectors with improved efficiency of endothelial-directed gene 
transfer has been demonstrated. AAV9, however, may have advantages over AAV2 because of a 
lower prevalence of neutralizing antibodies in humans and more efficient gene transfer in vivo. 
 
The present study provides evidence that random peptide libraries can be displayed on AAV9 and 
can be utilized to select for AAV9 capsids redirected to human endothelium, as previously shown 
for AAV2. An AAV9 peptide display library which ensures that the displayed peptides correspond to 
the packaged genomes was generated. Four consecutive selection rounds on human coronary 
artery endothelial cells (HCAEC) performed in vitro yielded AAV9 library capsids with distinct 
peptides that strongly outperformed transduction of wild type AAV9. A central point of this study is 
posed by the finding that incorporation of sequences selected from AAV2 libraries into AAV9 
capsids could not increase transduction as efficient as peptides selected in the AAV9 library 
context, justifying the generation and selection of an AAV9 library. Furthermore, AAV9 vectors with 
targeting sequences selected from AAV9 libraries revealed an increased transduction efficiency in 
presence of neutralising human intravenous immunoglobulins suggesting a reduced 
immunogenicity and a better suitability of AAV9 as a vector backbone. However, enriched peptides 
did not restrict AAV9 specificity towards HCAEC. The attempt to restrict transgene expression to 
this cell type by transcriptional targeting using a murine endothelium-specific promoter may be 
promising as an additional targeting level. To determine the potential of selected AAV on 
endothelial cells in the intact natural vascular context, murine mesenteric arteries and human 
umbilical veins were incubated in vivo or in situ, respectively, using the most efficient AAV9 vector. 
Analysis revealed a highly efficient transduction of human umbilical vein endothelial cells (HUVEC) 
by the vector mutant. Similar to the negligible transduction by wtAAV9 vectors, no transduction of 
murine mesenteric artery endothelial cell (MMAEC) could be detected. A closer comparative 
analysis of two selected vectors displaying peptides with divergent sequences revealed a HSPG-
independent transduction of and the partial use of a common transduction. The results obtained in 
the present study permit the conclusion that the novel AAV9 peptide library is functional and can 
be used to select for vectors for future preclinical and clinical gene transfer applications. 
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Deutsch 
 
Endothelzellen spielen eine zentrale Rolle in vaskulären Erkrankungen und stellen daher ein 
klinisch relevantes Ziel für gentherapeutische Ansätze dar. Die Transduktion des Endothels mit 
Hilfe von Wildtyp AAV (wtAAV)-Vektoren ist jedoch ineffizient. Die Selektion von randomisierten 
Peptidbanken, die im Kontext der AAV2-Kapsidoberfläche exprimiert wurden, hat das Potential zur 
Detektion und Herstellung von AAV2-Vektormutanten mit gesteigerter Transduktionseffizienz 
bezüglich des Endothels gezeigt. Es ist jedoch denkbar, das AAV9 als Serotyp aufgrund des 
niedrigeren Vorkommens neutralisierender Antikörper im Menschen und einer effizienteren 
Gewebstransduktion in vivo für die Konstruktion und Selektion solcher Peptidbanken besser 
geeignet ist. 
 
Die vorliegende Studie beweist, dass die Herstellung einer solchen AAV9-Peptidbank möglich ist 
und eine Selektion auf Endothelzellen ähnlich wie im Falle von AAV2 zur Isolation von Endothel-
gerichteten AAV9-Vektormutanten führt. Die nach vier aufeinander folgenden in vitro-
Selektionsrunden auf humanen koronarartriellen Endothelzellen (HCAEC) angereicherten AAV9 
Kapsidvarianten wiesen Transduktionseffizienzen auf, welche die von wtAAV9-Vektoren bei 
weitem übertrafen. Eine Expression von Peptiden, die im Rahmen einer AAV2-Bibliotheksselektion 
auf HCAEC isoliert wurden, auf AAV9-Vektoren ergab deutlich niedrigere Transduktionswerte im 
Vergleich zu Peptiden, die aus AAV9-Bibliotheken selektiert wurden. Weiterhin konnte gezeigt 
werden, dass die selektierten AAV9-Vektoren eine erhöhte Transduktion in Gegenwart 
neutralisierender humanen intravenösen Immunoglobuline aufweisen, wodurch eine geringere 
Immunogenizität angenommen werden kann und AAV9 als den besser geeigneten Serotyp für 
diesen Zweck erscheinen lässt. Diese Ergebnisse zeigen gemeinsam die Überlegenheit der AAV9 
Peptidbibliotheken. Nachfolgende Untersuchungen haben jedoch gezeigt, das die angereicherten 
Peptide AAV9 keine erhöhte Gewebsspezifität verleihen. Der Einsatz Endothel-spezifischer 
Promotoren konnte die Spezifität der Transgenexpression jedoch etwas erhöhen. Um das Potential 
der selektierten AAV-Vektoren zur Transduktion von im Blutgefäßkontext residierenden 
Endothelzellen zu bestimmen, wurden humane Nabelschnurvenen einer in situ und murine 
Mesenterialarterien einer in vivo Behandlung mit dem effizientesten Vektor unterzogen. Im 
Gegensatz zur hocheffizienten Transduktion der Nabelschnurendothelzellen (HUVEC) durch die 
Vektormutante, ermöglichte der Wildtyp-Vektor keinen Gentransfer. Überraschenderweise konnte 
keine Endotheltransduktion der murinen Mesenterialarterien durch die Vektormutante detektiert 
werden. Eine nähere Charakterisierung zweier Vektormutanten, die Peptide mit divergierender 
Sequenz exprimierten, ergab eine HSPG-unabhängige Transduktion zweier Zelltypen und wies auf 
eine partiell gemeinsame Nutzung des Transduktionspfades hin. Die vorliegenden Resultate 
erlauben den Rückschluss, dass die im Rahmen dieser Studie entwickelte AAV9-Peptidbank 
funktionell und zur Selektion von Vektoren geeignet ist, welche in künftigen präklinischen und 
klinischen Gentransferstudien eingesetzt werden könnten. 
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I. INTRODUCTION 
 
 
I.A Gene Therapy 
 
I.A.1 Definition 
 
Broadly defined, gene therapy is the concept of directed introduction of foreign genetic material 
into a cell, tissue or organ for correction of defective genes with the goal to improve the clinical 
status of a patient. The approach may be differentiated in germ line gene therapy, which would 
induce heritable changes passed from generation to generation and somatic gene therapy, that 
restricts the therapeutic effect to the treated individual. Germ line therapy would be highly effective 
in counteracting genetic disorders and hereditary diseases, however, application in humans is at 
present unimaginable for several technical and ethical reasons. The broadly accepted somatic 
therapy can be further discriminated by a fast and easy to perform direct gene transfer to the 
organism (in vivo) or a sophisticated but more specific and controllable transfer to explanted cells 
or tissues (ex vivo), which are re-implanted after treatment. 
 
 
I.A.2 Methods of gene transfer 
 
Gene transfer to cells can be attempted by the use of either viral or non-viral methods. The latter 
are based on physical procedures as in the case of micro-injection1 and electroporation2 or 
chemical treatment of naked DNA using transferrin-polycation conjugates3, polyethyleneimine4 or 
liposomes5. A more promising alternative may be represented by viruses that in the course of 
evolution have developed efficient strategies to deliver inherent DNA to the host cells. Partial 
replacement of viral genetic elements by therapeutic genes and exploitation of the virus' native 
tropism have yielded viral vectors that reliably and efficiently access the tissue of interest. To date, 
several human or animal viruses suitable for incorporation of transgenes including Adenovirus 
(Ad), Adeno-associated virus (AAV) and Retrovirus have been employed in gene transfer attempts 
with variable success, each of them having advantages and disadvantages in production, 
application and outcome (reviewed by6,7,8). 
 
 
I.A.3 General problems of gene transfer 
 
Transfer of naked DNA into target cells potentially avoids pronounced host immune response and 
has a negligible mutagenic capacity since only a low integration rate into the host genome can be 
assumed. The efficiency and specificity of such approaches, however, is limited. Due to their 
natural ability to infect a host and to replicate, viruses and derived viral vector systems represent a 
more efficient gene transfer alternative. Depending on the viral background, the specificity is only 
moderate, though, leading to off-target effects. 
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This may be a benefit in case the target cell type is within the host range but will represent a 
significant drawback when specific transduction is desired. Off-target transduction of healthy tissue 
lowers the therapeutic impact on targeted tissue and may unfold deleterious effects, such as 
toxicity, uncontrollable transgene expression or adverse immune reactions. In addition, a high risk 
of insertional mutagenesis exists due to the native property of latent viruses to integrate into the 
host genome. These drawbacks have lead to numerous debates on the safety of virus-based gene 
therapy vectors (reviewed by9,10,11,12,13). Despite the negative aspects, improved viral vector 
systems with an enhanced safety profile have been developed and were approved for clinical trials 
with promising outcomes. 
 
 
I.A.4 Gene therapy trials with AAV-derived viral vectors 
 
Some of the most successful gene therapeutic trials have been obtained from AAV-derived 
vectors. As of 2008, 38 clinical trials were approved by the Recombinant DNA Advisory Committee 
and the Food and Drug Administration (reviewed by14,15). The initial idea of therapy by gene 
replacement was applied in early phase I or II clinical trials targeting monogenic diseases, such as 
cystic fibrosis16 and haemophilia B17,18. More recent trials encompassed treatment of heart failure19, 
α-1-antitrypsin deficiency20, Parkinson's neurodegenerative disease21,22, Leber congenital 
amaurosis23 and several others. The spectrum is completed by a plethora of approaches targeting 
more complex diseases like cancer. Here, several pre-clinical models have been attempted that 
aim for anti-angiogenesis therapy, immunotherapy, suicide gene therapy and repair of tumour cells 
(reviewed by24). The most advanced clinical phase III trial for AAV as of today has been approved 
for therapy of prostate cancer (reviewed by25). 
 
 
I.B AAV Biology 
 
I.B.1 AAV in general 
 
AAV was discovered and isolated in 1965 as a contaminant of an Ad production26,27 and was later 
assigned to the Parvoviridae family28. Its inability to complete a replication cycle in absence of a 
co-infecting helper virus has earned AAV its own genus of Dependovirus. The name-giving helper 
virus Adenovirus reconstitutes the replication-deficiency of AAV by providing the early adenoviral 
proteins E1A, E1B, E4 and E2A involved in activation of S-phase and DNA replication of the host 
cell29. Besides Ad, several other unrelated DNA viruses, such as herpes simplex virus type 1 and 
230, human Cytomegalovirus31, Vaccinia virus32 or human Papilloma virus type 1633 are able to 
support the replicative cycle of AAV. In absence of a helper virus, AAV establishes a latent 
infection in which the genome persists episomally or integrates preferentially at site AAVS1 located 
on chromosome 19 of the host genome 34,35,36,37. Super-infection with a helper virus mediates the 
rescue of integrated genomes and reactivates the productive replication cycle29. 
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I.B.2 AAV serotypes 
 
The term serotype refers to distinct variations of antigenic properties within a virus (or bacterial) 
species. A new serotype is defined when no cross-reaction with antibodies directed against all 
known serotypes of the same genus can be detected. As of today, 12 different AAV serotypes are 
known, AAV1 to AAV12, which have been isolated from human (serotypes 238, 339, 540, 641 and 942) 
and non-human primate samples (serotypes 143, 444, 745, 845, 1046, 1146, 1247). The serotypes have 
been classified into six different phylogenetic clades A-F on the basis of their genetic sequence 
and antigenic reactivities, with AAV4 and AAV5 considered to be clonal isolates42 and AAV6 the 
only natural recombinant of AAV1 and AAV2 differing by only 6 amino acids41. All serotypes are 
capable of infecting cultured human cells, independent of their natural host and display upon in 
vivo application a distinct tropism. AAV2 has been subject to the most extensive studies so far, but 
recently also other serotypes gained importance in the field of gene therapy. Especially AAV9 has 
attracted much interest due to its strong transduction of rodent muscle, liver and lung with an about 
100-fold enhanced efficiency over AAV2. A central reason for the emerging popularity of AAV9 is 
its remarkable ability to cross the blood brain barrier (BBB, reviewed by48) and a strong and 
efficient in vivo cardiac transduction in mice49,50,51. 
 
 
I.B.3 AAV genomic organisation 
 
AAV packages a ~4.7 kb single stranded DNA genome of either polarity38,52. Due to the limited 
space for packaging of genetic material viruses have developed the ability to increase their coding 
capacity of short DNA fragments. Three mRNA transcripts from only two open reading frames 
(ORFs) are sufficient to synthesize a total of eight proteins. This is only possible by efficient 
combination of alternative promoter usage, transcript splicing and depositing of genetic information 
in alternative ORFs. The primary ORF contains the slightly overlapping rep and cap genes 
encoding four non-structural proteins (Rep, regulatory proteins53) and three structural proteins (VP, 
capsid proteins54,55), respectively. Recently, the presence of another non-structural protein was 
discovered in the AAV2 secondary ORF of cap (AAP, assembly-activating protein56). The rep and 
cap ORFs are under helper virus-dependent transcriptional control of three promoters, p5, p19 and 
p40, with the numbering related to their relative position on the AAV genome map divided in 100 
units. The transcription of the two major rep-encoded proteins Rep78 and its splice variant Rep68 
is controlled by p5, Rep52 and its splice variant Rep40 by p19 and the structural proteins VP1, 
VP2 and VP3 (90, 72 and 62 kDa, respectively) as well as AAP (23 kDa) by p40. All transcripts can 
be subject to splicing, since the rep and cap overlapping region contains a small intron flanked by a 
single splice donor (SD) and two alternative splice acceptors (SA), a major (SAmaj) and a minor 
one (SAmin). Rep and cap are flanked by inverted terminal repeats (ITRs) that complete the AAV 
genome. 
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I.B.3.1 The ITRs 
 
The ITRs consist of 145 complementary nucleotides (nt) that self-anneal and form t-shaped hair-
pin structures57. Each hairpin comprises three palindromic sequences of in total 125 nt that form 
stem and arms of the t-shaped structure. The ITRs function as cis-acting elements for viral genome 
replication, packaging, rescue from integrated state57,58,59 and were shown to regulate viral gene 
expression and host genome integration (reviewed by60,61). The palindromic sequences harbour 
two Rep-binding elements (RBE)62,63,64 and a terminal resolution site (trs). The ITR structure is 
completed by the remaining non-palindromic 20 nt that form the single-stranded D-sequence 
required for AAV DNA replication and genome packaging65,66,67. 
 
 
I.B.3.2 The rep ORF 
 
Synthesis of Rep proteins occurs from two transcripts initiated from p5 and p19. The SAmin 
mediates the splicing of Rep78 and Rep52 mRNA to Rep68 and Rep40, respectively. Spliced and 
unspliced Rep proteins therefore have distinct C-terminal zinc-finger domains that interact with 
cellular kinases PKA68 and PRKX69 in case of Rep78/68 or with members of the 14-3-3 protein 
family in case of Rep52/4070. The N-termini of Rep78/68 contain additionally a DNA endonuclease 
function which is missing in Rep52/40 due to transcription from p19. Both unspliced Rep are able 
to contact the RBE of the ITRs and to cleave the DNA strand at the trs, a process required for the 
replication of viral DNA. All Rep share a nuclear localisation signal (NLS) close to the C-terminus 
required for nuclear import and the Helicase/ATPase function of the core protein domain. 
Additionally, the Rep proteins were reported to function as effectors of viral replication, genome 
packaging and integration into host genome71,72,73,74,75,76, as well as to interact with cellular proteins 
involved in DNA replication, RNA processing, membrane transport, chromatin dynamics and 
ubiquitination77. Rep78/68 additionally function as negative regulators of AAV gene expression 
during latency78,79. 
 
 
I.B.3.3 The cap ORF 
 
The structural VP proteins and AAP are translated from one mRNA transcript initiated from the p40 
promoter. Depending on which SA is involved in mRNA splicing, a 2.6 kb (SAmin) or a 2.3 kb 
transcript (SAmaj) are formed. The longer transcript retains the first AUG start codon and enables 
translation of the entire cap ORF to produce VP1. Since SAmin has a lower efficiency than SAmaj, 
the shorter transcript predominates, excluding the first AUG start codon and preventing VP1 
translation. From this major transcript, capsid proteins VP2 and VP3 are created by accession of 
the non-canonical (weaker) start codon ACG which is surrounded by an optimal Kozak motif and 
the conventional AUG start codon, respectively55,80,81,82. The translation of the smallest AAV2 
protein AAP is mediated by non-canonical promoter bearing a CUG start codon located in the 
secondary ORF of the p40 transcript. 
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Due to the use of different start codons the VP proteins share C-terminal domains while the N-
termini remain unique to VP1 or VP2. VP1, the largest protein, harbours at its N-terminus a 
phospholipase A2 (PLA2) domain known to be involved in endosomal release and nuclear entry 
during viral infection83,84,85,86. The VP N-termini contain in total four conserved motives of positively 
charged amino acids (KKR) termed basic regions (BR), whereas BR1 is uniquely present on the 
VP1 N-terminus, BR 2 and 3 are shared by VP1/2 and BR 4 is common to all three VPs87. The BRs 
constitute putative NLS and may be involved in nuclear transfer of VP proteins for capsid 
assembly86,88,89. The C-terminus present in all VP contains five basic amino acids (R484, R487, 
K532, R585 and R588) responsible for the binding of AAV2 to its primary attachment receptor 
heparan sulphate proteoglycan (HSPG)90,91,92. Another motive shared between VPs from all AAV 
but 4, 5 and 11 is NGR (residues 511-513, VP1 numbering) that promotes binding to one of the 
AAV2 secondary internalization receptors α5ß119. The assembly-activating protein AAP targets 
capsid proteins to the nucleoli and fulfils a direct function in the capsid assembly process itself. 
 
 
I.B.4 AAV structure 
 
The icosahedral AAV capsid is formed by 60 VP1-3 subunits55 that assemble at a molar ratio of 
~1:1:10 (VP1:VP2:VP3). The 10-fold higher abundance of VP3 can be explained by the 
predominating major p40 transcript and the use of the conventional AUG start codon (Chapter 
I.B.3.3). The icosahedron has ~25 nm in diameter and may be divided in 20 triangular faces 
formed by any of the three VP proteins that share identical interaction sites and spatial 
arrangement. This geometrical set up results in 2-fold, 3-fold and 5-fold symmetry axes with a 
triangulation number of T=1 defining size and complexity93. The atomic structure of several 
serotypes has been resolved by x-ray crystallography to a resolution of 2-3 Å (AAV294, 3b95, 496, 
697 and 898) or by cryoelectron microscopy and image reconstruction to 10-16 Å (AAV299, 4100, 
5101). Currently, the crystal structures of AAV1102, 7103 and 9104 are being investigated. 
 
The VPs of all serotypes analysed so far share a common structure comprising of a conserved 
eight-stranded antiparallel ß-barrel (ßB-ßI) buried within the assembled capsid. This motif is 
common in virus capsids and has also been described for other parvoviruses like canine 
parvovirus (CPV)105 feline Panleukopenia virus (FPV)106, minute virus of mice (MVM)107 or the 
human parvovirus B19108. Each ß-sheet is connected to its neighbour by interstrand loops that 
define the landscape of the assembled capsid surface: a depression at the 2-fold axis (“dimple”), 
finger-like projections at the 3-fold axes (“spikes”), another depression surrounding the 
pore/cylinder at the 5-fold axis (canyon)94, and a flat region located between two spikes 
(“plateau”)109. The interstrand loops are grouped by convention into 5 groups (I-V)110 and comprise 
a total of 9 variable regions between the AAV serotypes (VR I-IX)100. Loop 4, the largest loop, is 
further divided in 4 subloops (1-4) and connects the ß-strands G and H (GH-loop). 
 
 22 
According to the known structure of AAV2, the GH-loop of two adjacent VP subunits form a spike. 
Subloops 1 (VR IV) and 4 (VR VIII) of one VP are located on the opposing sides of the spike while 
subloop 2 (VR V) of the other VP resides in between them111. The majority of the 2-fold symmetry 
interactions are provided by a conserved loop located after ßI and loop HI promotes interaction of 5 
adjacent VP monomers at the 5-fold symmetry axis112. X-ray crystallography allowed the detection 
of all but 14 N-terminal residues from AAV294. Consequently, the VP1/2 N termini buried within 
assembled capsids were not visible. However, cryoelectron microscopy and image reconstruction 
of AAV capsid cross-sections revealed globular structures located at the 2-fold axis inside the 
capsid, which may represent the VP1/2 N-termini that become externalized through the 5-fold 
cylinder during AAV infection83,86. 
 
 
I.B.5 AAV receptors 
 
The first step in AAV cell transduction is represented by binding of the capsid to cellular receptors. 
At the same time, this step determines the broadness of viral tropism which is enlarged in case the 
target receptor is commonly expressed on many cell types. Several glycans with different 
biochemical termini serve as attachment or primary receptors for different AAV serotypes. The 
attachment receptor of AAV2 and 3 is cellular HSPG92,113 while AAV1, 5 and 6 employ N-linked (α-
2,3 in case of AAV1 and 5 and α-2,6 in case of AAV6) and AAV4 O-linked sialic acid containing 
glycans114,115,116. Recently, AAV9 has been shown to use O-linked galactose containing glycans as 
a primary receptor117. However, evidence was given that AAV may use more than one receptor for 
efficient transduction of cells: in absence of HSPG, persistent transduction has been demonstrated 
for AAV2118 and 3119 and mutant AAV2 vectors with abrogated HSPG binding showed increased 
transduction of heart in vivo90. Subsequently, integrins αVß5120 and α5ß119, hepatocyte growth 
factor receptor (c-Met)121 and CD9122 were revealed to function as co-receptors for AAV2 and are 
believed by convention to mediate cellular uptake. AAV2 and AAV3 both utilize fibroblast growth 
factor receptor 1 (FGFR-1)123,124 and the 37/67 kDa laminin receptor (LamR) serves as a co-
receptor for AAV2, 3, 8 and 9125. In contrast, AAV5 transduction is mediated by the platelet derived 
growth factor receptor (PDGFR)126. 
 
 
I.B.6 Infection and replicative cycle 
 
The infection and replication process has been most intensively studied in case of AAV2. Upon 
binding to HSPG, structural rearrangements that render the capsid compatible to interaction with 
α5ß1 were proposed19 but could not be proven in a structural analysis of an AAV-2 heparin 
complex127. Interaction of AAV2 to cellular co-receptors mediates the dynamin-dependent 
endocytosis process via clathrin-coated pits into endosomes128 129. For AAV5, internalization has 
also been shown to take place in caveosomes via the caveolar pathway130. 
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Endocytosis of particles is a rapid process lasting only milliseconds131 and is promoted by the 
posphatidylinositol-3-kinase (PI3K) pathway via Rac1 that controls the intracellular trafficking of 
AAV to the nucleus along microfilaments and microtubules132. 
 
The vesicular trafficking is slow and represents a rate limiting step in many cell types133,134,135,136. 
To date, several potential intracellular trafficking pathways have been described for AAV2 and 
AAV5. Following internalization, the viruses residing in early endosomes may (I) be released into 
cytoplasm and travel in a vesicle-independent manner to the nucleus128,137, may (II) be directed to 
late endosomal compartments and alternatively be released into cytoplasm from there, or (III) may 
accumulate in perinuclear recycling endosomes (PNRE)138,139,140. From PNRE or late endosomes, 
virions could also be rerouted to the trans-Golgi network before nuclear translocation takes 
place141. The use of alternative trafficking routes is not only cell type specific but also dose 
dependent, since a high multiplicity of infection (MOI) relocated AAV2 capsid accumulation from 
late endosomes to PNRE142. All pathways assume a final escape of particles into the cytoplasm 
before lysosomal degradation can occur. 
 
The endosomal release of virions into the cytoplasm depends on externalization of the VP1/2 N-
terminal domains containing the PLA2 activity through the cylinders located at the 5-fold axis. The 
PLA2 domain is shared by all serotypes85 and essential for viral release143,144. A necessary but not 
sufficient trigger for the externalization seems to be the acidification of the endosomal 
compartment, and involvement of other unknown factors is probable86,99. Such factors could be 
posed by the endosomal proteases cathepsin B an L that are involved in uncoating of AAV2 and 8 
in vitro145 and may induce capsid modifications needed during externalization. 
 
Upon accomplished release into cytoplasm, AAV is subject to ubiquitination and ubiquitin-
dependent degradation by proteasomes. Employment of proteasome inhibitors133,146 or mutation of 
surface exposed tyrosines prone to phosphorylation and ubiquitination147 increased transduction 
efficiencies by preventing proteasomal degradation. Perinuclear accumulation of free AAV particles 
is probably mediated by Brownian diffusion or ATP-dependent cytoskeletal motor proteins132,131,148. 
The nuclear import is regarded as another inefficient and rate-limiting step and only little 
knowledge is existent about the process. One possibility involves the basic regions present within 
exposed VP1/2 N-termini (BR1-3) that would mediate the import via the nuclear pore complex 
(NPC)88 but also alternative NPC-independent entry pathways have been postulated135,137. Since 
assembled viral capsids were detected within nucleoli, import of intact viral shells into the nucleus 
is expected, revealing the uncoating of viral DNA as an intranuclear process128,86. 
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Another rate limiting step is posed by the conversion of the single-stranded viral DNA into the 
double-stranded state necessary for genome stability and gene expression149,150. Relocation of 
viral particles from nucleoli into nucleoplasm allows uncoating and may determine the efficiency of 
single-strand conversion151. The helper virus dependent DNA replication process is mediated at 
distinct nuclear foci and is antagonized by the host cell DNA repair complex MRN152. Here, the 
ITRs act as an origin of replication (reviewed by60) and contact domain of Rep78/68 proteins which 
interact with the RBE and trs sequences and unwind the double-stranded DNA. Rep52/40 are 
involved in the accumulation of single-stranded AAV genomes from double-stranded replicative 
intermediates. When latent, the Rep proteins mediate site-specific integration of AAV2 into the q-
arm of the host chromosome 19 (AAVS1) or, as observed mainly in vivo, extrachromosomal 
persistence as circular episomes153. 
 
Besides uncoating and DNA replication, also assembly of capsids and packaging of newly 
replicated DNA in to pre-formed capsid occurs in the nucleus, more specifically in nucleoli154. 
Nucleophosmin and nucleolin on the one hand155,156 and virus-own AAP56 on the other, represent 
proteins that co-localize with VP proteins and support capsid formation. Initiation of viral genome 
encapsidation into pre-formed capsids is at least partially controlled by Rep78/68 proteins, 
probably by establishing contact between DNA and capsid157,158,159. The progression of DNA 
insertion is mediated by the helicase activity of Rep proteins in a 3' to 5' direction76 through the 5-
fold pore complex of the capsid160. Finally, the release of newly produced AAV virions is aided by 
the helper virus mediated cell lysis. 
 
 
I.B.7 AAV Immunology 
 
Due to its apparent lack of pathogenicity and low immunogenicity, AAV poses an interesting 
candidate for gene therapy trials in humans. However, about 50–80% of the human population has 
neutralizing antibodies (NABs) against AAV2, the template of most vectors currently used in gene-
therapy trials, with the highest antibody prevalence shown for AAV2 and AAV1161,162. Antibodies 
against serotypes 5, 6, 8 and 9 were found less frequently but still remain a threat to satisfactory 
therapeutic returns. Despite the low general immunogenicity, interactions with the host immune 
system can be found at the level of innate, humoral and cell-mediated responses (reviewed 
by163,164). The innate responses to AAV investigated in animal models displayed a weak transient 
production of pro-inflammatory cytokines and chemokines and some infiltration of neutrophils and 
other leukocytes into the liver165,166. Triggering of Toll-like receptor (TLR) signalling was shown in 
mice167 to lead to an increased uptake of AAV into macrophages and activation of the humoral 
immune response163. In seropositive humans, circulating IgG antibodies for AAV2 are primarily 
composed of the IgG1 and IgG2 subclasses, with negligible levels of IgG3 or IgG4168. Comparable 
to persistent AAV specific antibody levels, prime-boost studies in animals and clinical trials 
revealed that the B-cell memory is also strong169,170. 
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But AAV-mediated immune response is not only restricted to B-cell activation, also the cell-
mediated response involving T-cell activation is involved. Mingozzi et al.171 reported the activation 
of AAV2 capsid-specific CD8+ memory T-cells in humans but not in mice, leading to a lack of 
hepatic transgene expression by rejection of transduced hepatocytes. Investigation of exposed 
AAV2 capsid domains revealed several sites prone to recognition by the cellular and humoral 
immune system. Moskalenko et al.172 identified seven regions of the capsid as epitopes for human 
polyclonal NABs. Especially the „spike“ and „plateau“ regions seem to play a crucial role in epitope 
formation. Point mutations of R471A or N587A as well as peptide insertion behind residue 587 
prevented binding and neutralization by antibodies173,174,109, suggesting that exposed capsid 
domains are more easily accessible to the immune system and may be preferred for epitope 
formation. As well, a number of candidate T-cell stimulating epitopes have been identified within 
the AAV capsid protein VP1, which may be attractive targets for modification of the capsid to avoid 
cell-mediated immune responses168,175. 
 
 
I.C AAV as a gene therapy vector 
 
I.C.1 AAV-derived gene vectors 
 
Recombinant AAV (rAAV) vectors are constructed by replacement of rep and cap ORFs with an 
expression cassette containing a transgene under the transcriptional control of a suitable promoter. 
Their synthesis occurs in a suitable producer cell line by transfection of three plasmids: one 
harbours the expression cassette flanked by ITRs (the only element required in cis), another 
provides the rep and cap helper sequences in trans and the third encodes adenoviral helper genes 
E2A, E4 and VA176,177. Alternatively, vectors can be produced from transfection of only two 
plasmids, since AAV and Ad helper genes can be combined in one plasmid178. These 
cotransfection approaches enable the generation of replication-deficient, wild type-free and 
adenovirus-free rAAV vector stocks at suitable titres. Since transduction by AAV vectors is 
characterized by a delayed onset of transgene expression derived from the rate-limiting process of 
double-strand conversion149, self-complementary AAV (scAAV) vectors have been created by 
deletion of the D sequence179 or by mutation of the trs sequence180 present in the ITRs. This vector 
type packages dimeric inverted repeat DNA molecules, circumventing double-strand conversion 
and providing pseudo-first order kinetics upon uncoating (reviewed by181) albeit with a 50% 
reduced packaging capacity. Such AAV vectors lead to a sustained and efficient transgene 
expression in a wide variety of non-dividing cells in vitro and in vivo and provide a low integration 
rate into the host cell genome. Drawbacks are represened by a broad tissue tropism, a low 
transduction of a set of cell types and the prevalence of pre-existing humoral immunity, especially 
against AAV2. 
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To overcome these limitations, modern vectorology has turned towards the molecular engineering 
of AAV capsids in order to improve transduction efficiency, target specificity and escape from 
neutralization by capsid antibodies, which may be regarded as the three main support structures 
sustaining a viral gene transfer vector (reviewed by6,182). 
 
 
I.C.2 Rational design of AAV vectors – the first steps 
 
Significant improvement of AAV-derived vectors with respect to efficiency, specificity and immune 
evasion will most likely occur mainly by modification of the capsid, which represents the interface 
to receptors and antibodies. During the last decade, designer gene delivery vectors using more 
and more sophisticated approaches were developed that addressed and partially improved 
performance of AAV. This chapter (and reviews by183,182,184) gives a brief overview over applied 
technologies and their impact on the three pillars of vectorology. 
 
 
I.C.2.1 Isolation of new serotypes and pseudotyping of vectors 
 
Vectors based on AAV2 have been the most studied and have been shown to deliver genes to a 
broad range of cells in muscle, brain, retina, liver, and lung in vivo. However, the broad tropism, 
inefficient transduction of a set of clinically relevant tissues as well as a high prevalence of NABs 
soon rendered AAV2 insufficient for targeted gene delivery. First efforts focused on exploitation of 
alternative serotypes and provided a first opportunity to improve gene transfer to tissues. Over 100 
serotypes from different animal species were isolated42,183 and many in vitro and in vivo studies 
proved that these various natural variants displayed distinct tropisms and transduction patterns. 
Pseudotyping, i.e. the cross-packaging of a genome of one serotype into the capsid of another 
serotype, created infectious vectors with the tropism of the new capsid. For instance, a 
pseudotyped vector harbouring an AAV2 genome and AAV4 capsid (AAV2/4) exhibited ependymal 
cell-specific transduction, whereas AAV2/2 showed transduction biased to neurons in the central 
nervous system185. Pseudotyping is not only a convenient technique to isolate and characterize the 
capsid properties of newly identified serotypes but may also tackle the issue of prevalent NABs 
that differ between serotypes in humans. Antibodies generated against AAV2 did not cross-
neutralize AAV1 vectors in mice43 and pseudotyped AAV2/7 and AAV2/8 vectors exhibited 
negligible neutralization following pre-administration of AAV2 vector45. Despite the improvements in 
tropism and immune evasion achieved by pseudotyping, an increase of specificity to a single cell 
type by this method remains improbable. 
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I.C.2.2 Mosaic and chimerical capsids 
 
A logical evolution in vector engineering was the combination of VPs from different serotypes, i.e. 
transcapsidation, thereby creating mosaic capsids that would combine the properties of the 
serotypes applied. By mixing the rep and cap helper plasmids during vector production, AAV1 and 
AAV2 VPs were combined in a vector that efficiently transduced both muscle (AAV1) and liver 
(AAV2)186. Rabinowitz et al.187 extended the approach by producing mosaic capsids made from 
pair wise combinations of AAV serotype 1 to 5 plasmids employed at different ratios. Combination 
of AAV3 and AAV5 at the 3:1 ratio yielded vectors with dual binding properties to heparin and 
mucin agarose, which mimic the primary binding receptors for AAV3 and AAV5, respectively. 
Shortcomings of the transcapsidation attempt may represent the potential neutralization by NABs 
directed against either serotype and the combination of tropism from employed serotypes which 
may furthermore broaden the host cell spectrum. 
 
 
I.C.2.3 Chemical and genetic engineering of capsids 
 
The first attempt to restrict AAV tropism was posed by chemical or genetic modification of capsids 
which enabled attachment of conjugates to the capsid. The conjugates bridge interactions between 
vector and specific receptors, thereby allowing AAV transduction of non-permissive cells. In a 
pioneer study, indirect labelling of AAV by a bi-specific F(ab')2 antibody188 or by avidin-biotin 
coupling to a fusion protein189 mediated interaction between AAV and specific surface receptors 
from cells, which were non-permissive for normal AAV infection. However, the potentially transient 
and immunogenic nature of these protein complexes may be a limiting factor for transduction in 
vivo. To provide a more stable ligand interaction, AAV capsids were genetically engineered to 
express ligands at the N-terminal region of VP2 proteins, such as single-chain antibodies, serpin or 
ApoE receptor ligands, which significantly improved transduction of AAV-refractory cells190,191,192. In 
a pioneer study193, insertion of a 14 amino acid peptide containing an RGD motif known to bind 
several cellular integrin receptors at capsid position 587 redirected AAV2 to αVß5 expressing cells. 
This approach was later employed on a regular basis for display of foreign peptides on the capsid 
surface. Position 587 was chosen via homology mapping to the known crystal structure of canine 
parvovirus110 since the AAV2 structure was solved several years later94 and has several 
implications. First, mutation of this essential HSPG-binding site at position 587194 or 588195,196 leads 
to a detargeting of AAV2 from liver after systemic application. Second, vectors modified at position 
587 have the potential to escape immune neutralization without losing the ability to transduce 
tissue via targeted receptors174. Third, structural modelling of AAV2 allocated R585/588 at an 
exposed position on the shoulder of the 3-fold spikes that are present 60 times on the capsid. 
Peptide display at this site may therefore be feasible for receptor-ligand interaction and does not 
hamper capsid assembly. 
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I.C.3 High-through put library systems 
 
Despite the success of AAV vectors based on serotypes other than AAV2, mosaic vectors, or 
rationally modified capsids, these approaches have only a limited potential for generating AAV 
tropism beyond those already present in natural serotypes. Ligand conjugation to AAV capsids 
improved targeting to non-permissive cells but modification of VP N-termini resulted in deficiencies 
of packaging and intracellular trafficking (reviewed by197). Encouraged by the results obtained from 
peptide insertion into the capsid, several groups have developed library-based systems that 
theoretically can be screened on any cell type of interest to detect variants that would maximize 
transduction efficiency, specificity and immune evasion. The selection process is performed by 
incubating target cells with virus library particles which will bind to cell surface receptors and enter 
the cell. Super-infection with Ad leads to selective amplification of internalized particles that can be 
purified and subjected to a new selection round for further enrichment of the most suitable mutants. 
The selection process not only leads to an enrichment of variants efficient in binding of receptors 
but also in intracellular processing, replication and progeny virus production. Peptide library-display 
on phage/AAV capsids, directed evolution and DNA family shuffling represent the basic techniques 
and individual or combined applications have yielded novel AAV vector variants with promising 
features for future clinical application. 
 
 
I.C.3.1 Peptide library-display on AAV capsids 
 
The display of randomized peptide libraries on phages represented the initial attempt to select for 
suitable ligands that retargeted vectors to previously inaccessible tissue198. Such phage-display 
selected ligands were later successfully incorporated into the AAV2 capsid and lead to selective 
targeting of AAV non-permissive cells199,200. Transfer of phage-derived peptides to the AAV capsid 
may however impose limitations. The peptide conformation may be altered when displayed in the 
AAV capsid context resulting in reduced or lost affinity to the receptor. Furthermore, selection of 
phage libraries occur only in favour of efficient receptor-ligand binding, while subsequent steps 
involved in efficient AAV transduction such as cell entry, intracellular trafficking and nuclear 
translocation remain unaffected. To overcome these limitations, two different peptide screening 
system have been developed independently Perabo et al.194 and Müller et al.195. Both systems 
shared the generation of a plasmid library encoding random peptide heptamers that are displayed 
behind AAV2 capsid residues 587 or 588, respectively. The differences between the two 
approaches arose during subsequent production steps. In their two-step protocol, Perabo et al. 
transfected library and helper plasmid containing Ad genes alone into producer cells, potentially 
producing mosaic library capsids assembled from several VP library variants. Thus, packaged 
genomes and capsid variants did not correspond and presence of several library peptides on the 
same capsid could potentially lead to inconsistent selection and mislead evaluation. 
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The three step protocol of Müller et al. solved the problem by transfecting a second helper plasmid 
encoding wtAAV2 rep and cap sequences, intentionally creating a mosaic capsid library assembled 
from library and wtAAV2 VP subunits that was termed transfer shuttle library (TSL). In the third 
step, the intermediate TSL was used to re-infect the HEK 293T producer cell line at a multiplicity of 
infection (MOI) of one, thus theoretically limiting the virus DNA transfer to one library genome/cell. 
Upon super-infection with Ad, the internalized genome was packaged in capsids assembled from 
only one subunit library variant, maximizing the likelihood of genome packaging into corresponding 
capsids. It was assumed that the presence of wtAAV2 subunits within the TSL capsids would 
ensure equal infection efficiency of each TSL particle, preventing a biased production process. A 
serious drawback of this approach is represented by the generation of wild type viruses from 
homologous recombination of wild type and library cap sequences during TSL production. The use 
of a synthetic wtAAV2 cap fragment generated by alternative codon usage prevented 
recombination events and lead to the production of a wild type-free AAV2 random peptide 
library201. In vitro and in vivo selection of combinatorial AAV2 libraries have lead to identification of 
distinct peptide sequences that improved but did not completely restrict transduction of targeted 
tissues201,202,196,203. The low cell specificity of selected mutants may arise from ubiquitous 
expression of targeted receptors or the fact that AAV requires more than one receptor for 
transduction which probably binds to different capsid domains. Insertion of peptides may therefore 
retarget AAV to a new primary receptor leaving secondary receptor affiliations unattended. These 
receptors might be able to mediate vector uptake into cells in absence of an adequate primary 
receptor119,118,90. As well, some improvement of escape from antibody neutralization could be 
reported by disruption of epitopes via insertion of peptides174,109,173. 
 
 
I.C.3.2 Directed evolution 
 
Directed evolution has been applied for creation of proteins with improved biological activities, 
antibodies with enhanced binding affinity or retroviral vectors with improved properties204,205,206. 
This powerful approach was independently adapted by Perabo et al.207 and Maheshri et al.208 
primarily to create AAV2 capsids devoid of HSPG-binding with an antibody-evading phenotype. 
Basically, a plasmid library was prepared by error-prone PCR amplification of the AAV2 cap gene 
followed by the staggered extension process209. Subsequent cotransfection with sequences 
containing Ad helper genes resulted in the final virus library with distributed random point 
mutations throughout the capsid protein. Heparin affinity fractionation and/or in vitro selection in 
presence of NABs yielded AAV2 mutants with low HSPG affinities, high immune evasion properties 
in vivo and differential tropism compared to parent serotypes. However, a maximum of six (two) 
mutations prior (post) selection was the upper limit for this library type, rendering respective lead 
candidates nearly identical to wtAAV2. This low level of mutagenesis in fact may have improved 
immune escape but a specific retargeting and efficient transduction of tissue strongly differing from 
parental serotypes can not be expected. 
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I.C.3.3 DNA family shuffling 
 
DNA shuffling is a process for directed evolution, which generates diversity by recombination210, 
combining useful mutations from individual genes of a family. Thus, libraries of chimerical genes 
can be generated by random fragmentation of a pool of genes, followed by reassembly of the 
fragments in a self-priming polymerase chain reaction (PCR). The molecular breeding was first 
applied for murine leukaemia virus (MLV)211 and conveyed to AAV by Koerber et al.212 and Grimm 
et al.213. Several AAV cap genes from different serotypes were fragmented by DNase I digestion 
using various incubation times and fragments various in length and origin were reassembled by 
PCR to obtain full-length shuffled cap genes. The shuffled capsid libraries were then produced by 
cotransfecting the library plasmid containing the shuffled cap genes and a helper plasmid 
containing Ad genes. Selection of such libraries in vitro lead to an enrichment of distinct capsid 
chimeras composed of cap fragments from different serotypes. Consequently, another group 
prioritized the selection of the shuffled capsid library in vivo to select for myocardium-tropic 
mutants214. The approach was extended by Grimm et al.213 who additionally inserted a peptide 
heptamer library (see Chapter I.C.3.1) into the AAV backbone capsid they previously selected from 
the shuffled capsid library in vitro to redirect and enhance transduction of lowly permissive tissue 
by subsequent in vivo selection. A subsequent study performed by Gray et al.215 combined the 
initial shuffling technique with the directed evolution method (I.C.3.2) to select for variants that 
would cross the blood brain barrier (BBB) and transduce tissue from the central nervous system. 
Finally, Jang et al.216 combined all three methods by first applying the shuffling technique, then 
inserting a peptide library and subsequently creating point mutations in the cap gene by error-
prone PCR (Chapter I.C.3.2) to select for neural stem cell-specific “designer” vectors. Together, 
the selection of shuffled AAV capsid libraries on the cell/tissue type of interest generated mutants 
that outperformed transduction of wtAAV vectors of different serotype origin in vitro and in vivo. 
The chimerical character of the vector shells reduced neutralization by capsid antibodies, 
especially when library selection occurred in presence of neutralizing antibodies in vitro. However, 
shuffled capsids still harbour wtAAV sequences which could represent epitopes for pre-existing 
antibodies that were not abundant during in vitro exposure. In addition, the serotypes employed in 
the shuffling process limit vector retargeting to the respective serotype tropisms, except the 
shuffling technique is combined with other library approaches as in case of Grimm et al.213, Gray et 
al.215 or Jang et al.216. 
 
 
I.C.4 The endothelium as a target for AAV-mediated gene transfer 
 
The endothelium is composed of a thin monolayer of endothelial cells (ECs) that line the interior 
surface of blood vessels, forming an interface between circulating blood and mural cells (smooth 
muscle cells, pericytes). 
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Endothelial tissue is a specialized type of mesenchymal tissue involved in many aspects of 
vascular biology, including atherosclerosis, blood clotting, inflammation, angiogenesis and 
vasoconstriction/vasodilatation. In some organs, highly differentiated and specialized endothelial 
cells perform filtering functions, as in case of the blood brain barrier. The endothelium acts as a 
selective barrier controlling the passage of molecular cargo and the transit of white blood cells into 
and out of the bloodstream. Endothelial dysfunction entails vascular diseases and may represent a 
key early event in the development of atherosclerosis. Impaired endothelial function is often seen 
in patients with coronary artery disease, diabetes mellitus, hypertension or hypercholesterolemia. 
A main mechanism of endothelial dysfunction is the decreased production of nitric oxide by 
increase in reactive oxygen species217. Thus, endothelium represents an interesting target tissue 
for therapeutic approaches and specific and efficient drug delivery or therapeutic gene transfer is 
in great demand. Since AAV has been discovered as a promising gene transfer vector, 
transduction of a multitude of cells and tissues has been attempted and depending on the 
permissiveness of cells for wtAAV, targeting occurred with more or less success. A less permissive 
cell is represented by the ECs and transduction efficiency with wtAAV was found to be very low in 
vivo218,219 and in vitro 218,220,141. Selection of a phage display peptide library on ECs in vitro221 
yielded peptides that upon insertion into the AAV2 capsid behind residue 587 improved 
transduction of endothelium over wtAAV2 in vitro200 and in vivo222. In a subsequent in vivo 
selection attempt of the phage display library, peptides were isolated that redirected AAV2 
successfully to the vascular bed in vivo223. These previous approaches used AAV2 serotype 
vectors which might not be ideal for future clinical approaches since there is a high prevalence of 
IgG against AAV2 in human serum161,162. In contrast, AAV9 serotype vectors are less affected by 
neutralizing factors in human serum161 and allow a highly efficient gene transfer after intravenous 
vector administration to rodents224,50,49,225. Thus, combinatorial approaches displaying a library of 
randomized peptides on the AAV surface or capsid modification by shuffled or error-prone PCR 
may represent reasonable alternatives. 
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I.C.5 Goal of the present study 
 
Efficiency of endothelial gene transfer using wtAAV vectors is low. The potential of random peptide 
libraries displayed on AAV2 to select for AAV2 vectors with improved efficiency for endothelium-
directed gene transfer has been demonstrated. Transduction efficiency of endothelial cells could 
be increased in vitro and in vivo by introduction of an endothelial targeting peptide identified by 
phage display within the AAV capsids or selection of random AAV display peptide libraries on 
endothelial cells. However, these previous approaches used AAV2 serotype vectors which might 
not be ideal for future clinical approaches since there is a high prevalence of IgG against AAV2 in 
human serum. 
 
In contrast, AAV9 serotype vectors are less affected by neutralizing factors in human serum 
peptide and allow a highly efficient gene transfer after intravenous vector administration. Thus, 
AAV9 vectors might be a more suitable basis for developing an endothelial gene transfer vector 
using endothelial targeting peptides. Therefore, the aim of the study was (I) to identify a suitable 
insertion site for targeting peptides within the AAV9 capsid surface, (II) to generate a random AAV9 
peptide display library for selection of an AAV9-based targeting vector on endothelial cells, and (III) 
to compare vectors selected from AAV9 libraries with those from previous AAV2 libraries and to 
closer characterize them in terms of transduction efficiency in vitro and in vivo, target cell specificity 
and ability to evade neutralisation by NABs. 
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II. MATERIAL AND METHODS 
 
 
II.A Material 
 
II.A.1 Eukaryotic and prokaryotic cells 
 
Primary eukaryotic cells 
Denotation Description Source, ordering number 
HCAEC Human coronary artery endothelial cells Promocell, C-12221 
HCASMC Human coronary artery smooth muscle cells Promocell, C-12511 
HUVEC Human umbilical vein endothelial cells Isolated from umbilical veins (Chapter II.F.7) 
 
 
Immortalized eukaryotic cells 
Denotation Description Source, ordering number 
911 Adenoviral E1A/B transformed human embryonic retinoblastoma cells Fallaux et al.
226 
HEK 293T Adenoviral E1A/B and SV40 large T-antigen transformed human embryonic kidney epithelial cells DuBridge et al.
227 
HeLa Human cervical adenocarcinoma epithelial cells, positive for HPV-18 sequences ATCC-No. CCL-2 
HepG2 Human hepatocellular carcinoma epithelial cells ATCC-No. HB-8065 
H5V Murine malignant hemangiosarcoma endothelial cells derived from heart capillaries Garlanda et al.
228 
 
 
Prokaryotic cells (E. coli) 
Denotation Source, ordering number 
ElektroMAXTM DH5α-E Competent Cells Invitrogen, 11319-019 
Subcloning Efficiency DH5α Competent Cells Invitrogen, 18265-017 
One Shot DH5α-T1R Chemically Competent Cells Invitrogen, K4595-01 
 
 
II.A.2 Cell culture media, supplements and associated solutions 
 
Basal media, solutions and supplements for eukaryotic cell culture 
Denotation Description Source, ordering number 
Cell dissociation solution (1x) Non-enzymatic Sigma-Aldrich, C5789 
CryoSFM Solution for cryo-preserving of cells Promocell, C-29910 
DetachKit Kit containing HepesBSS, Trypsin/EDTA and TNS Promocell, C-41210 
DMEM Dulbecco's modified Eagle's medium Sigma-Aldrich, D5796 
ECGM Endothelial cell growth medium kit Promocell, C-22110 
ECGM-MV Endothelial cell growth medium MV kit Promocell, C-22020 
FBS Fetal bovine serum PAA, A15-100 
Gelatine solution (2%) 2% w/v gelatine from bovine skin, 100 mM HCl  
in 1x PBS (dissolve at 37°C) 
 
HANKS (1x) w/o Mg2+ and Ca2+ PAA, H15-009 
L-glutamine (100x) 200 mM Invitrogen, 25030 
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PBS (1x) 8 g NaCl, 0.2 g KCl, 0.2 g KH2PO4, 1.15 g 
Na2HPO4•2H2O, ad 1 L ddH2O 
 
PSF (100x) Penicillin (10.000 IU/ml), streptomycin sulphate (10 
mg/ml), fungizone (25 µg/ml) 
Promocell, C-42020 
RPMI RPMI-1640 medium Sigma-Aldrich, R8758 
SMCGM 2 Smooth muscle cell growth medium 2 kit Promocell, C-22162 
Trypan blue 0.4% Sigma-Aldrich, T8154 
Trypsin (1x) 0.05% trypsin, 0.02% EDTA Invitrogen, 25300-062 
 
 
Ready-to-use media for eukaryotic cell culture 
Cell type Medium 
HCAEC Provided supplements, 1x PSF in ECGM-MV 
HCASMC Provided supplements, 1x PSF in SMCGM 2 
HUVEC Provided supplements w/o hydrocortisone, 1x PSF in ECGM 
HeLa, HEK 293T, 911, Hep G2, H5V 1x L-glutamate, 10% FBS, 1x PSF in DMEM 
 
 
Media, solutions and supplements for prokaryotic cell culture 
Denotation Description Source, ordering number 
Amp 100 mg/ml ampicillin in ddH2O, sterile-filtered See also II.A.11 
Kana 50 mg/ml kanamycin sulphate in ddH2O, sterile-filtered  
LB medium 10 g Bacto Tryptone, 5 g yeast-extract, 10 g NaCl ad 1 L 
ddH2O, autoclave  
LB-amp/kana medium 10 g Bacto Tryptone, 5 g yeast-extract, 10 g NaCl ad 1 L 
ddH2O, autoclave, add 1 ml Amp/Kana at < 50°C  
LB-amp/kana agar plates See LB-amp/kana, with additional 7.5 g Bacto agar, pour 
into 56.7 cm2 cell culture dishes  
SOC Ready-to-use bacterial broth w/o amp/kana Invitrogen, 15544-034 
 
 
II.A.3 Plasmids 
 
Denotation Size (kb) Description* References 
pBLCAT3 6.8 
CAT-vector containing the entire murine VE-cadherin 
promoter (-2486 to +24, EMBL databank accession no. 
Y10887) 
Prof. Dr. H. Augustin, DKFZ 
pDG∆VP 20.7 
Ad5 genes E4, E2A, VA essential for AAV packaging, 
cap2 partially deleted, used for serotype-independent 
AAV vector production 
Dubielzig et al.159 
pDP2(9)rs 23.6 (23.8) 
Based on pDG, rep2/wtcap2(9), RSV-promoter controlled 
RFP gene for transfection control, used for production of 
wtAAV2(9) vectors 
Grimm et al.178 
(Dr. R. Sprengel, MPI) 
pMT-187-XX2 
(pXX2-187) 8.3 
Rep2/cap2mut, no ITRs, mutated HSPG binding site 
(R484E), used for production of AAV2 vectors with 
peptide display behind VP1 residue 588 
Michelfelder et al.202 
p5E18-VD2/9 7.3 Rep2/wtcap9, no ITRs, used for creation of p5E18-VD2/9-SfiI1759 Gao et al.
45 
p5E18-VD2/9-
SfiI1759 7.3 
Based on p5E18-VD2/9, rep2/cap9mut, used for 
production of AAV9 vectors with peptide display behind 
VP1-3 residue 589 
This study 
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dsAAV-CMV-EGFP 5.8 ITRs, CMV-promoter controlled EGFP, used for serotype-independent production of scAAV vectors Wu et al.
179 
dsAAV-CMVenh-
MLC260-EGFP 
6.0 
Based on dsAAV-CMV-EGFP, CMV core element 
replaced by the myosin light chain promoter 260 bp 
fragment (MLC260) 
Boecker et al.229 
dsAAV-CMV-
EGFP∆G67 5.8 
Based on dsAAV-CMV-EGFP, non-fluorescent EGFP due 
to G67-deletion within ORF This study 
dsAAV-CMVenh-   
163-EGFP 5.9 Based on dsAAV-CMVenh-MLC260-EGFP, MLC260 
promoter replaced with the 163/313 bp fragment from 
murine VE-cadherin promoter 
This study 
dsAAV-CMVenh-   
313-EGFP 6.1 This study 
pRSV-VP3co 5.3 
RSV-promoter controlled codon-optimized cap2 (VP3), 
used for production of serotype-independent transfer 
shuttle library particles 
Waterkamp et al.201 
pGA4 3.8 Contains a 975bp cap9mut-fragment harbouring 2 SfiI sites, used for creation of p5E18-VD2/9-SfiI1759 Geneart 
pSSV9 (pSub201) 8.3 
pEMBL(+) containing the entire AAV2 genome, 2 flanking 
XbaI sites for rep2/cap2 excision, used for creation of 
pKV-AAV9Lib 
Samulski et al.230 
pKV-AAV9Lib 8.3 Based on pSSV9, rep2/cap2 exchanged for rep2/cap9mut, used for creation of AAV9 library plasmid This study 
pEBFP-C1 4.6 CMV-promoter controlled EBFP reporter gene Clontech, 6070-1 
*All plasmids contain the bla-ORF providing ampicillin resistance to transformed E.coli, except pEBFP, which features 
the npt-ORF providing kanamycin resistance. 
 
 
II.A.4 Single nucleotides and oligonucleotides 
 
Single nucleotides  
Denotation Description Source, ordering number 
dNTPs dATP, dTTP, dGTP and dCTP mix, PCR grade (10 mM each) Invitrogen, 18427-013 
α-32P dCTP Deoxycytidine 5'' triphosphate, [α-32P] in 10 mM tricine (pH 7.6) Perkin Elmer, NEG013H250UC 
 
 
Primer for regular PCR 
Denotation Sequence (5' to 3') 
AAV9cap-F CCA TAC CCG GAA GAA TTC CTT GGT TTT G 
AAV9cap-F2 GGA GGA TCC GCA GGT ACA GGT GTG T 
AAV9cap-R GCT TGA TGA ATT CTG GAC CTG CTA TGG C 
VE-Cad-R AAA AAG CCT AGT CTG TCC AGG GCC GAG 
VE-Cad-F1 AAA AGG ACC CCT GCA GGC AGC TCA CAA A 
VE-Cad-F2 AAA AGG ACC CAG CTT AGA GCC CCC ACA G 
 
 
Primer for plasmid library generation 
Denotation Sequence (5' to 3') 
NNK-Oligo CAG TCG GCC AAG CAG GC (NNK)7 GCC CAG GCG GCT GAC GAG 
NNK-Oligo-2nd CTC GTC AGC CGC CTG G 
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Primer for qRT-PCR  
Denotation Sequence (5' to 3') 
CMV-F TGC CCA GTA CAT GAC CTT ATT G 
CMV-R GAA ATC CCC GTG AGT CAA ACC 
CMV-P (probe) 6-FAM – AGT CAT GCG TAT TAC CAT GG – MGB 
Rep-F AAG TCC TCG GCC CAG ATA GAC 
Rep-R CAA TCA CGG CGC ACA TGT 
Rep-P (probe) 6-FAM – TGA TCG TCA CCT CCA ACA – MGB 
 
 
Primer for sequencing 
Denotation Sequence (5' to 3') 
AAV2cap-588ins GTG TTT AAG TCC GAA TCC AC 
AAV9cap-589ins CAA ACA AGG AAC TGG AAG AG 
EGFP-N Clontech, 6479-1 
 
 
Primer for PCR-mutagenesis 
Denotation Sequence (5' to 3') 
EGFP∆G67-F GAC CAC CCT GAC CTA CGT GCA GTG CTT CAG GGC G 
EGFP∆G67-R GCG GCT GAA GCA CTG CAC GTA GGT CAG GGT GGT C 
IVM-F CAA TTA CAG ATT ACG AGT CAG ATA TCG TGC CAA TGG GGC GAG 
IVM-R CTC GCC CCA TTG GCA CGA TAT CTG ACT CGT AAT CTG TAA TTG 
 
 
Oligonucleotides for AAV2 peptide insertion 
Orientation Linker 5’ Sequence (5’ to 3’) Linker 3’ 
Forward AGGC AAT GAT GTT AGG GCG GTG AGT GCCCAGG 
Reverse GGGC ACT CAC CGC CCT AAC ATC ATT GCCTCTC 
Peptide  N D V R A V S  
Forward AGGC TCT CTG AGG TCG CCT CCG TCA GCCCAGG 
Reverse GGGC CGA CGG AGG CGA CCT CAG AGA GCCTCTC 
Peptide  S L R S P P S  
Forward AGGC CGT GGT GAT TTG CGT GTG TCT GCCCAGG 
Reverse GGGC AGA CAC ACG CAA ATC ACC ACG GCCTCTC 
Peptide  R G D L R V S  
Forward AGGC AAT TTG CAT TCT CCT CCG GCT GCCCAGG 
Reverse GGGC AGC CGG AGG AGA ATG CAA ATT GCCTCTC 
Peptide  N L H S P P A  
Forward AGGC AAT TCC GTC TCC TCC GCC TCC GCCCAGG 
Reverse GGGC GGA GGC GGA GGA GAC GGA ATT GCCTCTC 
Peptide  N S V S S A S  
Forward AGGC AAT TCC TCC AGA GAT CTG GGG GCCCAGG 
Reverse GGGC CCC CAG ATC TCT GGA GGA ATT GCCTCTC 
Peptide  N S S R D L G  
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Oligonucleotides for AAV9 peptide insertion 
Orientation Linker 5’ Sequence (5’ to 3’) Linker 3’ 
Forward AGGC AAT GAT GTT AGG GCG GTG AGT GCCCAGG 
Reverse GGGC ACT CAC CGC CCT AAC ATC ATT GCCTGCT 
Peptide  N D V R A V S  
Forward AGGC TGG CTC ACC CTG GTC GGG AAG GCCCAGG 
Reverse GGGC CTT CCC GAC CAG GGT GAG CCA GCCTGCT 
Peptide  T E W D Q P F  
Forward AGGC CGT GGT GAT TTG CGT GTG TCT GCCCAGG 
Reverse GGGC AGA CAC ACG CAA ATC ACC ACG GCCTGCT 
Peptide  R G D L R V S  
Forward AGGC AAT AAT GTT CGG GGG TTT GTG GCCCAGG 
Reverse GGGC CAC AAA CCC CCG AAC AAT AAT GCCTGCT 
Peptide  N N V R G F V  
Forward AGGC TCT CTG AGG TCG CCT CCG TCA GCCCAGG 
Reverse GGGC CGA CGG AGG CGA CCT CAG AGA GCCTGCT 
Peptide  S L R S P P S  
Forward AGGC TCT ATT AGG TCT CCT CCT TCT GCCCAGG 
Reverse GGGC AGA AGG AGG AGA CCT AAT AGA GCCTGCT 
Peptide  S I R S P P S  
Forward AGGC AAT TTT ACT CGG TTG TCG GCG GCCCAGG 
Reverse GGGC CGC CGA CAA CCG AGT AAA ATT GCCTGCT 
Peptide  N F T R L S A  
Forward AGGC CGT GGG GAT TTT AGG GTT GGT GCCCAGG 
Reverse GGGC ACC AAC CCT AAA ATC CCC ACG GCCTGCT 
Peptide  R G D F R V G  
Forward AGGC AAT TTG CAT TCT CCT CCG GCT GCCCAGG 
Reverse GGGC AGC CGG AGG AGA ATG CAA ATT GCCTGCT 
Peptide  N L H S P P A  
Forward AGGC CCT TCT CTG CCT TCT AGG TCT GCCCAGG 
Reverse GGGC AGA CCT AGA AGG CAG AGA AGG GCCTGCT 
Peptide  P S L P S R S  
Forward AGGC TCT GAT TTG CGT CGT GGT GTG GCCCAGG 
Reverse GGGC CAC ACC ACG ACG CAA ATC AGA GCCTGCT 
Peptide  S D L R R G V  
Forward AGGC AAT TCC GTC TCC TCC GCC TCC GCCCAGG 
Reverse GGGC GGA GGC GGA GGA GAC GGA ATT GCCTGCT 
Peptide  N S V S S A S  
Forward AGGC AAT TCC TCC AGA GAT CTG GGG GCCCAGG 
Reverse GGGC CCC CAG ATC TCT GGA GGA ATT GCCTGCT 
Peptide  N S S R D L G  
 
 
 
 
 
 
 38 
II.A.5 Enzymes 
 
Denotation Source, ordering number 
Antarctic phosphatase (supplied w/ 10x Antarctic phosphatase reaction buffer) NEB, M0289S 
Benzonase Sigma-Aldrich, E1014-25KU 
Dispase Invitrogen, 17105041 
Restriction enzymes Roche, NEB, Fermentas 
T4 DNA ligase (supplied w/ 10x T4 DNA ligase reaction buffer) NEB, M0202S 
T4 DNA polymerase (supplied w/ 10x NEBuffer 2 and 100x BSA) NEB, M0203S 
Taq DNA polymerase (supplied w/ 10x TaqBuffer) NEB, M0273G 
TaqMan Universal PCR Master Mix Applied Biosystems, 4304437 
 
 
II.A.6 DNA standards and loading buffers 
 
Denotation Source, ordering number 
Gel Loading Dye Blue (6x) NEB, B7021S 
O'RangeRuler 50 bp DNA Ladder Fermentas, SM0613 
O'RangeRuler 1 kb DNA Ladder Plus Fermentas, SM1343 
 
 
II.A.7 Antibodies 
 
Denotation Description Source, ordering number 
ADK9 WtAAV9 capsid binding murine monoclonal antibody Prof. Dr. J. A. Kleinschmidt, DKFZ 
IVIG Human pooled intravenous immunoglobulin, 10%, Gamunex R Talecrid Biotherapeutics, 80A4895 
PECAM-1 FITC-conjugated mouse anti-human monoclonal antibody Lifespan Biosciences, LS-C43861 
 
 
II.A.8 Viruses 
 
Denotation Description Source, ordering number 
Ad5 Human wild type Adenovirus 5 Laboratoire de Thérapie Génique (II.A.15) 
 
 
II.A.9 Kits 
 
Denotation Source, ordering number 
DNeasy Blood & Tissue Kit Qiagen, 69504 
Mini Quick Spin Oligo Columns Roche, 11814397001 
PeqGOLD Plasmid Miniprep Kit I Peqlab, 12-6942-02 
QIAamp MinElute Virus Spin Kit Qiagen, 57704 
QIAGEN HiSpeed Plasmid Maxi Kit Qiagen, 12663 
QIAGEN Plasmid Giga Kit Qiagen, 12191 
QIAGEN Plasmid Mega Kit Qiagen, 12183 
QIAquick Gel Extraction Kit Qiagen, 28704 
QIAquick Nucleotide Removal Kit Qiagen, 28304 
QIAquick PCR Purification Kit Qiagen, 28104 
QuickChange II Site-Directed Mutagenesis Kit Stratagene, 200523-5 
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Random Primed DNA Labelling Kit Roche, 11004760001 
Rapid DNA Ligation Kit Fermentas, K1421 
Sequenase DNA Sequencing Kit 2.0 GE Healthcare, E70775Y 
TOPO TA Cloning Kit for Sequencing Invitrogen, K4595-01 
 
 
II.A.10 Buffers and solutions 
 
Denotation* Description Source, ordering number 
Annealing buffer 10 mM TRIS, 150 mM NaCl in ddH2O (pH not adjusted)  
CaCl2 (0.1M) 14.7 g CaCl2 ad 1 L ddH2O  
CaCl2/glycerol 14.7 g CaCl2, 16.1 ml 87% glycerol, ad 1 L ddH2O  
Denaturation buffer 1.5 M NaCl, 0.5 M NaOH in ddH2O  
Elution buffer 10 mM TRIS in ddH2O (adjust to pH 9 with 1 N HCl)  
EDTA (0.2 M) 58.45 g EDTA ad 1 L ddH2O  
EtOH (70%) 70% v/v ethanol in ddH2O  
HCl (40 mM) 40 ml 1 N HCl ad 1 L ddH2O  
HBSS Hank's buffered salt solution, w/o Ca2+ and Mg2+ Invitrogen, 14175 
HBSS Hank's buffered salt solution, w/ Ca2+ and Mg2+ Invitrogen, 14065 
HSNH 10 mM HEPES, 10 mM NaN3, 2% v/v NCS in 1x HBSS  
Hybridisation buffer 7% SDS, 125 mM Na2HPO4•2H2O, 125 mM NaH2PO4, 250 mM 
NaCl, 1 mM EDTA, 45% formamide in ddH2O (dissolve under 
stirring at 37°C) 
 
MgCl2 (0.1 M) 20.33 g MgCl2 ad 1 L ddH2O  
MNT 50 mM TRIS, 150 mM NaCl, 5 mM MgCl2 in ddH2O (adjust to pH 
8.5 with 1 M HCl, add 1x Protease Inhibitor Mix HP prior to use) 
 
NaCl (0.3M) 17.53 g NaCl ad 1 L ddH2O  
NaOAc (3 M) 408.24 g NaOAc ad 1 L ddH2O  
NaOH (2 M) 80 g NaOH pellets ad 1 L ddH2O  
NCS Newborn calf serum Sigma-Aldrich, N4762 
Neutralization buffer 0.5 M TRIS, 0.3 M Na3C6H5O7•2H2O, 3 M NaCl in ddH2O (adjust 
pH to 7 with 1 N HCl) 
 
Iodixanol (60%) OptiPrep Axis Shield, 1114542 
PBS-MK 1 mM MgCl2, 2.5 mM KCl in 1x PBS  
PBS-MKN 1 M NaCl in 1x PBS-MK  
PEI (7.5 mM) 0.323 g polyethyleneimine ad 1 L ddH2O See also II.E.1 
Phenol red (0.07%) 0.07 g phenol red ad 100 ml ddH2O  
SSC (20x) 3 M NaCl, 0.3 M Na3C6H5O7•2H2O in ddH2O (adjust pH to 7 with 
1M NaOH)  
Sodium heparin solution 280 mg/ml sodium heparin in ddH2O (42.000 IU/ml)  
Staining solution 1 µg/ml propidium iodide in 1x HSNH  
TAE 4.84 g TRIS, 0.37 g EDTA, 1.14 ml acetic acid, ad 1 L ddH2O 
(pH not adjusted) 
 
TE 1 mM TRIS, 0.01 mM EDTA, in ddH2O (adjust pH to 8 with 1 N 
HCl) 
 
TRITC-lectin solution 20 µg/ml TRITC-lectin in 1x HBSS w/ Ca2+ and Mg2+  
Washing solution 1x SSC, 0.1% SDS in ddH2O  
X-gal 40 mg/ml BCIG in DMF  
*All buffers and solutions are ready-to-use (1x) except when otherwise indicated. 
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II.A.11 Chemicals 
 
Denotation Description Source, ordering number 
Acetic acid Glacial Merck, 1.00063.1011 
Agar  Gerbu, 1340 
Agarose  Sigma-Aldrich, A9539 
Ampicillin  Sigma-Aldrich, A0166 
Bacto Tryptone  BD Biosciences, 0123-17-3 
BCIG (X-gal) 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside Roche, 10651745001 
CaCl2•2H2O Calcium chloride dihydrate Sigma, C7902 
Cryo-embedding compound Tissue-Tek O.C.T Sakura Finetek 
ddH2O Double-demineralised water (ultrapure water system)  
DMF N,N-dimethylformamide Sigma-Aldrich, 40250 
EDTA Disodium ethylenediamine tetraacetate Gerbu, 1034 
EtBr (ethidium bromide) 3,8-diamino-5-ethyl-6-phenylphenanthridiniumbromid, 1% Roth, 2218.2 
EtOH Ethanol, 99.8% VWR, 20821.321 
Formamide  Roth, 6749.1 
Gelatin from bovine skin Type B Sigma-Aldrich, G9391 
Glycerol 87% Applichem, A3561 
HCl Hydrochloric acid, 1N VWR, 1.09057.1000 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid Roth, 9105.2 
Kanamycin sulphate  Roche, 70162526 
KCl Potassium chloride Roth, 6781.1 
KH2PO4 Potassium dihydrogen phosphate Roth, 3904.1 
MgCl2•6H2O Magnesium chloride hexahydrate Merck, 1.05833.1000 
Mounting medium with DAPI Vectashield Hard Set  Vector Laboratories 
Sodium heparin  Neolab, 10475.0001 
Na2HPO4•2H2O Disodium hydrogen phosphate dihydrate Roth, T877.1 
Na3C6H5O7•2H2O Trisodium citrate dihydrate Sigma-Aldrich, 71405 
NaCl Sodium chloride VWR, 27810.364 
NaH2PO4 Sodium dihydrogen phosphate dihydrate Merck, 1.06342.1000 
NaN3 Sodium azide Serva, 30175 
NaOAc•3H2O Sodium acetate trihydrate Roth, 6779.1 
NaOH Sodium hydroxide pellets Roth, 6771 
PEI Polyethyleneimine Polysciences, 23966 
Phenol red Phenolsulphonphthalein Merck 137038 
Propidium iodide  Sigma-Aldrich, P4170 
Protease-Inhibitor Mix HP 100x Serva, 39106 
SDS Sodium dodecyl sulphate Gerbu, 1212 
TRIS Tris-(hydroxymethyl)-aminomethane Roth, 5429.3 
TRITC-lectin Lectin from Bandeireia simplicifolia, TRITC conjugated Sigma-Aldrich, L5264 
Yeast extract  Gerbu, 1133 
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II.A.12 Disposables 
 
Denotation Type Source, ordering number 
20G x 1½ needles Microlance 3 BD Biosciences 
384-well plate MicroAmp Optical Applied Biosystems 
96-well microtitre plates with agar  GATC 
Adhesive film MicroAmp Optical Applied Biosystems 
Cell culture dishes 56.7/145 cm2 Thermo Scientific 
Cell culture flasks 25/75/175 cm2 Greiner Bio-One 
Cell culture plates 6/12/96-well Thermo Scientific 
Cellulose chromatography paper Whatman Whatman 
Centrifuge tubes Falcon, 15/50 ml BD Biosciences 
Conical-bottom tubes 4.5 ml Greiner Bio-One 
Cryogenic vials CryoTube, 1.0/1.8/3.6/4.5 ml Thermo Scientific 
Cryomolds Tissue-Tek, intermediate Sakura Finetek 
Electroporation cuvettes GenePulser/MicroPulser, 0.2 cm gap Bio Rad 
Fat pen Dako pen Dako 
Glass bottles 50-2500 ml Brand 
Hybridisation transfer membrane GeneScreen Plus Perkin Elmer 
Large centrifuge tubes 500 ml Corning, 431123 
Microscope slides + coverslips Superfrost plus Thermo Scientific 
Microtome blades MX35 Premier+, 34°/80 mm Thermo Scientific 
Miniprep tubes 14 ml, round-bottom, dual-position snap cap BD Biosciences 
Pasteur pipettes  WU 
Pipette tips Micro/200/1000 µl Greiner Bio-One 
Reaction tubes 0.5/1.5/2 ml, safe-lock Eppendorf 
Round-bottom tubes 5 ml BD Biosciences, 352008 
Screw-cap tubes 1.5 ml, conical Sarsted 
Semi-micro cuvettes 3 ml Greiner Bio-One 
Serological pipettes Falcon, 5/10/25 ml BD Biosciences 
Sterile filter 0.2 µm pore size Renner 
Syringes 
2/5 ml BD Biosciences 
1 ml Soft-Ject Luer HSW 
Tissue culture chambers CellSTACK, 5/10-stack Corning 
U-bottom cell culture plates 96-well Greiner Bio-One 
Ultracentrifuge tubes Quick-Seal, 13.5/39 ml Beckman Coulter 
 
 
II.A.13 Laboratory equipment 
 
Denotation Type Source, ordering number 
Cell counting chamber Neubauer Brand 
Cell culture incubator B 5601 EC-CO2 Thermo Scientific 
Contamination monitor LB 122 C Berthold 
Crosslinker UV Stratalinker 1800 Stratagene 
Cryostat CM3050 S with MX35 Premier+ microtome blades Leica Microsystems 
Cryostorage system K series Tec-Lab 
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Culture myograph  DMT 
Electroporation instrument Gene Pulser Xcell Bio Rad 
Floor centrifuge RC 5C Plus (with GS3 rotor) Sorvall 
Flow cytometer FACSCalibur BD Biosciences 
Fluorescence microscopes DM IL (with incident light fluorescence unit and 
DFC 350 FX monochrome camera) 
DM RD (with incident light fluorescence unit and 
Hamamatsu ORCA 100 camera) 
Leica Microsystems 
Freezing container Cryo 1°C, PC Thermo Scientific 
Gel documentation system ImageQuant 100 Amersham Biosciences 
Gel electrophoresis chambers Horizontal, mini/midi, with combs Peqlab 
Hybridisation bottles BigShot III Fisher Scientific 
Hybridising furnace 400 HY-E Bachofer 
HybriDot manifold  Whatman 
Light microscope CK 2 Olympus 
Micro-volume spectrophotometer NanoDrop ND1000 Peqlab 
Mobile pipetor for serological pipettes Pipetboy Acu Integra 
Molecular imager Storm 860 Molecular Dynamics 
Multichannel pipette Transferpette (8/12 channel) Brand 
Pipettes Pipetman, 2/20/200/1000µl Gilson 
Power supply EPS 600 Amersham Biosciences 
Preparative ultracentrifuge Optima LE-80k Beckmann Coulter 
Radioactivity counter QC 2000 Bioscan 
Real-Time PCR System 7300 Fast Applied Biosystems 
Seal former Sealing of ultracentrifuge tubes Beckmann Coulter 
Spectrophotometer Ultrospec 3100pro UV/visible GE Healthcare 
Storage phosphor screens  Molecular Imaging 
Table-top centrifuge (large) 5810 R (with A-4-62 rotor) Eppendorf 
Table-top centrifuge (small) Biofuge Fresco Heraeus 
Thermal cycler GeneAmp 9700 (96-well) Applied Biosystems 
Tube sealer Sealing of ultracentrifuge tubes Beckman Coulter 
Ultracentrifuge rotors and spacers 50.2/70.1Ti Beckman Coulter 
Ultrapure water system Milli-Q Biocel A10 Millipore 
Ultrasound water bath Sonorex TK 30 Bandelin 
Vacuum concentrator  Bachofer 
 
 
II.A.14 Software 
 
Denotation Application Source, ordering number 
Adobe CS5 Graphic processing Adobe Systems 
CellQuest Pro 6.0 Acquisition of flow-cytometry data BD Biosciences 
FlowJo 7.6 Analysis of flow-cytometry data Tree Star 
ImageQuant 4.1 Scanning of storage phosphor screens Molecular Dynamics 
Geneious 5.3 Sequence alignment Biomatters 
ImageQuant Capture 1.0.1 Gel documentation GE Healthcare 
PyMol 1.4 Molecular visualisation www.jalview.org 
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OpenOffice 3.2 Text processing Oracle 
Primer X Mutagenic primer design http://www.bioinformatics.org/primerx 
SDS 1.4 Analysis of qRT-PCR data Applied Biosystems 
SigmaPlot 10.0 Statistical evaluation of data Systat Software 
 
 
II.A.15 Company affiliations 
 
Company name City*  Company name City* 
Adobe Systems München  Invitrogen Karlsruhe 
Amersham Biosciences Freiburg  Laboratoire de Thérapie Génique Nantes 
Applichem Darmstadt  Leica Microsystems Wetzlar 
Applied Biosystems Darmstadt  Lifespan Biosciences Eching 
Axis-Shield Heidelberg  Merck Darmstadt 
Bachofer Burladingen  Molecular Dynamics Krefeld 
Bandelin Berlin  MPI for Medical Research Heidelberg 
BD Biosciences Heidelberg  NEB (New England Biolabs) Frankfurt am Main 
Beckman Coulter Krefeld  Neolab Heidelberg 
Berthold Bad Wildbad  Oligo Synthesis Core Facility University of Freiburg 
Biomatters Auckland  Olympus Hamburg 
Biorad München  Oracle München 
Bioscan Paris  PAA Cölbe 
Brand Wertheim  Peqlab Erlangen 
Braun Melsungen  Perkin Elmer Rodgau 
Charles River Laboratories Sulzfeld  Polysciences Heidelberg 
Clontech Heidelberg  Promocell Heidelberg 
Corning München  Qiagen Hilden 
Dako Hamburg  Renner Dannstadt 
DMT Copenhagen  Roche Mannheim 
Eurofins MWG Ebersberg  Roth Karlsruhe 
Fermentas St. Leon Roth  Sakura Finetek Staufen im Breisgau 
Fisher Scientific Schwerte  Sarstedt Nümbrecht 
GATC Konstanz  Sigma-Aldrich Hamburg 
GE Healthcare München  Stratagene Waldbronn 
Geneart Regensburg  Systat Software Erkrath 
Gerbu Heidelberg  Talecrid Biotherapeutics Frankfurt am Main 
Gilson Limburg-Offheim  Thermo Fisher Langenselbold 
Greiner Bio-One Essen  Thermo Scientific  Schwerte 
Hamamatsu Herrsching  Tree Star Olten 
Heraeus Hanau  Vector Laboratories Eching 
HSW Tuttlingen  WU Mainz 
Tec-Lab Idstein  VWR Darmstadt 
Integra Zürich  Whatman Dassel 
*All companies are located in Germany, except Bioscan or Laboratoire de Thérapie Génique (France), Integra 
(Switzerland), Biomatters (New Zealand) and DMT (Denmark). 
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II.B Molecular biological methods 
 
II.B.1 Plasmid and virus DNA purification 
 
Bacterial cells were harvested by repeated centrifugation in suitable plastic vessels (5000 x g, 15 
min, 4°C) until the entire culture was processed and plasmid DNA was purified by QIAGEN 
Plasmid Purification Kits according to manual instructions (Table II.B.1-1). Elution of DNA took 
place in a suitable amount of elution buffer or ddH2O. 
 
Table II.B.1-1: Bacterial culture volumes and corresponding DNA purification kits 
Culture volumes Employed kit User guide 
1 ml PeqGOLD Plasmid Miniprep Kit I 07/2006, A. High copy-number plasmids, steps 2-9 
200 ml QIAGEN HiSpeed Plasmid Maxi Kit 11/2005, steps 4-21, guideline in red 
1000 ml QIAGEN Plasmid Mega Kit 11/2005, pages 25-28, steps 4-15, guideline in blue 
5000 ml QIAGEN Plasmid Giga Kit 11/2005, pages 25-28, steps 4-15, guideline in red 
 
 
Purification of plasmid DNA previously exposed to enzymatic digestion (Chapter II.B.2), 
electrophoretic separation (Chapter II.B.6) or PCR (Chapter II.B.8) was done with QIAquick kits 
noted in Table II.B.1-2 according to manufacturer's recommendations. Unless otherwise specified, 
elution from spin columns occurred in 30 µl ddH2O. If the amount of DNA to be purified exceeded 
the recommended amounts per column, DNA samples were separated on several columns. 
 
Table II.B.1-2: DNA purification kits used for plasmid DNA fragment purification 
DNA source Employed kit User guide (QIAquick Spin handbook 03/2008) 
Enzymatic digestion QIAquick Nucleotide Removal Kit pages 23-24, steps 1-7 
PCR QIAquick PCR Purification Kit pages 21-22, steps 1-7 
Electrophoretic separation QIAquick Gel Extraction Kit pages 27-29, steps 2-11 
 
 
Viral DNA was purified from capsid particles obtained by cell lysis (Chapter II.E.1) or density 
gradient centrifugation (Chapter II.E.2) with the QIAamp MinElute Virus Spin Kit (04/10, all steps) 
and DNA was eluted in 60 µl ddH2O. By purifying 6E+8 gc/sample, a final concentration of ~1E+7 
gc/µl or ~55 pg/µl DNA was obtained. 
 
 
II.B.2 Restriction digestion of plasmid DNA 
 
All restriction enzymes were purchased from Roche, NEB or Fermentas and digestion was carried 
out in corresponding buffers supplied by the manufacturer at enzyme-specific temperatures for 2 h, 
unless otherwise noted. In case double-digestion was required and enzymes were not compatible 
with the same buffer, DNA was purified with the QIAquick PCR Purification Kit (Chapter II.B.1) 
after the first digestion reaction. Success of digestion was controlled by gel electrophoresis 
(Chapter II.B.6) and, if required, repeated by adjusting amounts of enzyme, amounts of DNA or 
incubation time. 
 45 
A general protocol of a restriction digestion reaction is given in Table II.B.2. If FastDigest enzymes 
(Fermentas) were used, reaction parameters were set up according to manufacturer's 
recommendations applying doubled incubation times. 
 
Table II.B.2: Protocol for DNA restriction digestion 
Volume Final concentration Reagent 
Variable Max. 10 µg DNA 
5 µl 1x 10x enzyme buffer 
5 µl 1x 100x BSA, 1:10 pre-diluted in ddH2O* 
Variable 5-20 U/µg DNA Restriction enzyme 
Ad 50 µl  ddH2O 
*BSA-addition was only required for certain NEB enzymes 
 
 
II.B.3 Chemical modification of free DNA ends 
 
To enable blunt end ligation of incompatible cohesive DNA ends, a fill-in of 5' or removal of 3' 
overhangs was performed using the T4 DNA polymerase. The reaction (Table II.B.3-1) was 
incubated for 15 min at 12°C and was stopped by adding 1 µl 0.2 M EDTA and heating to 75°C for 
20 min. DNA fragments were then purified with the QIAquick Nucleotide Removal Kit (Chapter 
II.B.1). 
 
Table II.B.3-1: Protocol for T4 DNA polymerase-mediated DNA-blunting 
Volume Final concentration Reagent 
Variable Variable Plasmid backbone 
5 µl 100 µM 10 mM dNTP, 1:100 pre-diluted in ddH2O 
5 µl 1x 10x NEBuffer 2 
5 µl 1x 100x BSA, 1:10 pre-diluted in ddH2O 
1 µl 3 U/µg DNA T4 DNA polymerase 
Ad 50 µl  ddH2O 
 
 
To reduce vector re-ligation 5' phosphate groups from plasmid DNA backbones were removed 
using Antarctic phosphatase. The reaction (Table II.B.3-2) was allowed to take place 30 min at 
37°C, followed by an inactivation step at 65°C for 5 min. Dephosphorylated DNA fragments were 
purified with the QIAquick Nucleotide Removal Kit (Chapter II.B.1). 
 
Table II.B.3-2: Protocol for dephosphorylation of DNA ends 
Volume Final concentration Reagent 
Variable Variable Plasmid backbone 
5 µl 1x 10x Antarctic phosphatase reaction buffer 
1 µl 5 U/µg DNA Antarctic phosphatase 
Ad 50 µl  ddH2O 
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II.B.4 Ligation of plasmid DNA 
 
II.B.4.1 General ligation protocol 
 
Ligation of DNA fragments with cohesive or blunt ends was performed at a fivefold molar excess of 
insert-to-backbone using either the Rapid DNA Ligation Kit (06/2004, manual page 3, steps 1-3) or 
the protocol described in Table II.B.4.1 with an o/n incubation at 16°C. 
 
Table II.B.4.1: Protocol for DNA ligation 
Volume Final concentration Reagent 
Variable 100 ng Plasmid backbone 
Variable 5x molar excess Insert 
2.5 µl 1x 10x T4 DNA ligase reaction buffer 
1 µl 400 cohesive end units T4 DNA ligase 
Ad 25 µl  ddH2O 
 
 
II.B.4.2 Ligation of oligonucleotides into AAV2 or AAV9 plasmid backbones 
 
Complementary forward and reverse 32-mer oligonucleotides specified in Chapter II.A.4 were 
synthesized on a 0.01 µmol scale and HPSF-purified at Eurofins MWG. Reconstitution occurred in 
a ddH2O volume indicated by MWG to obtain a concentration of 100 pmol/µl. For insertion of 
oligonucleotides plasmids p5E18-VD-2/9-SfiI1759 or pMT-187-XX2 (Chapter II.A.3) were digested 
with 4 U/µg DNA SfiI for 4 h releasing a 15 bp DNA stuffer fragment that was separated from 
backbone DNA by gel electrophoresis (Chapter II.B.6). The plasmid backbone was recovered from 
preparative gel and DNA was purified with the QIAquick Gel Extraction Kit (Chapter II.B.1). Two µg 
each, forward and reverse oligonucleotides were mixed with annealing buffer ad 40 µl and 
annealing reaction was allowed to take place (95°C/5 min, 76°C/20 min and 37°C/20 min). Ligation 
of 100 ng SfiI-linearised plasmid backbones and 10 ng annealed oligonucleotides (23x molar 
excess) was done with the Rapid DNA Ligation Kit (Chapter II.B.4.1). Ligated plasmids were 
transformed into E. coli (Chapter II.C.2) and correct insertion of oligonucleotides was confirmed by 
sequencing of single clones (bacterial colonies) propagated by miniprep (Chapter II.C.2) using 
primers AAV2cap-588ins for AAV2 or AAV9cap-589ins for AAV9 constructs (Chapter II.A.4). 
 
 
II.B.5 Concentration of DNA 
 
Low DNA amounts of < 100 ng solved in ddH2O were concentrated in a vacuum concentrator until 
desired volume was attained. Low (high) DNA amounts solved in elution buffer were precipitated 
o/n (30 min) at -20°C (RT) with 0.1 volumes 3M NaOAc and 2.5 volumes 100% EtOH. DNA was 
pelleted and salts were removed by centrifuging once in presence of ice-cold (RT) 70% EtOH in a 
table-top centrifuge (13.000 x g, 15 min, 4°C). Ethanol traces were removed by aspiration and 
subsequent air-drying and DNA pellets were resuspended in desired volumes of elution buffer or 
ddH2O. 
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II.B.6 Gel electrophoresis of DNA 
 
Electrophoretic separation of DNA was done on agarose gels. As a rule, 0.8-2.5% gels were made 
to allow a proper separation of DNA fragments from 0.3-8 kb. Briefly, 0.8-2.5% w/v agarose was 
boiled in 1x TAE buffer, cooled to < 50°C under stirring and 2E-4 volumes EtBr solution were 
added. Gels were poured into gel electrophoresis chambers with appropriate combs, solidification 
was awaited and chambers were filled with 1x TAE. Blue Gel Loading Dye (Chapter II.A.6) was 1:6 
diluted in DNA samples and 5-10 µl (or up to 50 µl if preparative gels were made) were pipetted in 
a pocket. Five µl/pocket of O'RangeRuler DNA standards (Chapter II.A.6) covering the expected 
size range of the analysed DNA were applied and running conditions were set to 5 V/cm electrode 
distance and 1-2 h running time. Separated DNA fragments were analysed on an ImageQuant 100 
gel documentation system and, if necessary, DNA-bands were cut out from preparative gels with a 
scalpel and were purified (Chapter II.B.1). 
 
 
II.B.7 DNA quantification 
 
Concentration as well as purity of DNA amounts > 10 ng were determined with a NanoDrop 
ND1000 micro-volume spectrophotometer. The device was calibrated with 1.5 µl ddH2O and 1.5 µl 
DNA solution were measured versus solvent. DNA samples were regarded as pure when the 
260/280 nm ratio indicating protein contaminations exceeded 1.8. 
 
 
II.B.8 Polymerase Chain Reaction (PCR) 
 
II.B.8.1 Standard PCR 
 
Distinct DNA regions were amplified via PCR on a GeneAmp 9700 96-well thermal cycler. Table 
II.B.8.1 provides all information required to perform a standard PCR reaction. Depending on the 
amount of template DNA the total cycle number was varied between 25 and 35. 
 
Table II.B.8.1: Protocol for a standard PCR  
Volumes Final conc. Component Cycling steps Temperature (°C)/Time (s) 
2.5 µl 1x 10x standard Taq reaction buffer Initial denaturation 95/180 
0.5 µl 200 µM 10 mM dNTPs Denaturation 95/45 
0.5 µl 0.2 µM 10 µM forward primer Annealing 60/30 
0.5 µl 0.2 µM 10 µM reverse primer Elongation 72/90 
1 µl 0.05-10 ng Template DNA Final elongation 72/10 
0.125 µl 1.25 U Taq DNA polymerase Optional 4/∞ 
To 25 µl  ddH2O Total cycles 25-35 
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II.B.8.2 TaqMan quantitative real-time PCR (qRT-PCR) 
 
Prior to PCR amplification, 10 µl of iodixanol-purified virus or vector particles (Chapter II.E.2) or 10 
µl ddH2O as negative control were mixed with 10 µl TE buffer and 20 µl 2 M NaOH solution and 
were incubated for 30 min at 56°C to allow capsid disintegration. Neutralisation of pH occurred by 
addition of 960 µl 40 mM HCl solution. Plasmids containing rep (viral quantification) or CMV (vector 
quantification) sequences were quantified photometrically (Chapter II.B.7) and 1:10 serially diluted 
with ddH2O to create eight standard samples ranging from 3.5E+10 to 3.5E+3 plasmid copies per 
ml. A mastermix of 60 µl was prepared containing 40 µl TaqMan Universal PCR Master Mix, 2 µl 5 
µM probe, 2 µl 5 µM forward and reverse primer each (Chapter II.A.4) and 14 µl ddH2O. Ten µl 
standard dilution were combined with 60 µl mastermix and 3 x 20 µl/well were distributed on a 384-
well plate, allowing a triplicate quantification. Before onset of PCR the plasmid copies per well 
ranged from 1E+8 to 1E+1. An amount of 6.7 µl from samples were quantified in duplicate by 
adding 40 µl mastermix and distributing 2 x 20 µl/well. The reaction plate was covered with an 
adhesive film to avoid sample evaporation and was centrifuged (400 x g, 5 min, RT) to remove air 
bubbles from well bottom. The PCR reaction was run on a 7300 Fast Real-Time PCR System with 
conditions set to an unique 2 min step at 50°C, an initial denaturation step at 95°C for 10 min, 
followed by 40 cycles of denaturation (95°C, 15 min) and annealing/elongation (60°C, 1 min). 
Calculation of titres occurred with SDS software by setting the threshold at the beginning of the 
linear phase, where exponential PCR amplification is close to theoretical 2n. A total dilution factor 
of 3.5E+4 was multiplied to the quantified viral genomes/well. 
 
 
II.B.8.3 PCR-mediated in vitro-mutagenesis of DNA 
 
Manipulation of DNA sequences was performed using the QuikChange II Site-Directed 
Mutagenesis Kit (revision #064001d, page 8/step 3 to page 10/step 2) with forward and reverse 
primers (Chapter II.A.4) designed with Primer X software. Five µl PCR product were transformed 
into E.coli as described in the manual of the kit, and grown colonies raised by miniprep (Chapter 
II.C.2) were sequenced using sequencing primers (Chapter II.A.4) to confirm successful 
manipulation. More detailed information is provided in Chapters II.E.4.1 and II.F.5. 
 
 
II.C. Microbiological methods 
 
II.C.1 Propagation of Subcloning Efficiency DH5α Competent Cells 
 
Sterile solutions and working environment were required since antibiotics were omitted at any time. 
A 5 ml pre-culture containing LB-medium was inoculated using 2.5 µl Subcloning Efficiency DH5α 
Competent E.coli (Chapter II.A.1) thawed on ice. After an o/n incubation in miniprep tubes (150-
200 rpm, 37°C), 1 ml pre-culture was used to inoculate a 250 ml main culture. 
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The main culture was maintained at 37°C until an OD600 (see Chapter II.C.2) of 0.5 – 0.6 and was 
cooled on ice for 10 min prior to centrifugation (3000 x g, 5 min, 4°C) in 50 ml centrifuge tubes. 
The pellet was resuspended in 50 ml ice-cold 0.1 M MgCl2 solution, centrifuged again, 
resuspended in 50 ml ice-cold 0.1 M CaCl2 solution and incubated for 20 min on ice. After another 
centrifugation step the pellet was carefully resuspended in 5 ml ice-cold 0.1 M CaCl2/glycerol 
solution and cells were stored in 100 or 200 µl aliquots at -80°C. 
 
 
II.C.2 Transformation and maintenance of bacterial cells 
 
All incubation steps involving bacterial growth were carried out at 37°C. Liquid cultures were 
vigorously agitated (150-200 rpm) in vessels 4x larger than the culture volume to ensure proper 
aeration. For transformation, Subcloning Efficiency DH5α Competent Cells (Chapter II.A.1) were 
thawed on ice, a 50 µl aliquot was mixed with 25 ng (100 ng) untreated (ligated) plasmid DNA in a 
reaction tube and was incubated for 20-30 min on ice. Heat-shock treatment occurred for 90 s at 
42°C and was stopped by cooling down on ice for 2-3 min. Five hundred µl SOC medium pre-
warmed to RT were added, bacterial suspension was transferred into a miniprep tube and the 
sample was incubated for 45 min to initiate expression of ampicillin/kanamycin resistance. 
Depending on the source, 100 µl (untreated plasmid) or 200 µl (ligated plasmid) bacterial 
suspension were spread on LB-amp/kana agar plates (Chapter II.A.2) and incubated o/n to allow 
colony formation. A 5 ml LB-amp/kana pre-culture was inoculated with a single bacterial colony 
and incubated in a miniprep tube o/n. For preparation of smaller DNA amounts (miniprep), 1 ml 
pre-culture was purified with the PeqGOLD Plasmid Miniprep Kit I (Chapter II.B.1). If higher 
amounts of plasmid DNA were required, 200 ml (maxiprep), 1 L (megaprep) or 5 L (gigaprep) LB-
amp/kana main cultures were inoculated with 0.001 volumes of pre-culture and were raised o/n. 
For growth control, 100 µl aliquots were 1:10 diluted with fresh LB-medium and optical density was 
measured versus fresh medium at OD 600 nm (OD600) in semi-micro cuvettes with a 
spectrophotometer. Harvesting of bacterial cells occurred at OD600 values of 2.5-3. 
 
 
II.D Cytological methods 
 
II.D.1 Cell maintenance 
 
II.D.1.1 Primary cells 
 
Primary cells (Chapter II.A.1) are characterized by a limited number of cellular divisions and may 
experience different biochemical variations upon prolonged in vitro propagation. In order to largely 
avoid this drawback and at the same time to obtain high cellular yields, primary cells were first 
subjected to expansion until fourth passage and were then cryo-preserved in aliquots of 5E+5 or 
1E+6 cells. Therefore, experiments involving these cell types were conducted with cells in 
passages 4 through 8. 
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Cryo-preserved HCAEC or HCASMC were purchased from Promocell, while HUVEC were freshly 
isolated from umbilical veins (Chapter II.F.7). All solutions required for cell maintenance were pre-
warmed to 37°C, except the Trypsin/EDTA solution from the DetachKit, which was allowed to 
reach RT only. Cell culture vessels and media volumes are shown in Table II.D.1.2. 
 
The expansion phase was initiated by fast thawing (water bath, 37°C) and seeding at a density of 
7000 cells/cm2 in appropriate ready-to-use cell culture medium (Chapter II.A.2) in a 75 cm2 cell 
culture flask. For HUVEC propagation, flasks were pre-coated with 2% gelatine solution for 5 min 
at 37°C followed by rinsing twice with 1x PBS. All incubation steps occurred in a cell culture 
incubator under standard conditions (37°C, 5% CO2-atmosphere, 95% rel. hum.) with a medium 
exchange after 24 h, then every other day. Growth of cells was monitored under a light microscope 
and upon 70-80% confluence, passaging took place. Cells were rinsed once with HepesBSS, 
detached with Trypsin/EDTA solution and trypsin reaction was neutralized with TNS (all from 
DetachKit). Cells were transferred to 50 ml centrifuge tubes and pelleted at 220 x g for 4 min at 
RT, supernatant was removed and re-suspension and dilution was done with ready-to-use cell 
culture medium. If determination of cell number was required, 10 µl of resuspended cells were 
mixed 1:1 with trypan blue solution, incubated for 1 min and counted in a cell counting chamber, 
whereas blue stained (= dead) cells were not considered. Further expansion of cells was 
performed in 175 cm2 flasks with seeding densities of 7000 cells/cm2. For cryo-preserving, 5E+5 or 
1E+6 cells were resuspended in 0.5 ml and 1 ml 4°C CryoSFM (Chapter II.A.2), respectively, were 
transferred in cryogenic vials and were gradually cooled (-1°C/min) to -80°C in a freezing container 
o/n. For long-term storage vials were placed in a liquid nitrogen (LN2) cryostorage system. 
 
 
II.D.1.2 Immortalized cells 
 
Passaging of any cell line used in this study (Chapter II.A.1) occurred by default upon reaching 
~80% confluence with all solutions pre-warmed to 37°C (see also Table II.D.1.2). Briefly, cell 
culture medium was removed, cell monolayers were rinsed once with 1x PBS and detached with 
trypsin. Trypsin-neutralization occurred by adding respective ready-to-use cell culture medium and 
pelleting, re-suspension, counting and cryo-preserving was done as described in Chapter II.D.1.1. 
Depending on the cell line and generation time dilutions from 1:5 to 1:15 of ~80% confluent cells 
were seeded in new cell culture flasks. 
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Table II.D.1.2: Volumes1 of media and solutions used per cell culture vessel 
 Plates (wells) Dishes (cm2) Flasks (cm2) Chambers (stacks) 
Vessel 96-well 12-well 6-well 56.7 145 25 75 175 5 10 
Medium 0.1 1 2 n/a 20 4-5 10-12 20-25 500 1000 
1x PBS 0.03 0.2 0.5 n/a 10 2 3 5 250 500 
Trypsin 0.03 0.2 0.5 n/a n/a 1 3 5 50 100 
Medium2 0.03 0.2 0.5 n/a n/a 1 3 5 Old medium 
HepesBSS3  0.2 0.5 2 n/a 1 2 3 n/a n/a 
Trypsin3  0.2 0.5 2 n/a 1 2 3 n/a n/a 
TNS3  0.2 0.5 2 n/a 1 2 3 n/a n/a 
1in ml, 2ready-to-use cell culture medium used for trypsin neutralization, 3 from DetachKit 
 
 
II.D.2 Flow cytometry 
 
Flow cytometry analysis was employed to determine the transduction efficiency of AAV vectors of 
different cell types and the expression of cell surface receptors. Cell samples were collected by 
removing old medium, rinsing once with 1x PBS, trypsin treatment and trypsin neutralization with 
corresponding media (see Table II.D.1.2). Detached cells were transferred into conical-bottom 
tubes and centrifuged (272 x g, 5 min, RT). Pellets were resuspended in 150-1000 µl of ice-cold 
staining solution, transferred into round bottom tubes and kept on ice until FACS analysis. Data 
acquisition was carried out on a FACSCalibur flow cytometer using CellQuest Pro software. Below, 
a representative example of the acquisition and analysis process of HEK 293T cells is given. 
Relevant parameters are specified in table Table II.D.2. The flow cytometer was calibrated using a 
non-transduced cell sample (negative control) stained with propidium iodide solution (PI). 
 
On a FSC-H/FL3-H plot (Figure II.D.2 A), events were discriminated according to their size 
(forward scatter height, FSC-H) and incorporation level of propidium iodide (FL3-H channel), which 
is lower in intact cells. Sub-populations of events regarded as live cells were gated by assigning 
them to region R1. Consequently, events laying outside of region R1 represented artefacts (cell 
fragments, cell clumps, dead cells) and were excluded from further analysis. The subset of live 
cells gated in R1 was plotted on a FSC-H/SSC-H plot (Figure II.D.2 B). The side scatter height 
(SSC-H) allows for a more precise discrimination between single cells and cell clumps. Events 
regarded as single cells were gated by assigning them to region R2 thus excluding cell clumps 
from further analysis. Subsequently, the „spill-over“ of intense fluorescence signals from FL1 into 
FL2 channel was compensated. This step is necessary as only evaluation of events occurring in 
the FL1 channel (= EGFP-positive cells) is possible. First, the background fluorescence of gated 
cells (R1 + R2) from the negative control was set at 101 relative fluorescence units (RFU) for both 
channels. A positive control containing cells transduced with scAAV-CMV-EGFP was then used to 
correct FL1-to-FL2 „spill-over“ of intense EGFP signals (Figure II.D.2 C). The sample flow-rate was 
set between 50-300 events/second by adjusting flow speed and/or sample volume and for every 
sample 0.5-1E+4 live single cells were collected. 
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Table II.D.2: Common parameters in flow cytometry analysis 
Channel Parameter Description 
FSC-H Forward scatter height Correlates with cell volume (size) 
SSC-H Side scatter height Depends on inner complexity of a cell (granularity) 
FL1-H Fluorescence height Detects EGFP, FITC* fluorescence (filter 530/30) 
FL2-H Fluorescence height Detects PE* fluorescence (filter 585/42) 
FL3-H Fluorescence height Detects PI* fluorescence (filter 670 LP) 
*Examples of detectable fluorescent molecules: EGFP = green fluorescent protein, FITC = fluorescein 
isothiocyanate, PE = phycoerythrin, PI = propidium iodide 
 
 
Evaluation of transduction efficiencies was carried out with the FlowJo software. Gated events 
were plotted on a FL1-H histogram and histogram overlays of negative and positive control were 
generated (Figure II.D.2 D). Events within the overlapping histogram area of positive (orange line) 
and negative control (black line) were regarded as „false negative signals“ and two marker regions 
M1 and M2 joining at the intersection point of the overlays were set. All events within marker M2 
were defined as EGFP-positive cells and were calculated by the software as percentage of gated 
events (% EGFP-positive cells). M2-values from negative control were defined as „false positive 
signals“ and were subtracted from each analysed sample. 
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Figure II.D.2: Workflow for data acquisition by flow cytometry. (A) Data obtained from negative control (untreated 
cells stained with PI) was plotted on a FSC-H/FL3-H scatter-plot and live cell populations were gated by assignment to 
region R1. The distribution of cells is given in false colours, whereas red indicates a high and blue a low density. (B) The 
R1-subset of cells was plotted on a FSC-H/SSC-H scatter-plot and single cells were gated by assignment to region R2. 
(C) Fluorescence channels FL1-H and FL2-H were set to 101 RFU using the negative control and FL1-to-FL2 „spill-over“ 
(orange dots) was corrected (black dots) using cells transduced with AAV. (D) Gated events (R1 + R2) from negative 
(black line) and positive control (orange line) were overlaid on a FL1-H histogram and marker regions M1 and M2 were 
drawn joining at the intersection point of the overlays. By definition, marker M2 contains EGFP-positive cells. 
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II.E. Virological methods 
 
II.E.1 AAV vector production 
 
Recombinant scAAV vectors were produced by applying two different protocols. For wild type 
AAV2 or AAV9 vectors, plasmids pDP2rs and pDP9rs were used, respectively (Chapter II.A.3). 
Mutant AAV vectors were produced using plasmid pDG∆VP and pMT-187-XX2 (AAV2) or p5E18-
VD2/9-SfiI1759 (AAV9) containing distinct oligonucleotide inserts (Chapter II.A.4 and II.B.4.2) 
enabling peptide display behind VP1 residue 588 (AAV2) or 589 (AAV9). Plasmid dsAAV-CMV-
EGFP containing a CMV-EGFP expression cassette flanked by ITRs or, alternatively, plasmid 
dsAAV-CMV-EGFP∆G67 expressing a non-fluorescent EGFP variant was packaged into AAV 
vectors. 
 
Depending on the desired size of production 10, 20 or 40 145cm2 cell culture dishes or, 
alternatively, instead of 20 or 40 dishes, 5- or 10-stack tissue culture chambers corresponding in 
surface were employed. For transfection of plasmids, polyethyleneimine (PEI) was aseptically 
dissolved in ddH2O to 0.323 g/L, freeze-thawed 6 times (LN2/37°C) and stored in aliquots at -80°C. 
In general, cells were propagated for 24 h prior to transfection allowing proper adhesion to the 
dishes and plasmids were PEI-transfected at a N/P-ratio of 20231. 
 
For transfection 5E+6 HEK 293T cells per 145 cm2 cell culture dish were seeded in 20 ml 
appropriate medium (Chapters II.D.1.2 and II.A.2). The next day, two mastermixes were prepared 
separately with solutions pre-warmed to 37°C according to Table II.E.1 (values account for one 
dish), were mixed under vigorous stirring and were incubated for 10 min at RT to allow 
precipitation of PEI and DNA. Transfection occurred by adding 4 ml of combined mastermixes to 
each dish followed by an incubation of 48 h under standard conditions. In case of tissue culture 
chambers entire medium was carefully removed, mixed with the mastermix in appropriate-sized 
glass bottles and reapplied to the cells. After incubation, cells were collected from dishes in 500 ml 
large centrifuge tubes by washing-off with present medium and were pelleted (220 x g, 4 min, RT). 
Then, the pellets were washed once with 1x PBS. Cell collection from tissue culture chambers was 
done by removal of old medium and trypsin treatment (see Table II.D.1). Additionally, chambers 
were rinsed twice with 1x PBS to ensure complete removal of cells. 
 
Lysis was performed by re-suspension of cell pellets in 5 ml (from up to 20 dishes or a 5-stack 
chambers) or 20 ml (from up to 40 dishes or a 10-stack chambers) MNT buffer followed by 4 
freeze-thaw-cycles (LN2/37°C). Cell lysates were treated for 1 min at 48W in a ultrasound water 
bath and incubated with 100 U Benzonase (Chapter II.A.5) per ml of lysate for 30 min at 37°C. 
Repeated centrifugation (5000 x g, 10 min, 4°C) removed cellular debris completely and AAV-
containing supernatant was stored at -20°C until further processing. 
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Table II.E.1: Transfection mastermixes for AAV vector production 
 Volume (µl) Amount/ concentration 
Plasmids 
(mutant scAAV vectors) 
Plasmids 
(wild type scAAV vectors) 
M
as
te
rm
ix
 1
 
Variable 35 µg pDG∆VP pDP2rs or pDP9rs 
Variable 10 µg dsAAV-CMV-EGFP or dsAAV-CMV-EGFP(∆G67) 
dsAAV-CMV-EGFP or 
dsAAV-CMV-EGFP(∆G67) 
Variable 12 µg pMT-187-XX2 or p5E18-VD2/9-SfiI1759 n/a 
Ad 1 ml  ddH2O ddH2O 
1 ml 300 mM NaCl NaCl 
 
 Substance Concentration   
M
as
te
rm
ix
 2
 PEI 0.323 g/l 456 µl 360 µl 
ddH2O  544 µl 640 µl 
NaCl solution 300 mM 1 ml 1 ml 
    
 
 
II.E.2 AAV vector purification by density gradient ultracentrifugation 
 
Cell lysates (Chapter II.E.1) were thawed and were pipetted into 13.5 ml (5 ml lysates) or 39 ml 
(20ml lysates) ultracentrifuge tubes with the aid of a Pasteur pipette placed into the tube. Iodixanol 
solutions were prepared freshly according to Table II.E.2 were applied into the tubes with the 
lowest gradient concentration loaded first, followed by increasingly higher concentrations. After 
loading, the order of solutions inside the tube were: cell lysate, 15%, 25%, 40% and 60% iodixanol, 
top to bottom. The addition of phenol red into 25% (reddish colour) and 60% iodixanol (yellowish 
colour) facilitated discrimination between individual layers. Tubes were heat-sealed using a seal 
former and tube sealer and were balanced to ±0.01 g using fresh MNT buffer taking into account 
the weight of centrifuge rotor spacers. 
 
For ultracentrifugation, 39 ml (13.5 ml) tubes were loaded into 50.2 Ti rotors (70.1 Ti rotors) and 
centrifugation was carried out at 375.000 x g for 2 h 15 min at 10°C. Tubes were then fixed with an 
extension clamp on a support stand, a 20G 1½ needle was plunged atop the tube for air balance 
and the 40% iodixanol fraction containing full capsid particles was carefully aspirated by lateral 
puncture using another 20G 1½ needle and a 5 ml syringe, yielding volumes of ~1.0 ml (small 
gradient) or ~2.5 ml (large gradient). The 40% iodixanol fraction was not retrieved entirely due to a 
partially mixed layer interface between 25% and 40% iodixanol containing also empty capsid 
particles and small amounts of cell debris. Vector particle-containing fractions were stored in 1.5 
ml screw-cap tubes at 4°C (short-term) or -20°C (long term). 
 
 
 
 
 
 56 
Table II.E.2: Iodixanol solutions and their components 
 Concentration Total volume* Iodixanol PBS-MK PBS-MKN Phenol red 
S
m
al
l 
gr
ad
ie
nt
 60% 1.5 ml 1.5 ml - - ~ 15 µl 
40% 1.5 ml 1 ml 0.5 ml - - 
25% 2 ml 0.83 ml 1.17 ml - ~ 10 µl 
15% 3 ml 0.75 ml - 2.25 ml - 
       
 Concentration Total volume1 Iodixanol PBS-MK PBS-MKN Phenol red 
La
rg
e 
gr
ad
ie
nt
 60% 4 ml 4 ml - - ~ 30 µl 
40% 4 ml 2.66 ml 1.34 ml - - 
25% 5 ml 2.08 ml 2.92 ml - ~ 20 µl 
15% 7 ml 1.75 ml - 5.25 ml - 
*Volumes required for the purification of a 5ml (small gradient) or a 20ml (large gradient) cell lysate sample 
 
 
II.E.3 Quantification of AAV infectious titres 
 
HEK 293T cells were seeded at a density of 1E+4 cells/well in a 96-well cell culture plate in 100 µl 
corresponding cell culture medium (Chapters II.D.1.2 and II.A.2) containing only 5% FBS. The next 
day, the virus stock was 1:10 serially diluted by transferring 11 µl virus solution between wells and 
mixing. Each dilution was analysed in duplicate. Infection was allowed to take place in a cell culture 
incubator for 2 h at 37°C and internalized virus particles were amplified by super-infection with 20 
µl cell culture medium (5% FBS) containing wild type Adenovirus 5 (Ad) at a multiplicity of infection 
(MOI) of 10 IU/cell added to each well. Further incubation was carried out until a ~50% Ad-induced 
cytopathic effect was observed (usually within 2-3 days). For lysis, cells were freeze-thawed three 
times (-80°C/37°C) without removing the medium and 100 µl 1.5 M NaOH solution was added to 
each well. 
 
Plates were centrifuged (300 x g, 5 min, RT) to avoid carry-over of cellular debris and 180 µl 
supernatant were transferred to the HybriDot manifold avoiding air bubbles. Prior to transfer of 
supernatant, a trimmed hybridisation transfer membrane enveloped by two pieces of cellulose 
chromatography paper was soaked in 1x PBS and the HybriDot manifold was assembled. Transfer 
occurred by applying vacuum until the entire supernatant passed the membrane. The membrane 
was removed from manifold and viral DNA was denatured by placing the membrane on a fresh 
chromatography paper soaked with denaturation buffer (10 min, RT). Alkaline conditions were 
neutralized by placing the membrane on another chromatography paper soaked with neutralization 
buffer (10 min, RT) and the membrane was air-dried. DNA was cross-linked to its surface with a 
crosslinker at 120 mJ. Prior to addition of radioactively labelled DNA, the membrane was placed in 
a hybridisation bottle and was pre-treated with 10-15 ml hybridisation solution in a hybridisation 
furnace (>1 h at 42°C). 
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A DNA fragment for radioactive labelling was prepared by NcoI/HindIII-digestion (Chapter II.B.2) of 
plasmid p5E18-VD-2/9 (Chapter II.A.3). The 1.257 kb rep-fragment was gel-purified (Chapters 
II.B.6 and II.B.1), and 250 ng were used for α-32P dCTP radioactive labelling following the Random 
Primed DNA Labelling Kit protocol (02/2008, steps 2-4) with following modifications: DNA solution 
was completed ad 23 µl with ddH2O and 4 µl each dNTPs, reaction mixture and Klenow enzyme 
were added. The mixture was completed by adding 5 µl α-32P dCTP (50 µCi) and radioactive 
labelling was allowed to take place. After EDTA treatment/heating, unincorporated nucleotides 
were removed with the Mini Quick Spin Oligo Columns according to manual recommendations 
(version 09/2004, pages 6-7). Radiation of the eluate containing purified labelled oligonucleotides 
was determined with a radioactivity counter and probes yielding >106 cpm were heat-treated (10 
min at 95°C) and cooled instantly on ice to maintain single strand state. The entire amount of 
probe (~50 µl) was mixed with 450 µl hybridisation solution and pipetted to the pre-treated 
membrane. Hybridisation of probe and cross-linked DNA was allowed to take place in a 
hybridisation furnace (o/n at 42°C). 
 
The hybridisation solution was removed and excess radioactive contamination was washed off by 
repeated incubation in 10-15 ml washing solution (10-15 min at 42°C, hybridisation furnace). After 
each washing step, labelling intensity was roughly estimated by removing the membrane from the 
hybridisation bottle and measuring radiation with a contamination monitor. Upon reaching values of 
~1.000 cpm, membranes were shortly air-dried, wrapped in cling-film and were mounted on a 
storage phosphor screen. After 5-24 h exposure, read-out of screens was performed on a 
molecular imager with ImageQuant software. 
 
The infectious titre of analysed virus stocks was estimated by counting blackened dots. 
Theoretically, one infectious AAV particle per well is sufficient to generate a detectable radioactive 
signal upon amplification by Ad super-infection. Since serial dilutions of 1:10 lowering the amount 
of infectious particles to ~one/cell were made, each additional dot represents a tenfold higher 
infectious titre. Hence, 5 blackened dots represent a titre of 104 IU translating into 106 IU/ml. 
 
 
II.E.4 Production of an AAV9 random peptide heptamer library 
 
Detailed molecular biological techniques used for the cloning strategy in this chapter are described 
in Chapter II.B and II.C and more detailed information on plasmids or primer/oligonucleotides is 
given in Chapters II.A.3 and II.A.4, respectively. 
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II.E.4.1 Plasmid library 
 
Creation of an AAV9 library plasmid backbone 
A 975 bp fragment of the wtAAV9 cap ORF was synthesized (Geneart, plasmid pGA4) harbouring 
two incompatible SfiI restriction sites at nucleotide positions 1759 through 1786 of cap9 separated 
by two adenine molecules. Modified 975 bp cap9 fragment (cap9mut) was excised with XcmI and 
BsiWI from pGA4 and was inserted into equally-cut p5E18-VD-2/9, resulting in p5E18-VD-2/9-
SfiI1759. Correct insertion of the 975bp fragment into p5E18-VD-2/9-SfiI1759 was analysed by a 
double-digestion with SfiI and BsiWI. This plasmid served on the one hand as an intermediate 
construct for the generation of the ITR-positive plasmid library and on the other hand was used for 
insertion of oligonucleotides (Chapter II.B.4.2) to create AAV9 vectors displaying distinct peptides 
behind VP1 residue 589. In contrast, AAV2 vectors displaying peptides behind VP1 residue 588 
were generated using plasmid pMT-187-XX2. 
 
For generation of the ITR-positive plasmid library, several subcloning steps had to be performed 
due to unavailable restriction sites. In the first step p5E18-VD-2/9-SfiI1759 was digested with 
HindIII and EcoRV, releasing a 2774bp fragment containing the entire modified cap9 ORF as well 
as a part of the rep2 ORF and was cloned into equally-digested pMT-187-XX2. This step is 
necessary since p5E18-VD-2/9 lacks XbaI recognition sites required in a later step. To enable the 
HindIII/EcoRV-digestion of pMT-187-XX2, the EcoRV-site was generated by in vitro-mutagenesis 
using IVM-F/R primers following the manufacturer's protocol and successful mutagenesis was 
verified by EcoRV-digestion. The resulting plasmid was termed pMT-187-XX2-rep2/cap9mut. 
Then, the entire rep2/cap9mut sequence was excised from ITR-negative pMT-187-XX2-
rep2/cap9mut with XbaI and was ligated into equally-cut ITR-positive plasmid pSSV9 resulting in 
library plasmid backbone pKV-AAV9Lib/BB. Sequencing using primer AAV9cap-589ins confirmed 
the presence of the modified cap9 fragment. 
 
Creation of an oligonucleotide library 
For generation of an oligonucleotide library, degenerated single-stranded oligonucleotide NNK-
Oligo was synthesized encoding a random seven-residue peptide insert flanked by two 
incompatible BglI restriction sites (Oligonucleotide Synthesis Core Facility). Second strand 
synthesis of NNK-Oligo was done with the Sequenase DNA Sequencing Kit 2.0 (page 8, steps 1-2, 
6) and second strand primer NNK-Oligo-2nd according to manual recommendations with the 
following modifications: 2 µg oligonucleotide and 4 µg primer were inserted into the reaction and 
incubation (step 6) took place at 37°C for 1 h. Unincorporated nucleotides were removed with the 
QIAquick Nucleotide Removal Kit and the double-stranded oligonucleotide library was eluted in 80 
µl elution buffer (diluted 1:3 with ddH2O, first elution in 50 µl, second in 30 µl) per column and 
stored at -20°C until further use. 
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Ligation of plasmid backbone and oligonucleotide library 
Prior to ligation, oligonucleotide library and backbone plasmid pKV-AAV9Lib/BB were digested for 
4 h with BglI or SfiI, respectively, using 10 U enzyme/µg DNA each. SfiI-digestion released a 15 bp 
stuffer fragment within pKV-AAV9Lib/BB rendering it compatible to the BglI-digested 
oligonucleotide library. Backbone or insert were purified by gel-isolation and the QIAquick PCR 
Purification Kit, respectively, and elution occurred twice in the same 50 µl elution buffer 1:3 diluted 
with ddH2O. To determine the optimal insert-to-backbone molar ratio, test-ligations were prepared. 
Reactions specified in Table II.E.4.1 were completed to a total volume of 20 µl with ddH2O, were 
heat-incubated 2 min at 65°C and chilled on ice for 10 min. Ligation reaction was completed as in 
Chapter II.B.4.1 but with 1000 U ligase and reaction was allowed to take place. For concentration, 
ligated plasmids were ethanol-precipitated, resuspended in 50 µl elution buffer 1:10 diluted with 
ddH2O and DNA concentration was determined. One µl containing 10 ng of library plasmid ligated 
at any ratio was mixed with 25 µl ElektroMAXTM DH5α-E Competent Cells thawed on ice and 
transformed by electroporation (1.8 kV, 25 µF, 200 Ω, electroporation cuvettes cooled on ice) using 
the Gene Pulser Xcell electroporation instrument. Transformed bacteria were instantly collected in 
SOC medium pre-warmed to 37°C resulting in a total volume of 1 ml and incubated under vigorous 
shaking for 1 h at 37°C. Serial 1:10 dilutions of bacterial culture ranging from 1:1 to 1:10.000 were 
prepared with SOC and 100 µl of each were plated on LB-amp agar plates. The transformation 
efficiency ET was determined by counting colonies the next day according to formula (1): 
 
 
( ) ( )DNA CFU/µg factor dilution×
plated mlx 
1ml
×
DNA dtransforme µgx 
DNA 1µg × CFU counted
 =E  1 T  
 
 
A large-scale ligation 20x the amounts of the test-ligation specified in Table II.E.4.1 was attempted 
at a ratio of 1:30, since this ratio yielded the highest transformation efficiency. After ethanol-
precipitation the DNA pellet was resuspended in 400 µl 1:10 ddH2O-diluted elution buffer and 
concentration was determined. For reason of costs, new transformation parameters using less 
competent cells were applied. One electroporation approach consisted now of 2 µl (100 ng) library 
plasmid, 20 µl competent cells and was collected after electroporation in SOC medium resulting in 
a total volume of 2 ml. To exclude a lowering of transformation efficiency, one approach was 
analysed in advance as described above. Additionally, several colonies were picked, were raised 
by miniprep and plasmid DNA was sequenced to verify the correct insertion of library 
oligonucleotides using primer AAV9cap-589ins. The transformation of the large-scale ligation 
contained in total 104 approaches (see above). To facilitate handling, two approaches were 
combined into one cuvette for electroporation. Transformations from 13 cuvettes were pooled and 
were incubated under vigorous shaking 1 h at 37°C, resulting in a total of 4 separate batches (1 
batch = 13 cuvettes = 26 approaches). Again, aliquots from each batch were taken and 
transformation efficiency was analysed as described above. 
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Each batch was then completed with LB-amp medium to 250 ml and plasmids were amplified 
under shaking o/n at only 30°C and 200 rpm until cultures reached an OD600 of ~0.2. The plasmid 
library termed pKV-AAV9Lib was purified using the HiSpeed Plasmid Maxi Kit and stored at -20°C. 
 
Table II.E.4.1: Plasmid-to-insert ratios used for test-ligations 
Ratio Backbone (ng) Insert (ng) 
1:10 
500 
18.9 
1:30 56.7 
1:100 189.0 
Control - 
 
 
II.E.4.2 Production of the transfer shuttle library (TSL) 
 
TSL particles were produced by PEI-transfection of library plasmid pKV-AAV9Lib, codon-optimized 
wtAAV2 helper plasmid pRSV-VP3co or non-optimized wtAAV9 plasmid p5E18-VD-2/9, 
respectively, and pDG∆VP into HEK 293T cells. Different stoichiometric amounts of plasmids 
(Table II.E.4.2) were assayed to determine the optimal ratio leading to maximum genomic and 
infectious titres, at the same time saving library plasmid. Transfection of 5E+6 cells per plasmid 
combination occurred as described in Chapter II.E.1 by adjusting the PEI volume to the absolute 
amount of plasmids. Following combinations were assayed: TSL productions using wtAAV2 (Table 
II.E.4.2, code ABC), wtAAV9 (code ABD) or no helper plasmid (code AB) and TSL productions 
without library plasmid (codes AC and AD, only red highlights). TSL particles were harvested and 
purified (Chapters II.E.1 and II.E.2) and quantification of genomic titres (Chapter II.B.8.2) and 
infectious titres (Chapter II.E.3) was performed. The optimization process revealed a plasmid ratio 
of 1:1:15 (µg pKV-AAV9Lib, pRSV-VP3co and pDG∆VP, respectively) to result into maximal 
infectious titres. Using this protocol, the main TSL productions were upscaled 20x to 10E+8 HEK 
293T cells yielding an absolute infectious titre of 5E+7 IU each. 
 
Table II.E.4.2: Plasmid combinations used for optimisation of transfer shuttle library production 
Code Plasmids Absolute amounts (µg) 
A pDG∆VP 15 
B pKV-AAV9Lib 1 2 5 1 2 5 1 2 5 
 Ratio BC/BD 1:1 1:5 1:10 
C pRSV-VP3co 1.5 3.0 7.4 7.4 14.8 37.0 14.8 29.6 74.0 
D p5E18-VD-2/9 1.1 2.1 5.4 5.4 10.7 26.8 10.7 21.4 53.5 
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II.E.4.3 Production of the virus library 
 
The final AAV9 virus library expressing random heptapeptides behind VP1 residue 589 was 
generated by infection of HEK 293T cells with the TSL at a MOI of 0.5 IU/cell. Two small-scale 
productions using TSL prepared with wtAAV2 or wtAAV9 helper plasmids were attempted using 
one dish (5E+6 cells) each. Only one large-scale production using the entire remaining TSL 
prepared with wtAAV2 helper plasmid was produced using twenty dishes (1E+8 cells). The cells 
were seeded the day before (Chapter II.D.1.1) in appropriate medium and the TSL was applied to 
the cells. Half of cell culture medium (10 ml) was removed from each dish and was replaced with 
fresh medium lacking FBS containing the TSL. Thus, thorough mixing of viscous iodixanol solution 
and medium was possible and total FBS was reduced to 5%. After an incubation of 4 h, cell culture 
medium was removed and cells were carefully rinsed once with 1x PBS. Twenty ml fresh medium 
containing 5% FBS and 5 IU/cell Ad were supplied to each dish and super-infection was allowed to 
take place until a ~50% cytopathic effect induced by Ad (cell rounding, pending detachment) was 
observed (48-72 h). Library particles were then harvested and purified (Chapters II.E.1 and II.E.2) 
and quantification of genomic titres was performed (Chapter II.B.8.2). 
 
 
II.E.5 Characterization of plasmid and virus library 
 
Randomness, functional diversity and amino acid usage of plasmid or virus library were analysed 
by sequencing of randomly assigned clones. Plasmid or viral DNA was PCR-amplified (Chapter 
II.B.8.1) using AAV9cap F2/R primers (Chapter II.A.4). Virus DNA was supplied as a template by 
adding 1 µl virus stock solution directly to the PCR reaction. The primer pair used here yields a 467 
bp-fragment from the mutated AAV9 cap gene that includes the oligonucleotide insertion site and 
binding site of sequencing primer AAV9cap-589ins (Chapter II.A.4). PCR-amplification using Taq-
polymerase resulted in adenylation of DNA 3' ends enabling T/A-overhang ligation with the TOPO 
TA Cloning Kit for Sequencing (version O, 04/2006, pages 5, 10/steps 1-8). Four µl PCR product 
were used for ligation into TOPO vector as described in the user guide and One Shot DH5α-T1R 
Chemically Competent Cells supplied with the kit were transformed. Prior to plating of 50 µl 
bacterial suspension, 40 µl X-gal solution were spread on LB-amp agar plates for blue-white 
selection of insert-positive clones and plates were pre-incubated for 30 min at 37°C. The next day 
a 96-well microtitre plate with agar was inoculated with single white colonies and clones were 
sequenced using AAV9cap-589ins. 
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II.F Transduction and infection of cells 
 
II.F.1 In vitro selection of the AAV9 random peptide display library on HCAEC 
 
For in vitro biopanning of AAV9 random peptide libraries, 1E+6 HCAEC were seeded in 175cm2 
cell culture dishes in 20 ml corresponding medium (Chapter II.A.2). After an o/n incubation under 
standard conditions (Chapter II.D.1.1), the libraries were applied in different attempts at MOIs 10, 
100 and 1000 gc/cell by medium replacement. After a 4 h exposure medium was removed, cells 
were rinsed once with 1x PBS to remove unbound virus particles and 20 ml fresh medium with 20 
IU/cell Ad was supplied for super-infection. Incubation was continued until a cytopathic effect was 
observed. At a MOI of 20 IU Ad/cell HCAEC displayed a typical cell rounding after 48 h but 
remained still adherent. It was assumed that 48 h exposure to Ad should suffice for AAV 
replication. Cells were washed twice with 1x PBS and harvested by trypsin treatment (Chapter 
II.D.1.1). Cell pellets were washed twice with 1x PBS to remove the majority of library particles in 
the supernatant and intracellularly enriched variants were purified using 1 ml MNT buffer as 
described in Chapter II.E.1. Purification by density gradients was omitted to avoid particle loss. 
Titration of genomic copies was performed by qRT-PCR (Chapter II.B.8.2) and absence of 
contaminating wtAAV9 genomes was confirmed by gel analysis (2.5% agarose, Chapter II.B.6) of 
purified (Chapter II.B.1) and PCR-amplified (Chapter II.B.8.1) viral DNA using AAV9cap-F/R primer 
pair (Chapter II.A.4). This primer pair yields a 270 bp PCR fragment from wtAAV9 and 297bp 
fragment from the mutated AAV9 cap gene. The enriched library was subjected to further three 
selection rounds using the parameters described above and after the third and fourth round a total 
of 16 single clones from each attempt using a specific MOI were generated and sequenced (see 
Chapter II.E.5) to further characterise enriched peptide motives. 
 
 
II.F.2 In vitro gene transfer studies with wild type and selected AAV vectors 
 
In vitro AAV treatment of cells occurred usually in the 12-well plate format with parameters 
described in Table II.F.2. All parameters of each group (experimental code) were combined unless 
specific affiliations were indicated by an arrow. Cells were seeded the day before in 1 ml of 
corresponding medium (Chapters II.D.1.1 and II.A.2) at desired densities and were incubated o/n 
to allow cell attachment to the well bottom. The next day, cells were exposed to wild type or mutant 
scAAV-CMV-EGFP vectors displaying peptides behind VP1 residue 588 (AAV2) or 589 (AAV9) by 
mixing vector stock solution at desired MOIs and replacing old medium with 500 µl fresh medium 
containing maximum 5% FBS and vector. After exposure, vector-containing medium was 
aspirated, cells were rinsed once with 500 µl 1x PBS and, if necessary, incubation was continued 
in presence of 500 µl fresh medium. At the end of the incubation time, transduction efficiency of 
vectors was analysed by flow cytometry as described in Chapter II.D.2. In the chapters below, 
details or deviations to the protocol described here are indicated. 
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Table II.F.2: Parameters applied for AAV treatment of cells  
Experiment 
code Cell type 
Seeding 
density 
(cells/well) 
Exposure MOI 
(gc/cell) 
Vector 
(serotype/peptide1) 
Exposure 
time (h) 
Incubation 
time (ad h) n
2 
1 HCAEC  5E+4 1E+4 2/NDVRAVS 4 48 3 
2 HCAEC  5E+4 1E+4 2/NDVRAVS 4 48 3 
3 HCAEC  5E+4 5E+3 2/NDVRAVS 4 24, 48, 72 3 
4 HCAEC  5E+4 5E+3 2/NDVRAVS 2, 4, 8, 24, 48, 72 72 3 
5 HCAEC  7.5E+4 1E+4 2, 9/wild type  2, 9/NDVRAVS 72 72 4 
6 HCAEC  H5V 
→ 
→ 
7.5E+4, 
1E+5 
1E+3 and 
1E+4 9/see AI
3 48 48 4 1 
7 
HCAEC 
HCASMC 
HEK 293T 
HeLa 
911 
HepG2 
→ 
→ 
→ 
→ 
→ 
→ 
7.5E+4 
7.5E+4 
1.5E+5 
2E+5 
1.5E+5 
2E+5 
2.5E+3 
9/wild type 
9/SLRSPPS 
9/RGDLRVS 
48 48 3 
8 
HCAEC 
HCASMC 
HEK 293T 
911 
→ 
→ 
→ 
→ 
5E+4 
5E+4 
1.5E+5 
1.5E+5 
2.5E+3 9/SLRSPPS 48 48 3 
9 HUVEC  5E+4 1E+3, 1E+4, 5E+4, 1E+5 9/SLRSPPS 2 48 3 
10 HCAEC  5E+4 5E+3 2, 9/see AI3 48 48 3 
11 HCAEC  7.5E+4 
5E+3, 
25x-100x (see 
experimental 
codes) 
9/SLRSPPS 
9/RGDLRVS 
9/PSLPSRS 
9/SDLRRGV 
4 48 3 
1Peptides displayed behind VP1 residue 588 (AAV2) or 589 (AAV9), 2number of replicates performed each sample 
 
 
Experimental codes (additional information) 
1 Exposure occurred in 0.5 ml (131 µl/cm2), 1 ml (263 µl/cm2) or 1.5 ml (394 µl/cm2) medium 
 
2 Exposure occurred in presence or absence of 1%, 5%, 10% (vol/vol) iodixanol, including 
 iodixanol from vector stocks 
 
6 Wild type, TEWDQPF, RGDLRVS, NLHSPPA, SLRSPPS, SIRSPPS, RGDFRVG, 
NNVRGFV,  NFTRLSA, NDVRAVS 
 
8 CMV-EGFP, 163-EGFP or 313-EGFP expression cassettes were encapsidated in 
 scAAV9-SLRSPPS vectors 
 
10 Wild type, RGDLRVS, NLHSPPA, SLRSPPS, NDVRAVS, NSSRDLG, NSVSSAS 
 
11 Vectors packaging CMV-EGFP were applied at MOI 5E+3 gc/cell and vectors packaging 
 CMV- EGFP∆G67 were applied at 25x, 50x, 75x and 100x excess MOI 
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II.F.3 Transcriptional targeting 
 
Detailed information on required cloning techniques is given in Chapters II.B and II.C. For 
generation of plasmid constructs that put EGFP under the control of the murine VE-cadherin 
promoter (EMBL databank accession no. Y10887 ), plasmid dsAAV-CMVenh-MLC260-EGFP was 
used as a basis (Chapter II.A.3). A plasmid backbone for insertion of the 163 or 313 bp VE-
cadherin promoter fragments was prepared by PpuMI/HindIII-digestion of dsAAV-CMVenh-MLC260-
EGFP, that released the myosin light chain promoter fragment (MLC260) but retained the CMV 
enhancer sequence (CMVenh). The PpuMI recognition site is located between the 3' end of the 
CMVenh and the 5' end of MLC260, while the HindIII site is situated at the 3' end of MLC260. The 
cadherin promoter was provided within plasmid pBLCAT3. Since no PpuMI/HindIII sites were 
present, artificial synthesis was required by PCR. Primer pairs were designed that allowed PCR-
amplification of either the 163 bp or the 313 bp fragment from the cadherin promoter, at the same 
time adding a HindIII site downstream of the +24 nucleotide position (Chapter II.A.4, VE-Cad-R, 
bold highlights) or a PpuMI site upstream of the -139/-289 nucleotide position (Chapter II.A.4, VE-
Cad-F1/VE-Cad-F2, bold highlights). The endogenous HindIII recognition sequence present at the 
-289 site of the cadherin promoter was destroyed upon creation of a PpuMI site by PCR (Chapter 
II.A.4, VE-Cad-F2, underlined bases). Purified PCR fragments were rendered compatible for 
ligation into backbone plasmid by PpuMI/HindIII-digestion, eventually creating plasmid dsAAV-
CMVenh-163-EGFP and dsAAV-CMVenh-313-EGFP. These plasmids were used for production 
AAV9 vectors displaying peptide SLRSPPS (Chapter II.A.4) behind VP1 residue 589 (Chapters 
II.E.1, II.E.2 and II.E.3). Transduction of cells was performed with parameters described in Table 
II.F.1, code 8. At the end of the incubation time, transduction efficiency of vectors was analysed by 
flow cytometry as described in Chapter II.D.2. 
 
 
II.F.4 In vitro neutralization of AAV transduction 
 
In a u-bottom 96-well cell culture plate that facilitates accurate pipetting of low volumes, serial 1:2 
dilutions of intravenous immunoglobulin (IVIG) and ADK9 (Chapter II.A.7) or no serum (positive 
transduction control) were made in a total of 30 µl/well using HEK 293T cell culture medium 
lacking FBS (Chapter II.A.2). Additional 30 µl serum-free medium containing wtAAV2, wtAAV9 or 
selected scAAV9-CMV-EGFP vectors displaying peptide sequences RGDLRVS, SLRSPPS or 
NDVRAVS were added to the serial dilutions resulting in a preliminary MOI of 2.25E+4 gc/cell and 
neutralization reaction was allowed to occur for 45 min at room temperature. The final 
concentration of ADK9 antibody in the lowest dilution (1:10) represented 0.4 ng. Forty out of 60 µl 
antibody-treated vector solution resulting in final MOIs of 1.5E+4 gc/cell were added to 1E+4 HEK 
293T cells seeded the day before in a 96-well plate in 100 µl corresponding medium (Chapter 
II.D.1.1). Cells were incubated for a total of 48 h and transduction efficiencies were evaluated by 
flow-cytometry as described in Chapter II.D.2. 
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II.F.5 Capsid competition assay 
 
The capsid competition assay was performed by co-incubation of vectors harbouring fluorescent 
EGFP expression cassettes and competing vectors containing non-fluorescent EGFP∆Gly67. A 
non-fluorescent EGFP reporter gene variant was generated by subcloning of the EGFP ORF from 
plasmid dsAAV-CMV-EGFP into plasmid pEBFP-C1 (Chapter II.A.3). This step was beneficial for 
the mutagenesis reaction since it reduced the total size of the plasmid and avoided the presence 
of ITRs. KpnI/NotI-digestion released EGFP and EBFP, respectively, and the EGFP fragment was 
ligated into pEBFP-C1 backbone. To abolish EGFP fluorescence, glycine residue G67 was 
removed by PCR mutagenesis (Chapter II.B.8.3) using EGFP∆G67 forward and reverse primers 
(Chapter II.A.4). Sequencing using EGFP-N sequencing primer (Chapter II.A.4) confirmed correct 
deletion of G67 codon. The EGFP∆G67 ORF was cloned back into dsAAV-CMV backbone with 
KpnI/NotI resulting into dsAAV-CMV-EGFP∆G67. A more detailed description of molecular 
biological techniques required for the cloning steps is provided in Chapter II.B and II.C. Plasmid 
dsAAV-CMV-EGFP∆G67 was compared to fluorescent dsAAV-CMV-EGFP by co-transfection with 
plasmid pDP2rs (Chapter II.A.3, transfection control) into HeLa cells (see Chapter II.E.1 for details 
on transfection). After a 24 h incubation fluorescence signals were monitored with a fluorescence 
microscope. 
 
For the capsid competition assay, 7.5E+5 HCAEC were exposed to scAAV9-CMV-EGFP mutants 
displaying SLRSPPS or RGDLRVS alone or co-incubated with mutant scAAV9-CMV-EGFP∆Gly67 
vectors displaying peptide sequences RGDLRVS or SLRSPPS, as well as mutants displaying the 
scrambled counterparts SDLRRGV and PSLPSRS (Chapter II.A.4). Before use, all vectors were 
tested individually on HCAEC at MOI 5E+3 gc/cell to ensure the absence (EGFP∆Gly67) or 
presence (EGFP) of fluorescence signals. The transduction assay was performed using 
parameters described in Table II.F.2, code 11. At the end of the incubation time, transduction 
efficiency of vectors was analysed by flow cytometry as described in Chapter II.D.2. 
 
 
II.F.6 Heparin competition assay 
 
The assay was performed by exposing 1E+5 HCAEC or 2.5E+5 HepG2 cells to wild type or 
scAAV9-CMV-EGFP vectors displaying peptide sequences RGDLRVS or SLRSPPS at MOI 5E+3 
gc/cell in presence or absence of 210 IU sodium heparin solution. Medium was replaced with 500 
µl/well cell culture medium containing vectors and – in case of heparin application – 2.5 µl 280 
mg/ml heparin stock solution (see also Chapter II.F.2). A wild type scAAV2-CMV-EGFP vector was 
used as positive control. The exposure time was set to 4 h and further incubation in presence of 
fresh medium was conducted ad 48 h. Transduction efficiency of vectors was analysed by flow 
cytometry as described in Chapter II.D.2. 
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II.F.7 In situ gene transfer studies with wild type and selected AAV vectors 
 
II.F.7.1 Gene transfer of murine Arteria mesenterica endothelium 
 
Female immunocompetent NMRI mice 6-8 weeks of age were purchased by the German branch of 
Charles River Laboratories. All animal procedures were carried out in accordance with the 
guidelines outlined by the local committee for animal experiments (DKFZ Heidelberg and 
Regierungspräsidium Karlsruhe). The experiments described in Chapter II.F.7 were performed in 
collaboration with Anja Feldner and Ender Serbest at the Institute for Physiology and 
Pathophysiology, Heidelberg, Germany. 
 
 
Isolation and preparation of Arteria mesenterica pieces 
The animals were sacrificed by cervical dislocation and were fixated on their backside with a pin 
each limb. Skin and abdomen were opened by a longitudinal cut along the linea alba from the 
groin to the sternum using surgical instruments. Two small transversal cuts at either end of the 
longitudinal cut exposed the viscera. The colon was spread and mesenteric artery secondary 
branch pieces ~5 mm in length were isolated after careful removal of adipose and connective 
tissue. The vessels were inserted into a culture myograph and artery ends were knotted to the 
cannulae using surgical suture to avoid vector leakage. The infusion system was operated by an 1 
ml syringe that was attached to the tubing of one cannula. 
 
 
In situ-exposure of murine mesenteric artery endothelial cells (MMAEC) 
Artery pieces mounted on the culture myograph were perfused with 50 µl endothelial cell culture 
medium (used for HCAEC, Chapter II.A.2) with or without 2.3E+9 gc/µl scAAV9-CMV-EGFP vector 
that displayed peptide SLRSPPS behind VP1 residue 589. The supply chamber was filled with 
medium until the artery pieces were covered and exposure was carried out for 48 h at 37°C. After 
vector treatment, the arteries were rinsed with 1x HBSS (w/ Ca2+ and Mg2+) and endothelium was 
counter-stained by perfusion with 50 µl 1x TRITC-lectin solution and 15 min incubation at RT in the 
dark. After rinsing with 50µl 1x HBSS, artery pieces were removed from the infusion system and 
were mounted on microscope slides. Transduction of MMAEC was evaluated with a fluorescence 
microscope at 20x magnification and EGFP and TRITC signals were acquired separately. 
 
 
In vivo-exposure of murine mesenteric artery endothelial cells (MMAEC) 
Mice were injected each 200 µl 4.6E+11 gc scAAV9-CMV-EGFP vector that displayed peptide 
SLRSPPS behind VP1 residue 589 or mock via tail vein using 27G x ¾ needles (n = 2). Two 
weeks later the animals were sacrificed and mesenteric artery pieces were stained and evaluated 
as described above. 
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II.F.7.2 Gene transfer of human Vena umbilica endothelium 
 
All experimental sets were performed in triplicate using human umbilical cords from independent 
donors. Cords were obtained from surrounding hospitals in Heidelberg and were kept at 37°C until 
use but not for longer than 8 h. A total of 12 cords were required to perform the final experiments 
below. Table II.F.7.2 gives an overview over the amount of cords needed for each experimental 
group. 
 
Table II.F:7.2: Amount of human umbilical cords needed for in situ/in vitro gene transfer studies on HUVEC 
 Amount of cords needed Experimental replicates 
In vitro-exposure 1 n = 3 each MOI 
In situ-exposure 6 n = 3 for wtAAV9 and AAV9-SLRSPPS each 
CD31 staining 1 n = 3 
Vector gc quantification in vitro 1 n = 3 each MOI 
Vector gc quantification in situ 3 n = 3 for AAV9-SLRSPPS 
 
 
Isolation of HUVEC from umbilical veins 
Residual blood clots were removed by gently dispersing the cords and veins were rinsed with RT 
1x HANKS buffer. HUVEC isolation occurred by perfusion with 3.125 mg/ml dispase solution and 
incubation at 37°C for 30 min. Detached cells were collected by gently dispersing the cords and 
flushing veins with 1x HANKS buffer. After pelleting (220 x g, 4 min, RT), cells were resuspended 
in medium and maintained in 25 cm2 flasks (see Chapter II.D.1.1) in corresponding medium 
(Chapter II.A.2) for 96 h with medium exchange occurring every other day. If a higher amount of 
cells was required, in vitro-propagation was extended to > 96 h as described in Chapter II.D.1.1. 
 
 
In vitro-exposure of HUVEC 
HUVEC were isolated as described above without vector pre-treatment and were cultivated until 
the desired cell number was achieved. Cells were seeded as described in Chapter II.D.1.1 and 
treated with AAV9-SLRSPPS vector as described in Chapter II.F.2, code 9. Transduction efficiency 
was analysed by flow cytometry as described in Chapter II.D.2. 
 
 
In situ-exposure of HUVEC 
Cleaned umbilical veins were perfused with HUVEC medium (Chapter II.A.2) supplied with 
scAAV9-CMV-EGFP wild type or mutant vector displaying peptide sequence SLRSPPS. Umbilical 
veins had diameters of 0.4-0.5 cm translating into a volume of ~0.125-0.196 cm3 (or µl) volume for 
a 1 cm long fragment. Therefore, perfusion occurred with 250 µl vector solution/cm of vessel 
containing 4.3E+8 vector gc. To avoid leakage of vector solution, cord ends were sealed by 
knotting with surgical suture. 
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After 2 or 24 h exposure at 37°C, vector solution was removed and veins as well as parts of the 
cord potentially contaminated with vector solution were rinsed thoroughly with 1x HANKS buffer. 
Transduction of HUVEC by wild type or mutant scAAV9-CMV-EGFP vectors was analysed by 
cryo-fixation and cross-sectioning as described below or after dispase-isolation by flow cytometry 
as described in Chapter II.D.2. 
 
 
Cryo-fixation and cross-sectioning of umbilical veins 
 
Umbilical veins were carefully removed from cords after 24 h vector treatment and cut into small 
pieces of about 0.5 cm. For cryo-fixation the vessel pieces were embedded in cryomolds using 
cryo-embedding compound and were frozen and stored at -80°C. Cross-sections were prepared in 
a cryostat at 10 µm thickness and were mounted on microscope slides and stored at -20°C. For 
endothelial counter-staining, cross-sections were 20 min air-dried, encircled with a fat pen, 50 µl 1x 
TRITC-lectin solution each section were added and the reaction was allowed to take place for 15 
min at RT in the dark. After rinsing with 50µl 1x HBSS, the sections were covered with coverslips 
using mounting medium with DAPI and transduction of HUVEC was evaluated with a fluorescence 
microscope at 20x magnification by separately acquiring EGFP, TRITC and DAPI signals. 
 
 
CD31-staining of isolated HUVECs 
Endothelial origin of isolated and cultivated cells was confirmed in a separate attempt by labelling 
endothelial marker protein CD31 with a FITC-conjugated PECAM-1 antibody (Chapter II.A.7). 
HUVEC were isolated from umbilical veins as described, but were not exposed to vector before. 
After 96 h in vitro-propagation, cells were rinsed once with 1x PBS, 2-3 ml non-enzymatic cell 
dissociation solution pre-warmed to 37°C was applied and cell detachment was monitored under a 
light microscope. The sample was separated in two portions and after centrifugation (220 x g, 4 
min, RT), cells were resuspended in 50 µl PECAM-1 antibody diluted 1:2 with 1x PBS or in 50µl 1x 
PBS only. Binding of PECAM-1 to CD31 was allowed to take place in the dark for 45 min at 4°C. 
Unbound antibodies were removed by centrifugation and washing once with 1x PBS and presence 
of CD31 was analysed by flow cytometry as described in Chapter II.D.2. 
 
 
Quantification of intracellular vector genome copies 
For quantification of intracellular genome copies umbilical veins were in situ-exposed to scAAV9-
CMV-EGFP displaying peptide SLRSPPS for 2 h and HUVECs were isolated by dispase treatment 
as described before. The isolated cell sample was divided in two parts. One part was propagated 
in HUVEC medium in a 25 cm2 flask as described (Chapter II.D.1.1) while the other was prepared 
for qRT-PCR quantification of genomes. A propagation of cells < 20 h prevented growth but 
enabled counting of adherent cells, since contaminating erythrocytes or other non-adherent cells 
were removed by rinsing with 1x HANKS. 
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It was assumed that the doubled number of counted cells after < 20 h propagation would 
correspond to the total amount of cells isolated the day before. Quantification of intracellular gc 
from the other part of isolated HUVEC occurred by isolation of total DNA with the DNeasy Blood & 
Tissue Kit according to the manufacturer's recommendations (07/2006, pages 25-26, steps 1c-8). 
DNA was eluted twice in the same 100 µl AE buffer supplied with the kit. In a separate attempt, 
HUVECs were in vitro-exposed to the vector (Chapter II.F.2, code 9), were collected using trypsin 
(Chapter II.D.1), and total DNA was purified with the DNeasy Blood & Tissue Kit. Vector genome 
copies among total DNA were quantified via qRT-PCR (Chapter II.B.8.2) using CMV primers and 
probe (Chapter II.A.4) and were calculated as genome copies/cell. 
 
 
II.G Statistical methods 
 
For statistical evaluation data obtained by FACS analysis (% EGFP-positive cells, Chapter II.D.2) 
was provided in duplicate (n = 2), triplicate (n = 3) or quadruplicate (n = 4). SigmaPlot software 
was used to calculate mean values, standard deviation (SD) and significance level (p-values) of 
samples, whereas SD and p were only calculated for samples with n > 2. An unpaired Student's t-
test was performed to calculate p-values and differences of means with p < 0.05 and p < 0.01 were 
regarded as significant or highly significant, respectively. All charts were generated using 
SigmaPlot and were further designed with Adobe Illustrator CS 5. 
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III. RESULTS 
 
 
III.A In vitro transduction of cells by AAV – preliminary experiments 
 
AAV transduction of cells in vitro can be influenced by various experimental parameters. To 
establish a reliable readout of transduction efficiencies, four parameters were analysed by 
incubating human coronary artery endothelial cells (HCAEC) with a self-complementary (sc) 
Adeno-associated virus serotype 2 (AAV2) vector displaying endothelium-targeted peptide 
NDVRAVS behind VP1 residue 588195. The vector encapsidated a CMV-EGFP expression 
cassette enabling analysis of transduction efficiency by flow cytometry. HCAEC were used as a 
cell model since library selection and related experiments were carried out predominantly on this 
cell type. The terms exposure and incubation subsequently used to describe cell treatment differ by 
the presence (exposure) or absence (incubation) of vector in cell culture medium. 
 
 
III.A.1 Influence of medium volume during exposure 
 
Exposure of cells to AAV occurs in cell culture vessels supplied with vector-containing medium and 
the applied volume influences the rate of vector-to-cell contacts. Since transduction depends on 
interaction of vectors and cell surface molecules, application of unnecessary high volumes will 
reduce the rate, resulting in lower transduction that in turn could render analysis of less efficient 
vectors difficult. At the same time, media volumes must be applied that ensure optimal 
maintenance of cells over several days. HCAEC were exposed to the vector mixed with 0.5 
ml/well, 1 ml/well and 1.5 ml/well (12-well plates) corresponding to 131 µl/cm2, 263 µl/cm2 or 394 
µl/cm2, respectively (Chapter II.F.1, code 1). The volumes included the range of 200-300 µl/cm2 
recommended by the manufacturer of the cell culture plates. Exposure in 0.5 ml/well yielded 
significantly (p < 0.01) the highest transduction of HCAEC (Figure III.A A). Notably, no 
morphological changes of HCAEC or other cell types maintained in this volume for a maximum of 4 
d could be observed. Thus, future in vitro transduction experiments were performed in a medium 
volume of 131 µl/cm2 unless otherwise noted. 
 
 
III.A.2 Influence of iodixanol during exposure 
 
In this study, AAV vector or virus purification occurred via step gradient (isopycnic) ultra-
centrifugation using iodixanol, a biologically inert contrast agent normally used for coronary 
angiography. Full capsids sedimented within the 40% iodixanol layer. Depending on titre of AAV 
stock and applied MOI, different amounts of iodixanol solution were mixed to medium, changing its 
viscosity. Since rate of vector-to-cell contact not only depends on amount of vector but also on 
medium viscosity, a high iodixanol incidence enforced by low vector stock titres could reduce the 
rate, thereby influencing transduction efficiencies. 
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To investigate the role of iodixanol concentrations, HCAEC were exposed to the vector in medium 
supplied with 1%. 5% and 10% total iodixanol concentrations (Chapter II.F.1, code 2). The 
presence of 10% iodixanol significantly (p < 0.01) reduced transduction efficiency by ~10% when 
compared to the 1% iodixanol sample (Figure III.A B). Only ~4 % reduction was observed between 
5% and 1% iodixanol samples (p < 0.02). The presence of 10% iodixanol in 0.5 ml medium 
requires mixing of 125 µl vector stock solution containing 40% iodixanol. Assuming typical 
experimental parameters of 5E+4 HCAEC/well and a MOI of 1E+4 gc/cell, a low vector stock titre 
of 4E+9 gc/ml is necessary to obtain final iodixanol concentrations of 10%. To avoid falsification of 
efficiencies by high iodixanol concentrations, vector preparations below 5E+10 gc/ml were not 
used for transduction studies, thus enabling total iodixanol concentrations of < 1%. 
 
 
III.A.3 Influence of incubation time on transduction 
 
Successful transduction of cells implicates the presence of decapsidated transgene DNA within the 
nucleus. Post-entry processing of vector particles can vary in time and efficiency thus influencing 
the abundance of vector genomes within the nucleus. Here, the time required for a complete 
transgene expression post vector-exposure was analysed by pulse-treatment of HCAEC with 
vector and continued incubation in absence of vector (Chapter II.F.1, code 3). Obviously, the 
amount of vector that has entered the cell during the 4 h vector exposure, is processed completely 
during the first 24 h of continued incubation, since no increase of transduction efficiency can be 
monitored upon extending incubation time to 72 h (Figure III.A C). This experiment however, must 
not necessarily represent other vectors or cell types used in this study and therefore an incubation 
time of 48 h was generally regarded as adequate for in vitro transduction experiments unless 
noted otherwise. 
 
 
III.A.4 Influence of exposure time on transduction 
 
As shown in III.A.3, post-entry processing of AAV2-NDVRAVS particles within HCAEC occurs 
during one day leading to maximum transgene expression. The uptake of all functional vector 
particles from medium into the cell, however, may take more than 4 h exposure time. To analyse 
this effect, exposure time of HCAEC to the vector was increased gradually from 2 to 72 h. After 
corresponding time points medium was replaced and incubation was continued up to 72 h allowing 
analysis of transduction in an exposure time-dependent manner (Chapter II.F.1, code 4). An 
increase of transduction was observed during the first 48 h of exposure, which plateaued at 48/72 
h (Figure III.A D). Thus, it was assumed that a total exposure time of 48 h should generally allow a 
comparable analysis of transduction efficiency between different vectors and was therefore applied 
subsequently for in vitro transduction experiments unless otherwise noted. 
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Figure III.A: Four different parameters affecting in vitro AAV transduction. Human coronary endothelial cells 
(HCAEC) were exposed to a scAAV2-CMV-EGFP vector displaying NDVRAVS behind VP1 residue 588 and exposure 
was terminated by removal of vector-containing medium. EGFP-expression was allowed to be established by continued 
incubation in presence of fresh medium. Transduction efficiencies obtained by flow cytometry analysis are given in % 
transduced HCAEC as means + SD (n = 3). (A) Influence of medium volume was assessed by pulse-exposing cells 4 h 
to vector using a MOI of 1E+4 gc/cell in 0.5 ml, 1 ml, or 1.5 ml medium. EGFP-expression was determined 48 h 
thereafter. (B) Absolute iodixanol amounts of 1%, 5% or 10% as well as vector at MOI 1E+4 gc/cell were mixed with 
medium and cells were exposed for 4 h. Influence of iodixanol presence was analysed after a continued 48 h incubation. 
(C). An exposure of 4 h to vector at MOI 5E+3 gc/cell followed by continued incubations ad 24 h, 48 h, or 72 h in 
presence of fresh medium indicated the time necessary for complete EGFP-expression. (D) Time-dependent 
transduction of cells incubated with vector at a MOI of 5E+3 gc/cell was investigated by applying variable exposure times 
of 2 h, 4 h, 8 h, 24 h, 48 h or 72 h. Incubation in presence of fresh medium was performed ad 72 h (except for the 72 h 
sample). 
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III.B Design of an adequate peptide display site on the AAV9 capsid surface 
 
III.B.1 Theoretical considerations 
 
Artificial modulation of tropism and transduction efficiency requires knowledge of functional capsid 
surface domains and their corresponding amino acid residues. Resolution of AAV2 atomic 
structure by x-ray crystallography94 together with identification of membrane-attached heparan 
sulphate proteoglycan (HSPG) as a primary receptor for AAV2 binding and infection92 as well as 
isolation of capsid regions involved in HSPG-binding90,91 enabled a more precise design of AAV2 
capsid mutants with altered tissue tropism and improved transduction efficiencies. Insertion of a 
random peptide heptamer library displayed behind VP1 arginine residue 588 (R588) and selection 
thereof on HCAEC resulted in enrichment of peptide sequences that conferred improved 
transduction efficiencies of AAV2 vectors for this cell type195. R588 is localized at the shoulder of 
the three-fold protrusions (Figure III.B.1-1 A-C, red highlights) that are formed partially by VP1-3 
loop IV (subloop 4), according to canine parvovirus (CPV) sequence alignment110. By another 
definition R588 is part of the variable region VIII (VR VIII, Figure III.B.1-1 D-F, red highlights) as 
first determined by Padron et al.100. A corrected version of VRs is shown in Govindasamy et al.96 or 
Figure III.B.1-2. 
 
Lacking structural information of the AAV9 capsid at the onset of the project as well as unknown 
capsid binding sites and cellular receptors limited the possibilities by which rational peptide 
insertion sites could be predicted for AAV9. A VP1 sequence alignment of AAV serotypes 1 to 9 
revealed VR VIII and other VRs to be shared by all analysed serotypes100, suggesting that these 
regions could be generally involved in differential AAV tropism. ClustalW2 analysis of AAV2 and 
AAV9 VP1 sequences (NCBI database accession numbers YP_680426.1 and AAS99264, 
respectively) performed online at EBI (http://www.ebi.ac.uk/ Tools/msa/clustalw2) pinpointed an 
alanine residue at position 589 (A589) to correspond to R588 from AAV2 (Figure III.B.1-2, blue 
highlights). It was therefore assumed, that display of foreign peptides behind A589 could also 
influence the tropism of AAV9. 
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Figure III.B.1-1: In silico modelling of an AAV2 VP mono- or trimer. A trimer (A, B, C) or a monomer (D, E, F) were 
modelled using PyMol software and data from protein data bank (PDB). AAV2 accession number is 1LP3. For orientation, 
T454 located at the tips of the three-fold protrusions formed by VR IV were labelled blue. Red-labelled R588 is located at 
the inward-oriented side of the shoulder (easily visible in A), that is formed by VR VIII. VP monomer and trimer are 
displayed from the perspective of a capsid cross-section (A, C), a ~45°C inclination towards the observer (B, E) or from 
top (C, F). Fusion of 20 such trimer subunits forms the AAV2 icosahedral capsid. 
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Figure III.B.1-2: Alignment of AAV2 and AAV9 VP1 peptide sequences. Sequence information was retrieved from 
NCBI (accession numbers YP_680426.1 and AAS99264 for AAV2 and AAV9, respectively) and ClustalW2-alignment was 
performed at EBI. Sequence editing was done with Geneious software and the illustration was manually modified with 
Adobe Illustrator CS5. The respective amino acids encoded by start codons of VP1-3 are framed in a box. Identical 
sequences of both serotypes are unlabelled while variable residues are highlighted orange. In addition, nine variable 
regions (VR) defined by Govindasamy et al.96 are indicated with Roman numerals. VR VIII of AAV2 sequence contains 
R588 and is paralleled by A589 from AAV9 (blue highlights). Discrepancies in numbering arise from additional or missing 
amino acids within VRI and IV. 
 
 
III.B.2 Adequacy of candidate residue A589 for peptide insertion 
 
The generation of a random peptide library displayed on the AAV capsid surface is laborious and 
cost-intense. The poor predictive accuracy for the outcome of AAV9 capsid modifications 
demanded the testing of VP1 residue 589 as a site for foreign peptides display before the virus 
library was produced. The sequence of the AAV9 cap gene was modified according to Müller et 
al.195 to allow insertion of oligonucleotides. Subsequently, AAV2 or AAV9 vectors displaying 
endothelium-targeted peptide NDVRAVS were generated to analyse the transduction efficiency of 
HCAEC. 
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III.B.2.1 Modification of the AAV9 cap ORF for oligonucleotide insertion 
 
The introduction of two SfiI restriction sites by base exchange (Chapter II.E.4.1) enabled cloning of 
oligonucleotides into plasmid backbone p5E18-VD-2/9-SfiI1759 (Chapter II.B.4.2) allowing display 
of foreign peptides behind AAV9 VP1 residue 589 (Figure III.B.2.1). The modification induced 
several amino acid exchanges/insertions within the wtAAV9 cap ORF: A587G, Q592A, and two 
new amino acids G and A flanking the peptide heptamer insertion (Figure III.B.2.1, red highlights). 
The anatomy of the oligonucleotide insertion site had two advantages: first, cloning of 
oligonucleotides occurred in an oriented fashion, since the two SfiI recognition sequences were not 
religation compatible (GGCC-AAGCA-GGCC versus GGCC-CAGGC-GGCC). Second, the two 
adenosine nucleotides separating the SfiI recognition sequences induced a frame-shift in the 
AAV9 cap open reading frame (ORF) creating an early stop codon downstream of the insertion 
site. Hence, production of AAV particles from plasmids lacking oligonucleotide inserts was 
prohibited. SfiI-cleavage of the 15 bp stuffer fragment from p5E18-VD-2/9-SfiI1759 (Figure III.B.2.1 
arrows) and ligation of an distinct oligonucleotide or a oligonucleotide library restored the frame 
and production of AAV capsids displaying foreign peptides behind VP1 residue 589 was possible. 
SfiI-treatment of oligonucleotides encoding peptide heptamers was not necessary since the single-
stranded 21-mers were flanked by several nucleotides generating SfiI-compatible overhangs. 
 
 
 
Figure III.B.2.1: Design of an oligonucleotide insertion site within the AAV9 cap gene. A representative section of 
the AAV9 cap ORF encompassing VP1 residue 589 is shown in a 5' to 3' orientation (see also Figure III.B.1-2). Sequence 
alignment revealed wtAAV9 alanine residue A589 to correspond to AAV2 arginine residue R588 (green highlights). 
Modification of the wtAAV9 cap ORF allowed insertion of two incompatible SfiI recognition sites (framed boxes). Only 4 
amino acid residues were affected (red highlights), leaving the residual cap ORF unchanged. 
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The oligonucleotides encoding distinct peptide heptamers or the peptide library were flanked by nucleotides that would 
create SfiI compatible sticky ends upon annealing. Separation of SfiI recognition sites by two adenines induced a frame-
shift within the cap ORF. Correct insertion of a 32-mer (dashed box) restored the frame-shift and enabled capsid 
formation from VP proteins displaying inserted peptide heptamers. 
 
 
III.B.2.2 Transduction efficiency of AAV9 vectors displaying peptides selected with AAV2 libraries 
 
Wild type or mutant scAAV9-NDVRAVS vectors displaying endothelium targeted peptide 
NDVRAVS behind VP1 residue 589 were produced and their transduction efficiency of HCAEC 
was compared to wtAAV2 and AAV2-NDVRAVS (Chapter II.F.1, code 5). While wtAAV2 and 
wtAAV9 showed transduction efficiencies of 19.2±10.7% and 12.4±3.9%, respectively, AAV2- and 
AAV9-NDVRAVS improved efficiencies to 71.7±15.7% and 74.2±8.9% transduced cells, 
respectively (Figure III.B.2.2), confirming the theoretical assumption that peptide display behind 
VP1 residue 589 modulates tropism and increases transduction efficiency of AAV9 vectors. 
Therefore, VP1 residue 589, comparable to VP1 residue 588 of AAV2, is suitable for introduction 
of foreign peptides or a peptide library. 
 
 
 
Figure III.B.2.2: Transduction efficiencies of wild type and mutant AAV2 and AAV9 vectors. HCAEC were exposed 
for 72 h to AAV2 (white bars) or AAV9 (black bars) wild type or mutant vectors displaying peptide NDVRAVS behind VP1 
residues 588 or 589, respectively. Each construct was analysed at MOI 1E+4 gc/cell using two independent vector 
productions. Transduction efficiencies obtained by flow cytometry analysis is given in % EGFP-positive cells as means + 
SD (n = 4). 
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III.C Generation and characterization of an AAV9 random heptapeptide display library 
 
After verifying the role of VP1 residue 589 as a potential peptide insertion site, the AAV9 random 
peptide display library production was attempted. A three step procedure described by Müller et 
al.195 was applied: first, the plasmid library was created by introduction of a randomized 
oligonucleotide library into a plasmid backbone containing the modified AAV9 genome (see 
Chapter III.B.2.1). In the second step, the plasmid library together with a helper plasmid encoding 
wtAAV rep and cap and a wild type Adenovirus serotype 5 (Ad) helper plasmid were transfected 
into HEK 293T producer cells to obtain transfer shuttle library (TSL) particles. The mosaic AAV 
capsids of the TSL are formed by wild type and mutant VPs that randomly package the genomes 
present in the respective cell. In the third step, the TSL was used to re-infect HEK 293T cells at a 
MOI of 0.5 IU/cell, ensuring theoretical uptake of one viral genome/cell. Subsequent super-
infection with Ad lead to synthesis of virus library particles from VP proteins that were transcribed 
from only one genome present in a cell, ensuring the display of heptamer sequences that 
correspond to the packaged genomes. A schematic overview of the three production steps is given 
in Figure III.C and Chapters III.C.1-III.C.3 provide more detailed information about the individual 
steps and implications related to them. 
 
 
 
Figure III.C: Schematic representation of the AAV9 library production steps. (A) The randomized oligonucleotide 
library was cloned into the library plasmid backbone via SfiI-digestion. The library plasmid contains AAV2 ITRs (ITR2), 
the rep gene from wtAAV2 (rep2) and the modified AAV9 cap gene (cap9lib). (B)The library plasmid, wtAAV helper 
plasmid providing wild type AAV2 or AAV9 VP proteins and a helper plasmid containing essential Ad genes E4, E2A and 
VA were triple-transfected into HEK 293T producer cells. Thus, the transfer shuttle library (TSL), mosaic capsid particles 
consisting of wild type and mutant VP proteins displaying random heptamers is produced. (C) The TSL is applied at a 
MOI 0.5 IU/cell to ensure infection of HEK 293T cells with only one particle/cell. Wild type VP proteins present on the TSL 
shells provide a theoretically an infection of HEK 293T from each TSL particle (dashed arrow line). 
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Super-infection with Ad (wtAd5) enables amplification of internalized TSL genomes and generation of pure virus library 
particles that display peptide heptamers encoded by the encapsidated genomes. 
 
 
III.C.1 The plasmid library 
 
III.C.1.1 Design of the randomized oligonucleotide library 
 
The degenerated genetic code discloses the opportunity to modify the DNA sequence of a protein 
without affecting its peptide chain. In most cases, prohibiting the appearance of a certain base at 
the third position of the codon lowers the occurrence of that particular amino acid. Exemplary, 
changing the NNN architecture to NNK reduces the codons of arginine by half (CGG, CGT, AGG, 
see Table S2), as N permits all 4 bases within the first two codon positions and K limits the third 
position bases to G and T. This modification also affects the number of stop codons, which in case 
of NNK are reduced by one third, at the same time prevailing the occurrence of all amino acids. 
Therefore, the NNK architecture was chosen as a basis for the synthesis of the random peptide 
display library. Theoretically, a peptide chain consisting of seven amino acid residues featuring all 
20 amino acids yields 1.28E+9 (207) different sequences. 
 
 
III.C.1.2 Plasmid library complexity 
 
A crucial step in the generation process of the plasmid library that can reduce the complexity is 
posed by the insert-to-backbone ratio used for ligation of oligonucleotide library and plasmid 
backbone (pKV-AAV9Lib/BB). The complexity is estimated by counting of bacterial colonies after 
transformation (transformation efficiency) and is given in colony forming units (CFU)/µg 
transformed DNA (see Chapter II.E.4.1). Assuming the transformation of only one library plasmid 
copy per bacterial cell that later forms a colony, the total amount of colonies is an approximation for 
the complexity. To test the most feasible insert-to-backbone ratio, three different test-ligations 
without or with 10x, 30x or 100x molar excess of oligonucleotide library to backbone were 
prepared. Counting of colonies assigned highest complexity to the attempt using the 30x excess of 
insert with a background from re-ligation of empty plasmid backbones of 0.17% (Table III.C.1.2, left 
panel). The 20x up-scaled ligation attempt using this ratio yielded a total of 6.02E+7 CFU/µg 
plasmid (Table III.C.1.2, right panel) translating into 6.02E+8 CFU/10 µg that represents at the 
same time the total plasmid library complexity. 
 
Table III.C.1.2: Estimation of plasmid library complexity by calculation of transformation efficiencies 
Excess Insert CFU/µg1 plasmid Background2 (%)  Batch1 CFU/µg plasmid Mean CFU/µg 
10x 2.09E+7 0.28  1 5.35E+7 
6.02E+7 
30x 3.47E+7 0.17  2 3.90E+7 
100x 7.80E+6 0.74  3 5.64E+7 
Control 5.80E+4 1  4 9.20E+7 
1see Chapter II.E.4.1, 2quotient of „control“ and „excess inserts“ 
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The NNK-architecture of the plasmid library allows only G or T nucleotides at the third codon 
position and thus reduces the total amount of codons from 64 to 32. This influences also the 
theoretical occurrence OT of stop codons (equation (2)) that are reduced from 35% for NNN (x = 3, 
y = 60) to 21.9% for NNK (x = 1, y = 32) within the peptide heptamer. 
 
 
100 × residues 7 × 
codons totaly 
codons stopx 
  =O   (2) T  
 
 
Still, the amber stop codon can be encoded and its occurrence within the heptamer lowers the 
complexity of the plasmid library. Within 79 sequenced plasmid library clones 30 stop codons were 
identified (37.9%), exceeding the calculated OT of the NNK or NNN architectures. In total, 28 
sequences (35.4%) contained one or more stop codons at random positions within the heptamer 
rendering them infeasible for virus production (Figure S1 A). Therefore, the plasmid library 
complexity of 6.02E+8 CFU/10 µg was corrected by factor 0.354 to its functional complexity of 
3.89E+8 clones. 
 
 
III.C.1.3 Amino acid distribution of peptide heptamers encoded by the plasmid library 
 
The theoretical mean occurrence of a NNK-encoded amino acid over the entire peptide heptamer 
was calculated with equation (3) as a quotient of codons encoding that amino acid and total 
available codons: 
 
 
( ) 100  ×  residues 7 ×  
codons totaly 
codonsx 
  =O   3 T  
 
 
In case of alanine the theoretical mean occurrence is 6.3% (x = 2, y = 32). In reality, after counting 
alanine appearances within 79 analysed sequences, its mean occurrence was 5.4% (see Table 
S1). Theoretical and real mean occurrences were calculated for the remaining amino acids and are 
summarized in Figure III.C.1.3. Overall, the occurrence of amino acids within the plasmid library 
(Figure III.C.1.3, dotted line) fits theoretical calculations (continuous line), with exception of cystein 
(C), phenylalanine (F), valine (V) and tyrosine (Y) that seem to be slightly over-represented. A 
more disclosed amino acid distribution shown in Figure S1 A reveals no accumulation or 
consecutive repetition of more than 2 amino acids. Together, the plasmid library can be regarded 
as sufficiently complex with an exhaustive amino acid usage that is represented in an residue-
unbiased manner. 
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Figure III.C.1.3: Representation of amino acids within plasmid and virus library. Individual clones from plasmid (79) 
or virus library (70) were sequenced and amino acid distribution for each residue within the heptapeptide was 
determined. The occurrence of each amino acid at any position was calculated as percentage and the average over the 
entire heptamer is plotted here as % of mean occurrence for each amino acid. Theoretical means (continuous line) were 
assessed by calculating the probability an amino acid would to occupy a residue according to the NNK-architecture of the 
library oligonucleotide. Data for the plasmid and virus library are given in dotted and dashed lines, respectively. * = stop 
codon (amber). 
 
 
III.C.2 The transfer shuttle library (TSL) 
 
A categorical feature of the TSL is a high infection efficiency of the producer cell line, since this 
eventually represents the key to a high virus library complexity. Transfection of the plasmid library 
alone would yield TSL viruses from VP proteins encoded by several cap variants from the plasmid 
library and viral genomes would be encapsidated in mosaic capsid particles, as in case of Perabo 
et al.194. Such particles potentially display different infective properties and if applied for infection, a 
preferential uptake of some TSL particles over other may occur, lowering the final library 
complexity. Co-transfection of an ITR-negative helper plasmid containing the wtAAV2 cap ORF 
cleared this imbalance in case of AAV2-based TSL productions. WtAAV2 vectors have a strong 
transduction efficiency of HEK 293T cells and transcapsidation of the TSL with wtAAV2 VP proteins 
theoretically ensures an approximately equal efficiency of infection for each TSL particle. 
 
However, wtAAV9 vectors display only a very low transduction of HEK 293T cells (Figure III.F.1) 
and transcapsidation with wtAAV9 VPs may lower the general TSL infectiousness and complexity. 
A transcapsidation of the AAV9 TSL with wtAAV2 VPs may solve the problem, however, at the risk 
of a lowered packaging efficiency as observed for transcapsidation of AAV subgroups A and C187. 
Hence, TSL test-productions with wtAAV2 and wtAAV9 VPs at variable ratios of 1:1, 1:5 and 1:10 
library to wild type VPs (Table III.C.2) were attempted to analyse the most feasible combination. In 
theory, a stoichiometric plasmid ratio of 1:1, 1:5 or 1:10 would result in TSL particles assembled 
from 30:30, 12:48 or 6:54 VPs from wtAAV9 and wtAAV2, respectively. 
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In addition, different amounts of plasmid library pKV-AAV9Lib per cell were assayed. In the 
following description TSL productions from wtAAV2 or wtAAV9 helper plasmids (pRSV-VP3co and 
p5E18-VD-2/9, respectively) are referred to as 2-TSL or 9-TSL, respectively. The use of Ad helper 
plasmid pDG∆VP is not mentioned explicitly below. 
 
No DNase-resistant particles (DRP) were detectable from 2-TSL (code AC) or 9-TSL (code AD) 
control productions performed in absence of library plasmid proving a helper plasmid stock free of 
wild type-contaminations. Another control production using library plasmid only (code AB) yielded 
genomic titres comparable to productions employing helper plasmids (codes ABC, ABD), albeit 
with a reduced infectiousness of HEK 293T. Insertion of foreign peptide heptamers behind VP1 
residue 589 obviously does not hamper efficient genome packaging and formation of infectious 
particles from VP protein library variants but the reduced infectiousness indicates the need of 
wtAAV VP proteins as described above. The infectiousness of TSL particles was tested on HEK 
293T cells (Chapter II.E.3), since this cell type was also used for the production of the final virus 
library. Although expected, no differences of infectiousness between 2-TSL or 9-TSL particles were 
present (codes ABC and ABD). Comparable genomic titres of 2-TSL and 9-TSL productions prove 
an efficient packaging capacity of transcapsidated AAV particles. Independent of helper plasmid, a 
slight decrease of TSL infectiousness was detected when higher amounts of library plasmid or a 
higher library to helper plasmid ratio was employed. According to these results a stoichiometric 
library to helper plasmid ratio of 1:1 together with the application of only 1 µg library plasmid for 
5E+6 cells (1 dish, see Chapter II.E.4.2) resulted in TSL particles with the maximum infectiousness 
of HEK 293T cells (Table III.C.2, framed boxes). 
 
Table III.C.2: Genomic and infectious titres of TSL produced at different plasmid ratios 
Code Ratio1 pKV-AAV9Lib (µg) Infectious titre (IU/ml) Genomic titre (gc/ml) 
AB 1:1 n/a n/a 5 n/a n/a 1E+4 n/a n/a 1.1E+9 
AC 1:1 n/a n/a 5 n/a n/a 0 n/a n/a 0 
AD 1:1 n/a n/a 5 n/a n/a 0 n/a n/a 0 
           
ABC 
1:1 1 2 5 1E+6 1E+6 1E+5 1.4E+9 1.5E+9 2.8E+9 
1:5 1 2 5 1E+5 1E+5 1E+4 2.3E+9 1.1E+9 1.6E+9 
1:10 1 2 5 1E+6 1E+5 1E+5 6.9E+8 1.9E+9 1.4E+9 
           
ABD 
1:1 1 2 5 1E+6 1E+5 1E+5 2.2E+9 2.5E+9 7.4E+9 
1:5 1 2 5 1E+5 1E+6 1E+5 1.9E+9 5.2E+8 2.6E+8 
1:10 1 2 5 1E+5 1E+4 1E+5 1.5E+9 4.4E+9 9.1E+8 
Codes: A = pDG∆VP, Ad-helper plasmid; B = pKV-AAV9Lib, library plasmid; C = pRSV-VP3co, wtAAV2 helper 
plasmid; D = p5E18-VD-2/9, AAV9 helper plasmid; 1code B to C or D 
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III.C.3 The virus library 
 
III.C.3.1 Virus library titres and complexity 
 
Using the production parameters established in Chapter III.C.2, 2-TSL and 9-TSL productions were 
upscaled to 20x of the amounts of test productions (see Chapter II.E.4.2). These productions 
yielded comparable absolute genomic and infectious titres (see Table III.C.3.1). The functional 
complexity of the plasmid library of 3.89E+8 was reduced to 5E+7 for both TSL, as the complexity 
can not exceed the amount of infectious particles present in a virus stock. To generate the final 
virus library, the HEK 293T producer cell line was infected using the TSL productions at MOI 0.5 
(Chapter II.E.4.3). First, two small-scale library productions employing TSL of either origin were 
produced and analysed. Determination of infectious titre was not possible due to a inhomogeneous 
infectiousness of library particles. The absolute genomic titre of both small-scale library 
productions yielded 3E+9 gc each and confirmed similar production efficiency from both TSL 
backgrounds. Due to reasons explained later in Chapter III.C.4 only the 2-TSL was used for the 
large-scale final library production. This final library yielded an absolute genomic titre of 4.6E+11 
gc or 4.6E+3 gc/cell which is comparable to those of AAV vectors displaying peptides (Chapter 
III.E.1), suggesting a easily scalable and hence cost-effective production method. Again, the 
infectious titre can not be analysed directly, but since the entire TSL with a complexity of 5E+7 was 
employed in the production process, a final library complexity of up to 5E+7 can be expected, 
taking into account the loss of variants during production and purification steps. 
 
Table III.C.3.1: Genomic and infectious titres of upscaled TSL and virus library 
Absolute titres PL1 TSL2 (pRSV-VP3co) TSL (p5E18-VD-2/9) VL3 
Genomic (gc) n/a4 3.8E+12 3.2E+12 3E+9 
Infectious (IU) n/a 5E+7 5E+7 n/a 
Complexity 3.89E+8 5E+7 5E+7 n/a 
1plasmid library, 2transfer shuttle library, 3virus library from both TSL sources, 4not assayed 
 
 
III.C.3.2 Amino acid distribution of peptide heptamers encoded by the virus library 
 
Sequencing of 70 individually assigned clones (Chapter II.E.5) allowed the analysis of amino acid 
usage and randomness of peptide heptamer inserts. A decreased average presence of cysteine 
(C), aspartic (D) and glutamic acid (E) and threonine (T) was detected, while presence of 
asparagine (N) and serine (S) was slightly increased when compared to theoretical means (Figure 
III.C.1.3, Supplementary Table 1). Notably, N was strongly over-represented at the first (25.7% vs 
theoretical 3.1%) and S at second and sixth residue (both 18.4% vs theoretical 9.6%). The biggest 
differences in mean occurrence between plasmid and peptide library (Figure III.C.1.3) were 
observed for amino acids C (5.2%), N (4.5%) and S (5.3%). 
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Similarly, involved heptamer residues were the first (N), second and fifth to seventh (all S). Despite 
this slight bias for the presence of certain amino acids, the virus library can be regarded as 
sufficiently complex with an acceptable amino acid usage and distribution. 
 
 
III.C.4 Wild type contamination of the AAV9 random peptide display library 
 
The lack of ITRs flanking the AAV genomes of helper plasmids avoids packaging of wtAAV 
genomes during TSL production. However, an exchange of wild type and mutant cap sequences 
by intracellular DNA recombination between helper and library plasmid would create wild type 
genomes flanked by ITRs leading to a wild type contamination of TSL and final virus library 
particles. Such a wild type contamination lowers the library complexity and leads to co-selection of 
wtAAV on wild type-permissive cells, thus impairing the selection process. To compensate this 
drawback, the codon-optimized helper plasmid pRSV-VP3co bearing a synthetic wtAAV2 cap gene 
was developed and enabled the production of a wild type-free AAV2 peptide library201. No codon-
optimized wtAAV9 helper plasmid was available for the creation of an AAV9 random peptide library, 
rendering DNA recombination between p5E18-VD-2/9 helper and pKV-AAV9LIB library plasmids 
probable. 
 
All plasmids involved in AAV9 library production, TSLs and final virus libraries were subjected to 
PCR analysis (Chapter II.F.1) to detect the presence of contamination with wtAAV9 sequences. 
The primer pair AAV9cap-F/R amplifies a 270 bp fragment within the wtAAV9 cap ORF or a 297 bp 
fragment within an AAV9 cap ORF containing an oligonucleotide insertion. Easy discrimination of 
fragments is possible by electrophoretic separation on a 2.5% agarose gel. Stocks of pRSV-VP3co 
and pDG∆VP were free of wild type contamination and plasmid p5E18-VD-2/9 showed the 
expected 270 bp wtAAV9 fragment (Figure III.C.2, “Plasmids”). Library plasmid pKV-AAV9Lib, 
however, reproducibly showed along with the typical library fragment at 297 bp also a faint wild 
type fragment at 270 bp, indicating primordial wild type-contamination. The persistence of the 
contamination in both TSLs and the final virus libraries (Figure III.C.2, “TSL” and “Library”) prove 
that the wild type-contamination of the plasmid library stock originates from wild type genomes 
containing ITRs. Consequently, an AAV9 random peptide display library free of wtAAV9 
contamination using this plasmid library stock was not possible. High overall library plasmid 
production costs lead to the decision to continue the project with the present plasmid library. It was 
assumed that the low permissiveness of wtAAV9 towards HCAEC (see Chapter III.B.2.2) would 
exclude a co-selection of wtAAV9 and would allow enrichment of distinct virus variants, as shown 
for the selection of a wtAAV2-contaminated AAV2 library on human saphenous vein ECs201. The 
less intense 270 bp fragment from the library production using 2-TSL (pRSV-VP3co) suggests 
contamination to a lower degree. Thus, only the 2-TSL was used for the large-scale production of 
the final virus library which then was employed for selection of endothelium-targeted peptides. 
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Figure III.C.4: Detection of wtAAV9-contaminations during the virus library production. PCR-amplification of DNA 
occurred with primer pair AAV9cap-F/R that amplifies a 270 bp fragment of wtAAV9 cap ORF or a 297 bp fragment from 
cap ORFs containing an oligonucleotide insert. Five µl PCR products previously mixed with 6x Gel Loading Dye Blue 
were loaded on a 2.5% agarose gel and electrophoresis was run for 2 h at 5 V/cm electrode distance. For positive control 
(PC), 100 pg of plasmids p5E18-VD-2/9 or p5E18-VD2/9-SfiI1759 with an oligonucleotide insert were PCR-amplified 
separately and 5 µl PCR reaction each were mixed and loaded on the same lane, facilitating discrimination between wild 
type and library fragments. One µl ddH2O instead of DNA template was used as negative control (NC). Ten ng of each 
plasmid employed in library production (Plasmids) or ~55 pg purified DNA from 2-TSL and 9-TSL, unselected virus library 
(Library) and virus library selected once (R1) or four times (R4) at MOIs 10, 100 and 1000 gc/cell on HCAEC were 
inserted into the PCR reaction. For a better visualisation the gel photography is displayed as a black/white-inversion and 
brightness/contrast were adjusted to enable visualization of faint bands. 
 
 
III.D. In vitro selection of the AAV9 random peptide display library on HCAEC 
 
The AAV9 peptide library consists of a multitude of capsid variants (Figure III.D-1) that may display 
different levels of transduction efficiencies. Selection therefore will favour the propagation of virus 
particles that have beneficial attributes related to the infection process of the host cell. Peptide 
display on the capsid surface does not only influence binding to cell surface receptors and 
endocytosis, but modulates also the downstream processing of viral particles, like endosomal 
release, nuclear import, uncoating or packaging of replicated genomes. Only capsid variants that 
master all these steps with good efficiency will be enriched during repeated selection of the library 
on host cells (Figure III.D-1, red hexagons). But also less efficient variants will propagate during 
the initial selection round, for instance variants with poor binding and internalisation properties but 
efficient in the downstream processing (Figure III.D-1, green hexagons). Such variants can be 
theoretically eliminated by application of several consecutive selection rounds. In addition, 
defective viruses that bind to receptors but fail to enter the cell represent a potential source of 
contamination as they would mix with efficient variants during library purification by cell lysis. To 
largely avoid the presence of such false positive variants, purification of enriched virus particles 
involved trypsination of cells, which is expected to remove cell surface receptors and with them 
bound viral particles (Figure III.D-1, orange hexagons). 
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An important role for proper amplification of internalized AAV particles plays the MOI used for 
super-infection of cells with Ad. Excessive amounts of Ad will lead to an untimely cell lysis lowering 
the titre of AAV library particles. 
 
 
 
Figure III.D-1: Schematic representation of the selection process of the AAV9 library in vitro. HCAEC were 
exposed for 4 h to the library at MOIs of 10, 100 and 1000 gc/cell in separate attempts (Infection). After exposure, 
unbound library particles (yellow, blue, violet) were removed and fresh medium containing Ad was supplied (Super-
infection). Super-infection with Ad lead to the amplification of internalized library particles which then were purified by cell 
lysis. Prior to lysis, cells were harvested using trypsin, thereby removing bound but not internalized library particles 
(orange). Purified enriched library particles were re-applied to HCAEC for a new selection round (New infection). After 
the third and fourth selection round, DNA clones were prepared and were sequenced to reveal the sequence of the 
enriched library peptide. 
 
 
The AAV9 peptide library was selected four consecutive rounds on HCAEC, each round using 
three different MOIs of 10, 100 and 1000 gc/cell in separate attempts (Chapter II.F.1). Preliminary 
experiments performed with variable MOIs of Ad on HCAEC revealed a 50% cytopathic effect after 
48 h incubation at MOI 20 IU/cell. It was assumed that these parameters would be acceptable for a 
proper amplification of internalized library particles. After the third and fourth selection round 
aliquots of purified viral DNA were PCR-amplified, sub-cloned into plasmids and transformed into 
bacteria. Independently assigned single colonies were analysed to reveal enriched peptide 
heptamer sequences (Chapter II.E.5). Independent of selection round or applied MOI, peptide 
sequence RGDLRVS represented the most prominent peptide (Figure III.D-2). Second most 
common peptides were NFTRLSA and SLRSPPS with a more restricted distribution. Notably, 
some peptides shared certain residues or had similar sequences (RGDLRVS/FRVG, S/TL/IRS/APPS/A) 
while others were differed in amino acid composition (DAKWDYR, GAIPDLR). 
 88 
These results prove that three to four selection rounds of the AAV9 library on HCAEC yielded a 
consistent enrichment of certain peptide sequences independent of applied MOI or wtAAV9 
contamination of the library. PCR-analysis of the library after the first and the fourth selection round 
showed a low wild type-contamination, confirming the assumption that co-selection of wtAAV9 in 
non-permissive cells is less likely to happen (Figure III.C.4). Remarkably, any of the enriched 
peptides descended from the same DNA clones in an MOI or selection round-independent manner. 
In contrast, enriched peptides from a HCAEC-selected AAV2 library195 were from different DNA 
clones (not shown). 
 
 
 
Figure III.D-2: Peptide sequences detected after selection of the AAV9 random peptide library on HCAEC. 
Nucleotide sequences from independently assigned clones were translated into protein sequences using Geneious 
software and amino acids were highlighted in unique colours. Peptide sequences are displayed as amount of 
peptides/total analysed clones each applied MOI (gc/cell). A compilation of all detected peptides is shown in “All 
sequences” in a most to less abundant fashion, top to bottom. R3, R4 = selection round 3, 4. 
 
 
III.E In vitro efficiency of AAV9 vectors displaying enriched peptide sequences 
 
The efficiency of a targeted vector system is the first of three parameters that determines its quality 
as a gene transfer vector. The enrichment of library variants after 3-4 selection rounds does not 
reflect the effective transduction efficiency they would confer to an AAV vector since a strong 
enrichment reflects a good virus uptake but not necessarily a good intracellular processing. 
Selection of an AAV2 random peptide library on HCAEC yielded peptides with high abundances 
(NSSRDLG, NSVSSIA) after three selection rounds but the less represented NDVRAVS conferred 
to AAV2 vectors the highest transduction efficiencies of HCAEC195. 
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Therefore, investigation of more and less abundant peptide sequences is advisable. As a second 
selection criterion the sequence of enriched peptides was considered. Below, an assortment of 
several enriched peptides were characterized by vector titre and transduction efficiency on 
HCAEC. 
 
 
III.E.1 Vector production efficiency 
 
Mutant AAV vectors harbouring an EGFP reporter gene controlled by the Cytomegalovirus 
promoter (CMV) were produced by transfection of plasmids pDG∆VP providing Ad-helper genes, 
dsAAV-CMV-EGFP providing the CMV-EGFP expression cassette flanked by ITRs and p5E18-
VD2/9-SfiI1759 (or pMT-187-XX2) that provide rep2 and cap9 (cap2) ORFs with oligonucleotide 
insertions enabling expression of peptide heptamers behind amino acid residue 588 (AAV2) and 
589 (AAV9), respectively (Chapter II.B.4.2). For a better comparison, the titres of vector 
productions were normalized to the amount of genome copies obtained from a single producer cell 
(gc/cell). 
 
Independent of serotype, wild type vectors yielded the highest titres of 2E+4 gc/cell (Table III.E.1) 
translating into absolute titres of 1E+12 gc obtained from 5E+7 HEK 293T cells (10 dishes, small 
gradient, see Chapter II.E.1). AAV9 vectors containing peptide inserts ranged from 5.8E+3 to 
1.4E+4 gc/cell. The titre of only one AAV9 vector that displayed peptide sequence SDLRRGV was 
reproducibly below 1.0E+3 gc/cell (5E+10 gc) and its production was upscaled to 5E+8 cells (20 
dishes) to meet the requirements described in Chapter III.A.2. Peptide SDLRRGV represents a 
randomized sequence of peptide RGDLRVS, the most prominent peptide after four selection 
rounds of the AAV9 library on HCAEC (Figure III.D-2). SDLRRGV has not been subjected to 
selective pressure and probably reduces the stability of AAV9 vectors it is displayed on, thus 
creating lower vector titres. However, this did not happen for peptide PSLPSRS (1.1E+4 gc/cell) 
that represents a randomized sequence of enriched SLRSPPS. The titres of AAV2 vector 
productions employed in this study were generally slightly lower. Together, peptide displaying 
AAV9 vectors yield genomic titres about 0.5 log steps below their wild type counterpart, a result 
comparable to AAV2 vectors, proving that display of peptide heptamers behind VP1 capsid residue 
589 does not impair packaging efficiency of AAV9 vectors. 
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Table III.E.1 Productions of mutant AAV vectors and their titres 
Peptide AAV2 vectors (gc/cell) AAV9 vectors (gc/cell) 
Wild type 2.0E+4 2.0E+4 
NDVRAVS 2.4E+3 9.4E+3 
NSSRDLG 2.6E+3 8.2E+3 
NSVSSAS 1.0E+3 9.4E+3 
SLRSPPS 7.8E+3 1.2E+4 
RGDLRVS 7.2E+1 7.6E+3 
NLHSPPA 1.2E+3 1.5E+4 
TEWDQPF - 1.0E+4 
RGDFRVG - 6.4E+3 
NNVRGFV - 5.8E+3 
NFTRLSA - 8.0E+3 
SIRSPPS - 1.2E+4 
SDLRRGV - 1.3E+3 
PSLPSRS - 1.1E+4 
 
 
III.E.2 Transduction efficiency 
 
A total of seven enriched peptide sequences detected after the third and fourth selection round 
were chosen for a closer characterisation: RGDLRVS/FRVG, SLR/SIRSPPS, NFTRLSA, NNVRGFV and 
NLHSPPA. To assess the potential of enriched peptides to transduce HCAEC or H5V, a murine 
malignant hemangiosarcoma endothelial cell line derived from heart capillaries, cells were exposed 
to vectors from the same stock and transduction efficiencies were compared to those of wtAAV9, 
AAV9-NDVRAVS, as well as to AAV9-TEWDQPF, which displays a random (non-selected) control 
peptide (Chapter II.F.2, code 6). In case of HCAEC, two independent vector stocks each construct 
were assayed in duplicate to compensate fluctuations in transduction efficiency among different 
productions. WtAAV9 and AAV9-TEWDQPF vectors showed a very low (2.3±1.6%) to absent 
transduction of HCAEC at MOI 1E+4 gc/cell. In contrast, AAV9-NDVRAVS improved transduction 
efficiency to 58.4±5.1% (Figure III.E.2 A). Almost all mutant AAV9 vectors displaying any of the 
selected peptides significantly outperformed endothelium-targeting NDVRAVS vector at MOIs 
1E+3 (p < 0.05) and 1E+4 gc/cell (p < 0.001), except NFTRLSA and NNVRGFV which showed no 
significant differences to NDVRAVS at MOI 1E+3 gc/cell. Peptides SLR/SIRSPPS and NLHSPPA 
enabled by trend the highest transduction efficiencies at MOI 1E+4 gc/cell when compared to the 
other enriched peptides. 
 
A reduction of applied vector dose could be achieved with mutant AAV9 vectors on HCAEC. The 
most efficient peptide SLRSPPS yielded at MOI 1E+3 gc/cell efficiencies of 46.8±25.8% on 
HCAEC, a cell type that is refractory to wtAAV transduction and normally requires higher vector 
does for efficient transduction195,201. In contrast, transduction efficiencies of H5V were far below 
those detected for HCAEC, although no significance could be calculated, since only one attempt 
was undertaken for each construct and MOI (Figure III.E.2 B). 
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The results obtained so far point out several aspects. In vitro selection of an AAV9 library on 
HCAEC yields peptides that outperform transduction efficiency of wtAAV9 and, more important, of 
the most potent peptide NDVRAVS obtained by selection of an AAV2 library on HCAEC. It's worth 
mentioning that AAV9-NDVRAVS tested here has an efficiency similar to AAV2-NDVRAVS 
(Chapter III.B.2.2) and thus both vectors can be compared directly. Furthermore, no correlation 
could be detected between abundance of a peptide after several selection rounds and the 
transduction efficiency it confers to the vector. Less represented SLRSPPS yielded significantly (p 
< 0.01) higher efficiencies than most abundant peptide RGDLRVS, an observation that has been 
also made for AAV2-NDVRAVS and most abundant peptides AAV2-NSSRDLG/NSVSSIA195. Due 
to this outcome, most abundant or most efficient peptide RGDLRVS and SLRSPPS, respectively, 
were regarded as the most interesting selected peptides in this study. 
 
 
 
Figure III.E.2: Transduction efficiencies of wild type and mutant scAAV9-CMV-EGFP vectors. (A) HCAEC (B) H5V. 
CMV-EGFP bearing wild type and mutant vectors displaying enriched peptides behind VP1 residue 589 were exposed at 
MOIs 1E+3 (white bars) or 1E+4 (black bars) gc/cell for 48 h and transduction efficiencies were determined by flow 
cytometry. Besides peptide NDVRAVS (positive control) from selection of an AAV2 library on HCAEC and a non-selected 
random peptide TEWDQPF (negative control), seven other peptides were chosen based on their frequency of 
occurrence. Efficiencies for HCAEC are given in % EGFP-positive cells as means + SD (n = 4, two independent vector 
productions) and efficiencies for H5V are given in % EGFP-positive cells as single values. 
 
 
III.F. In vitro-specificity of AAV9 vectors displaying enriched peptide sequences 
 
The improvement of AAV9 transduction by display of endothelium-targeted peptide sequences 
raised the question whether also cell specificity, the second crucial parameter that determines the 
quality of a gene therapy vector, would be increased. Cell specificity can largely be obtained when 
the displayed peptide retargets AAV towards a cell surface receptor expressed uniquely on the 
target cell, since a receptor commonly expressed on several cell types will broaden AAV tropism. 
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III.F.1 Target cell specificity 
 
Transduction efficiencies of wild type and mutant AAV9 vectors displaying SLRSPPS and 
RGDLRVS were assessed on several cell types (Chapter II.F.2, code 7). At a MOI of 2.5E+3 
gc/cell, wtAAV9 vectors showed efficiencies of below 10% on primary cells (HCAEC, HCASMC) or 
cell lines (HEK 293T, HeLa, 911 and HepG2). Both, AAV9-SLRSPPS and AAV9-RGDLRVS 
increased transduction efficiencies of other cell types as they did for HCAEC, although to a 
different degree depending on the inserted peptide. Remarkably, transduction patterns of AAV9-
SLRSPPS and AAV9-RGDLRVS correlated with the type of the investigated cells. AAV9-
SLRSPPS significantly (p < 0.01) outperformed AAV9-RGDLRVS on primary cells (HCAEC, 
HCASMC) while AAV9-RGDLRVS showed higher transduction efficiencies on cell lines (p < 0.01 
for HEK 293T, HeLa, and HepG2; p < 0.05 for 911). Overall, AAV9-SLRSPPS seems to be more 
specific to HCAEC than AAV9-RGDLRVS. Nonetheless, retargeting of AAV9 vectors towards 
HCAEC by display of foreign selected peptides on the capsid surface does not restrict in vitro 
tropism, probably because vector mutants target cellular surface receptors commonly expressed 
on several cell types. 
 
 
 
Figure III.F.1: Transduction efficiencies of wild type and two scAAV9-CMV-EGFP mutants of different cells. CMV-
EGFP bearing wild type and mutant vectors AAV9-SLRSPPS and AAV9-RGDLRVS were applied for 48h at MOI 2.5E+3 
gc/cell and transduction efficiencies of primary (HCAEC, HCASMC) or immortalized cells (HEK 293T, 911, HeLa, HepG2) 
were determined by flow cytometry. Efficiencies are given in % EGFP-positive cells as means + SD (n=4, two 
independent vector productions). 
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III.F.2 Improvement of target cell specificity by transcriptional targeting 
 
Transgene expression limited to the desired cell type is of high interest, since the broad tropism of 
AAV promotes gene delivery to foreign tissues and could entail deleterious, even toxic effects. 
Given that restriction of AAV9 tropism towards HCAEC by retargeting is insufficient, control of 
transgene expression can be exercised by the use of cell- or tissue-specific promoters. The non-
regulated CMV promoter used to control EGFP expression in this study is inadequate for 
transcriptional targeting, in that it is constitutively activated in multiple cell types. In the past, a set 
of murine and human endothelium-specific promoters have been characterized (reviewed by232). 
Robust transgene expression obtained from the 313 bp fragment of the murine VE-cadherin 
promoter in bovine aortic ECs (BAEC) but not in murine fibroblasts (NIH-3T3)233 and availability of 
a plasmid source containing the entire VE-Cadherin promoter (EMBL databank accession no. 
Y10887) favoured the choice of this promoter as a candidate for transcriptional targeting in 
HCAEC. 
 
To enforce endothelium-specific EGFP expression, the CMV core promoter was replaced by the 
163 bp fragment containing the basal transcriptional machinery or the 313 bp fragment containing 
additionally the major specific inhibitory region of the VE-Cadherin promoter (Chapter II.F.3). 
However, the CMV enhancer element was not removed and potentially acted also in combination 
with the 163/313 bp fragments. CMV, 163, or 313-EGFP expression cassettes were packaged into 
an AAV9 vector that displayed peptide SLRSPPS, which is regarded as the most potent peptide of 
the present study (Figure III.E.2 A). The level of transgene expression was then analysed on 
AAV9-SLRSPPS permissive primary (HCAEC, HCASMC) or immortalized cells (HEK 293T, 911; 
Chapter II.F.2, code 8). Transgene expression directed by both the 163 bp and the 313 bp 
fragment occurred by trend at slightly elevated levels compared to CMV in HCAEC, however their 
activity in non-ECs could not be completely downregulated (Figure III.F.2). EGFP-expression levels 
driven by the 163/313 bp fragments in human coronary artery smooth muscle cells were similar to 
CMV and robust expression was also present in immortalized cells (HEK 293T, 911), although at a 
~50% reduced efficiency in case of the 163 bp fragment. Taken together, the employment of the 
short 163 bp or 313 bp fragments from murine VE-cadherin promoter yielded only poor 
improvement of endothelium-specific transgene expression over CMV, however, their size may be 
advantageous in contrast to CMV, since they occupy less space within the transgene expression 
cassette, leaving more space for larger transgenes. 
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Figure III.F.2: Transcriptional targeting of HCAEC by the murine VE-cadherin promoter. The transcriptional activity 
of the 163 bp and the 313 bp fragment of the murine vascular endothelial (VE) cadherin promoter was compared to the 
CMV promoter on primary cells (HCAEC, HCASMC) or cell lines (HEK 293T, 911). Cell types were chosen according to 
their susceptibility towards the AAV9-SLRSPPS vector (see Chapter III.E.3) that packaged either the CMV-EGFP or the 
163/313-EGFP expression cassettes containing the CMV enhancer region. Exposure of cells took place at MOI 2.5E+3 
gc/cell for 48 h. The 163 bp fragment of the VE-cadherin promoter contains the basal transcriptional machinery and the 
313 bp fragment additionally the major specific inhibitory region necessary for endothelium-specific activation. 
Efficiencies are given in % EGFP-positive cells as means + SD (n = 3). 
 
 
III.G Serotype specificity of AAV vectors displaying enriched peptide sequences 
 
The selection of a randomized peptide heptamer library displayed on the AAV2 capsid surface on 
HCAEC yielded peptides that improved AAV2 and AAV9 vector transduction of this cell type over 
both wild types (Chapter III.B.2.2 and195). This raised the question whether display of peptides 
derived from selection of AAV2 libraries on the AAV9 capsid would not be sufficient for AAV9 
retargeting towards endothelium, avoiding a laborious and expensive generation and selection of 
an AAV9 library. An attempt to answer this question was posed by analysis of transduction 
efficiencies from vectors of either serotype that displayed peptides derived from AAV2 and AAV9 
library selections on HCAEC. A set of peptides selected in the context of an AAV2 library195 or the 
AAV9 library on HCAEC were chosen according to highest abundance after 3-4 selection rounds 
or highest efficiency (Table III.G). The peptides were cross-displayed on AAV2 or AAV9 CMV-
EGFP vectors behind VP1 residues 588 or 589, respectively, and transduction of HCAEC using 
parameters described in Chapter II.F.2 (code 10) was analysed by flow cytometry. Below, library 
source (X) and vector serotype context (Y) of peptides are given as “X-peptide-Y”. 
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Table III.G: List of most abundant/efficient peptides from AAV2/AAV9 library selections on HCAEC 
 AAV2 library selection AAV9 library selection 
Most abundant peptides NSSRDLG, NSVSSAS RGDLRVS 
Most efficient peptides NDVRAVS SLRSPPS, NLHSPPA 
 
 
Either serotype showed as usual basal transduction efficiencies of HCAEC below 10% (Figure 
III.G). Overall, 9-peptides-9 yielded higher transduction efficiencies of HCAEC when compared to 
2-peptides-2. Most importantly, 9-peptides-9 significantly (p < 0.01) outperformed 2-peptides-9, 
proving the advantage of an AAV9 library selection. In contrast, 9-peptides-2 yielded very low to 
absent transduction and 2-peptides-9 performed similarly to 2-peptides-2, as seen in case of 
NSSRDLG and NSVSSAS, which represent the peptides with the highest abundance after a three 
round AAV2 library selection. An unexpected outcome was represented by cross-display of the 
most potent peptides from both AAV-library selections, NDVRAVS and SLRSPPS. The efficiency 
of 9-SLRSPPS-2 was absent, while 2-NDVRAVS-9 yielded results similar to 2-NDVRAVS-2 (see 
also Figure III.B.2.2). This outcome substantiates that the peptides are not solely responsible for 
the modulation of transduction efficiency but depend on the capsid context of the serotype they are 
displayed on. 
 
 
 
Figure III.G: Transduction efficiencies of AAV2 and AAV9 cross-displayed peptides. Most abundant and most 
efficient peptides yielded by selection of AAV2 or AAV9 peptide libraries on HCAEC were chosen and cross-displayed on 
AAV2 or AAV9 vectors behind VP1 residues 588 and 589, respectively. The library source of a peptide is indicated with a 
2 or a 9 prefix and the vector serotype the peptides are displayed on is given in the legend. HCAEC were exposed to 
vectors at MOI 5E+3 gc/cell for 48 h and transduction efficiencies analysed by flow cytometry are given in % EGFP-
positive cells as means + SD (bars, n = 3). 
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III.H In vitro immune evasion of AAV9 vectors displaying enriched peptide sequences 
 
The third quality-related parameter of a gene transfer vector is reflected by its ability to evade 
neutralization by host immune system. Pre-existing antibodies within human or animal serum 
sensitively alter the outcome of a gene transfer attempt by binding to AAV capsids and impairing 
transduction of target tissue. Removal of antigenic epitopes from surface-exposed capsid domains 
could represent a solution to this issue. In contrast to AAV9, epitopes of several binding and 
neutralizing antibodies have been mapped for AAV2 assigning them to more exposed structures of 
the capsid surface174,173. It is therefore imaginable, that insertion of foreign peptides at the exposed 
AAV9 capsid site including VP1 residue 589 not only affects targeting and transduction efficiency 
but also recognition by neutralizing antibodies. To test this hypothesis, the effect of antisera on 
transduction efficiency of a set of wild type and mutant AAV vectors was analysed in vitro. HEK 
293T cells are well permissive for wtAAV2, mutants AAV9-SLRSPPS/RGDLRVS and to a lesser 
extent also for wtAAV9 (Figure III.F.1) and thus were adducted as a cell model. Intravenous 
immunoglobulin (IVIG), pooled human antisera on the one hand, and ADK9, a murine monoclonal 
antibody raised against wtAAV9 capsids on the other, were pre-incubated with vectors at several 
dilutions. Subsequently, cells were exposed to pre-treated vectors (Chapter II.F.4). Present or 
absent transduction efficiencies were regarded as reciprocal neutralization values, whereas vector 
transduction in absence of neutralizing antibodies was set to 100% (controls). As a threshold, 
neutralization of transduction was assumed when transduction efficiency of samples treated with 
IVIG or ADK9 was reduced by 50% to that of controls. 
 
WtAAV2 and AAV2-NDVRAVS vectors that displayed in absence of IVIG transduction efficiencies 
of >98%, were neutralized throughout the entire range of dilutions (Figure III.H A). Similarly, 
wtAAV9 vectors were neutralized by both, IVIG and ADK9 up to dilutions of 1:1280. However, 
AAV9 mutants SLRSPPS and RGDLRVS improved in vitro antibody evasion over wtAAV9, 
wtAAV2 and AAV2-NDVRAVS about four and eight times, respectively, (~1:320 and ~1:160, 
Figure III.H A) and were only affected by IVIG (Figure III.H A, B). These results suggest that 
besides an efficient endothelium-targeting, the AAV9 vectors displaying selected peptides also 
confer improved (in vitro) evasion from neutralizing antibodies, rendering AAV9 more suitable as a 
serotype backbone for targeted peptide display than AAV2. 
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Figure III.H: Neutralization of AAV-transduction by IVIG or ADK9. HEK 293T cells were exposed for 48 h to wild type 
or mutant scAAV-CMV-EGFP displaying SLRSPPS, RGDLRVS or NDVRAVS at MOI 1E+4 gc/cell. Vectors were 
previously treated with serial dilutions of IVIG (A) or ADK9 capsid antibody (B). Neutralization of transduction was 
assumed when efficiency dropped below 50% of values obtained with vectors in absence of serum or antibody (not 
shown). Efficiencies determined by flow cytometry (% EGFP-positive cells) were calculated as means - SD (n=3) and are 
shown here as reciprocal % neutralization of transduction - SD. The dilution of IVIG or ADK9 at which immune escape 
has occurred by definition can be extrapolated at the intersection of continuous and dashed lines (50% threshold). 
 
 
III.I. Secondary characterisation of endothelium-targeted peptides 
 
The results obtained so far from transduction experiments involving AAV vectors that display 
endothelium-targeted peptides pointed out some interesting aspects: (I) AAV9-SLRSPPS and 
AAV9-RGDLRVS vectors selected in this study showed differential transduction efficiencies when 
incubated with different cell types (Figure III.F.1). Primary cells were transduced more efficiently by 
AAV9-SLRSPPS while immortalized cells showed a higher permissiveness towards AAV9-
RGDLRVS. This finding, together with the disparity of the peptide sequences raised the impression 
of a differential transduction pathway, that was closer characterized using a capsid competition 
assay. (II) Also the differential transduction pattern of different cell types these two peptides confer 
to AAV9 attracted attention to arginines present within their sequences. AAV9 does not possess 
arginine residues within VR VIII (Figure III.B.1-2) but gains them by displaying the peptides. Thus, 
the hypothesis of an AAV9 retargeting towards HSPG, the attachment receptor of arginine-bearing 
AAV2, was analysed using a competition assay with soluble heparin. 
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III.I.1 Modulation of transduction in presence of a competing vector 
 
The successful transduction of a cell depends on pre- and post-entry efficiency of vectors. On the 
pre-entry part, the rate of endocytosis is regulated both by capsid properties that influence the 
binding of the vector to one or more dedicated cell receptor(s) and the abundance of the 
receptor(s) on the cell surface. On the post-entry part, the capsid is the main factor determining the 
intracellular processing efficiency of the vector. Thus, vectors based on two different capsids can 
exploit diverse starting points or pathways for efficient transduction, that are not mutually exclusive. 
The disparity of SLRSPPS and RGDLRVS peptides that conferred to AAV9 vectors a differential 
transduction pattern of several cell types prompted a closer investigation of whether the vectors 
would use identical or different pathways. To elucidate the differences, a competition assay using 
both vectors was performed. Competition occurs only when the vectors use a common pathway or 
parts of it, for instance extracellular receptors or checkpoints involved in intracellular processing. A 
vector supplied in excess, i.e. the competitor, will out-compete the analyte vector upon targeting 
the same pathway, thus exhibiting superior transduction or lowering that of the analyte, but will not 
interfere in case completely different transduction pathways are employed. In the present case the 
readout was focused on the analyte whose uptake in to the cell would be lowered in case of a 
common pathway usage. To enable distinguishing, the analyte vector encapsidated a CMV-EGFP 
expression cassette, while the competitor packaged a non-fluorescent CMV-EGFP∆G67 transgene 
(Chapter II.F.5). Thus, only cell transduction originating from analyte vectors was measured by flow 
cytometry. 
 
The hypothesis of differential transduction pathway usage of AAV9-SLRSPPS and AAV9-
RGDLRVS was analysed on HCAEC by assigning to either vector the role of the analyte supplied 
at MOI 5000 gc/cell or the competitor supplied at 25x-100x excess MOI. Transduction efficiencies 
of either analyte vector in absence of competitor were set to 100% (Figure III.I.1 A, white bars). 
First, the assay was validated by co-incubating analyte and competitor vectors with identical 
capsids using a 75x excess MOI for the competitor. Transduction in presence of competitor 
decreased from 100% to 58.2±3.8% for AAV9-SLRSPPS and 56.7±5.0% for AAV9-RGDLRVS, 
validating the assay (Figure III.I.1 A, light grey bars). Then, analyte vectors were co-incubated with 
75x excess competitor vectors that displayed the scrambled sequences PSLPSRS and SDLRRGV, 
respectively. In contrast to the previous experiment, the transduction efficiency of analyte vectors 
was not significantly altered (Figure III.I.1 A, dark grey bars). This control experiment showed that 
the lowering of analyte transduction does not arise from unspecific steric inhibition exercised by 
massive competitor presence but rather is vector (or peptide sequence) specific. This outcome was 
further supported by the finding, that an increase of competitor excess from 25x to 100x gradually 
lowered transduction of HCAEC for both analytes to a certain point of saturation that was achieved 
at 75x excess (Figure III.I.1 B). 
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Importantly, co-incubations of analyte and competitor vectors with adverse capsids supplied at 75x 
excess lowered the transduction efficiencies to 60.8±2.8% for AAV9-SLRSPPS and 51.7±4.2% for 
AAV9-RGDLRVS, respectively (Figure III.I.1 A, black bars), proving a competition effect between 
these two mutants and the usage of a common pathway or parts of it. 
 
 
 
Figure III.I.1: Transduction efficiencies of mutant AAV9 vectors in presence of competitors. (A) Transduction 
efficiencies of analyte vectors displaying peptides SLRSPPS or RGDLRVS behind VP1 residue 589 were analysed on 
HCAEC. Each analyte was incubated at MOI 5000 gc/cell in absence (no competitor, transduction set to 100%) or 
presence of competitor vectors displaying SLRSPPS, scrambled peptides PSLPSRS and SDLRRGV or RGDLRVS 
supplied at 75x excess MOI. Co-incubations were terminated by medium exchange after 4 h and incubation in presence 
of fresh medium was continued ad 48 h. Transduction efficiencies were analysed by flow cytometry and are given in % 
EGFP-positive cells as means + SD (bars, n = 3). (B) AAV9 analyte vectors displaying SLRSPPS and RGDLRVS were 
co-incubated in absence (no competitor, transduction set to 100%) or presence of competitor vectors displaying 
RGDLRVS and SLRSPPS, respectively, supplied at 25x-100x excess MOI and data was evaluated as in (A). Dots 
represent means ± SD (n = 3). 
 
 
III.I.2 Modulation of transduction in presence of soluble heparin 
 
In case of AAV2, a cluster of several basic arginines, R588 among them, represent binding sites 
for HSPG receptor. Mutants lacking one or several of these arginine residues exhibit a lowered 
infectiousness91,90. As both, SLRSPPS and RGDLRVS deliver arginine residue(s) to the otherwise 
arginine-negative AAV9 capsid at this site, the question arose whether the enriched peptides could 
have retargeted AAV9 to the HSPG receptor. To answer this question, HCAEC and HepG2 cells 
were exposed to wild type or mutant AAV9 displaying SLRSPPS or RGDLRVS in presence or 
absence of solute heparin. 
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HCAEC is only poorly permissive for transduction by both serotypes (< 10%, Figure III.I.2, EC). 
Since HepG2 (Hep) is expressing HSPG, wtAAV2 in contrast to wtAAV9 efficiently transduced this 
cell type in the absence of heparin (94.8±1.5%) but failed to do so in its presence. Heparin did not 
alter the transduction patterns of SLRSPPS on any cell type but did for RGDLRVS to a small, but 
significant extent (p < 0.05 for HCAEC and p < 0.01 for HepG2). In case of SLRSPPS and 
probably also RGDLRVS, the gain-of-arginines through display of selected peptides does not 
retarget AAV9 towards a HSPG-dependent transduction pathway. 
 
 
 
Figure III.I.2: Transduction of cells by wild type and mutant AAV vectors in presence or absence of heparin. Wild 
type AAV2 or wild type and mutant AAV9 vectors displaying peptides SLRSPPS (9SLR) and RGDLRVS (9RGD) behind 
VP1 residue 589 were incubated at MOI 5E+3 gc/cell with HCAEC (EC) or HepG2 (Hep) in presence or absence of 210 
IU solubilised heparin. Exposure was terminated after 4 h and cells were incubated ad 48 h in presence of fresh medium. 
Transduction efficiencies were analysed by flow cytometry and are given in % EGFP-positive cells as means + SD (bars, 
n = 3). 
 
 
III.J In vivo efficiency of AAV9 vectors displaying enriched peptide sequences 
 
In vitro-selection of the AAV9 library on HCAEC yielded vector AAV9-SLRSPPS, that in 
combination with the short 163 bp fragment of the murine VE-Cadherin promoter could represent a 
powerful tool for in vitro gene transfer studies on ECs. However, the promising results obtained so 
far on cultivated ECs can not be extrapolated to cells embedded in their natural context of a blood 
vessel. The most evident difference between the cultivated and naturally occurring ECs is their 
state of proliferation: cultivated ECs divide, naturally occurring ECs remain under normal 
circumstances quiescent. Also, the artificial environment cultivated cells are exposed to poorly 
mimics the context of a blood vessel with mural cells blood components interacting with the EC 
monolayer. This differences may affect the in vivo transduction of ECs by AAV. 
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To elucidate the feasibility of this study's endothelium-targeted vectors in vivo, an adequate model 
had to be chosen. A broad palette of animal models and evaluation techniques has been 
developed in the past for preclinical studies on AAV vector transduction. Due to lower overall costs, 
broad availability, easy handling and low-dosed vector application by tail vein injection, mice were 
favoured over other animals in this study. Several evaluation tools were considered: in vivo-
imaging of whole organ transduction in live animals, analysis of isolated and sectioned organs by 
immune-histochemistry (IHC) and real-time PCR-quantification of vector genomes isolated from 
organs. These techniques allow reliable investigation of AAV transduction, albeit with a certain 
detection limit that strongly depends the amount of present vector genomes. However, the low 
number of ECs that are widely disseminated throughout the filigree vascular system of a mouse 
and a difficult isolation in sufficiently high amounts might easily undercut the detection limits of the 
mentioned techniques rendering them less suitable for the present study. Additionally, the poor 
transduction efficiency of H5V using AAV9 vectors displaying selected peptides at the high MOI of 
1E+4 gc/cell (see Figure III.E.2 B), could point out a low transduction efficiency of murine ECs, 
further impairing evaluation. Therefore, a technique was employed that allowed a more direct 
visualisation of endothelium. 
 
 
III.J.1 In situ/in vivo transduction of murine endothelium 
 
Due to the low thickness and good accessibility of the murine mesenteric artery branches (Arteria 
mesenterica), easy vessel isolation and direct visualisation of stained murine mesenteric artery 
endothelial cells (MMAEC) by fluorescence microscopy is possible. This is advantageous, since 
chemical or cryo-fixation of tissue usually needed for immunohistochemic (IHC) analysis can be 
avoided, leaving the physiological structure of endothelium unaltered. Healthy female NMRI mice 
were sacrificed and secondary branch artery pieces of ~5 mm length were excised (Chapter 
II.F.7.1). Exposure to leading vector AAV9-SLRSPPS or mock occurred immediately upon removal 
from mice in a myograph device by in situ perfusion of vessel pieces with 2.3E+9 gc/µl vector 
solution followed by a 48 h exposure. A detachment of endothelial tissue was observed from vector 
incubations that exceeded 48 h, determining the maximum possible maintenance time of 
endothelium in physiological condition ex vivo. After TRITC-labelled lectin counter-staining of 
MMAEC, transduction by vector was monitored using a fluorescence microscope. The presence of 
an endothelial layer within the blood vessel pieces was confirmed after 48 h treatment with vector 
or mock (Figure III.J.1, TRITC-lectin). However, no EGFP-fluorescence above background (mock, 
EGFP) could be detected in AAV9-SLRSPPS treated arteries (48 h, EGFP). 
 
Assuming a successful transduction, 48 h exposure of endothelium to the vector may be sufficient 
for a proper uptake of vectors into the cells in situ but unfolding of EGFP expression strongly 
depends on rate-limiting post-entry processes like endosomal release, nuclear import and 
uncoating of the transgene and may require a prolonged time. 
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Since ex vivo-maintenance of endothelium for more than 48 h was not possible, mice were in vivo-
exposed to mock or 4.6E+11 vector gc/animal AAV9-SLRSPPS vector by tail vein injection. Two 
weeks later the animals were sacrificed and transduction of mesenteric artery endothelium was 
analysed as shown above. Again, endothelium presence but no EGFP fluorescence could be 
detected in vessel pieces from mice treated with vector (results not shown). Although a low 
efficiency of the CMV promoter in quiescent ECs cannot be ruled out, this outcome, together with 
the poor transduction of H5V in vitro (Chapter III.E.2) points rather towards a low efficiency of 
AAV9-SLRSPPS in murine endothelium rather than to an inadequate dose or evaluation technique. 
 
 
 
Figure III.J.1: In situ visualisation of murine mesenteric artery fragments treated with an AAV vector. Vessel 
pieces (~5 mm) were isolated from sacrificed female NMRI mice and were perfused with HCAEC medium containing 
2.3E+9 gc/µl of a scAAV-CMV-EGFP vector displaying SLRSPPS or medium only (mock). After an exposure of 48 h, 
fragments were rinsed with 1x PBS and endothelium-counterstaining with TRITC-labelled lectin was performed. Red 
(TRITC) and green (EGFP) fluorescence were separately monitored with a fluorescence microscope at 20x 
magnification. The vessel margins can be recognized in the lower left and upper right corners of the images. 
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III.J.2 In situ transduction of human endothelium 
 
The AAV9-SLRSPPS mutant vector developed in this study was efficient for in vitro transduction of 
human ECs but failed to transduce murine ECs in vitro (H5V) and in situ (MMAEC). The AAV9 
library was selected on ECs of human origin and a specificity of vectors towards species is 
imaginable. Therefore, a new model based on the human umbilical vein (Vena umbilica) 
endothelium was assayed. Direct evaluation of longitudinal vein stretches by fluorescence 
microscopy as performed in the case of murine mesenteric arteries, however, was not possible due 
to the opaqueness and size of the umbilical vein. Thus, evaluation of transduction occurred by 
cryo-fixation and cross-sectioning of treated veins (Chapter II.F.7.2). Preliminary attempts reduced 
the ex vivo maintenance time to 24 h as longer incubations lead to a detachment and loss of 
endothelium. Endothelial tissue was exposed for 24 h to 4.3E+8 gc/cm vein AAV9-SLRSPPS 
bearing a CMV-EGFP expression cassette without separation of veins from cords, thus maintaining 
the natural environment of human umbilical vein endothelial cells (HUVEC) and avoiding 
endothelial damage. The endothelium was detectable after 24 h via TRITC-lectin counter-staining 
of cross-sectioned veins but no EGFP fluorescence was present (data not shown). In vitro 
transduction of human umbilical vein ECs (HUVEC) by AAV9-SLRSPPS was confirmed in a 
separate attempt (Figure III.J.2). Analogously to transduction of murine mesenteric artery 
endothelium it was assumed that unfolding of EGFP-expression may require more than 24 h. In a 
new attempt to detect in situ-transduction of HUVEC, umbilical veins were exposed only 2 h to wild 
type or mutant AAV9 vectors displaying SLRSPPS. After exposure, HUVEC were isolated from 
veins by dispase treatment and propagated in vitro for 4 d (Chapter II.F.7.2). The advantage of in 
vitro cultivation was a removal of non-adherent cells and an increase of available cell numbers for 
transduction analysis by flow cytometry, the method applied to analyse transduction of HUVEC.  
 
First, the endothelial character of vector-untreated cells was confimred after isolation and in vitro-
cultivation by flow cytometry using a FITC-conjugated PECAM-1 (CD31) antibody. CD31 is an 
endothelial marker also expressed on several other cell types like platelets, macrophages, 
granulocytes, lymphocytes, megakaryocytes, killer cells and neutrophils but not on other cell types 
of the vascular wall (vascular smooth muscle cells, pericytes). Over 99% of cultivated cells were 
CD31+ (Figure III.J.2. A, green dots) proving their endothelial character. Moreover, no detectable 
contamination with CD31– mural cells was present in the analysed population. 
 
To detect transduction by AAV9 vectors, in situ-exposure was performed as described above. After 
4 d of in vitro propagation, isolated HUVEC (further referred to as in situ-exposed HUVEC) showed 
a high transduction efficiency of 80.3+11.9% from AAV9-SLRSPPS, in contrast to wtAAV9 which 
had an efficiency of below 1% (Figure III.J.2 B, grey bars). Due to an unknown amount of cells 
lining the umbilical veins, calculation of MOI was not possible but a high MOI can be expected at 
4.3E+8 vector gc/cm vein. 
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A parallel in vitro transduction assay was performed by exposing HUVEC to AAV9-SLRSPPS at 
four different MOIs (further referred to as in vitro-exposed HUVEC; see Chapter II.F.2, code 9). 
Here, a correlation of applied MOI and increment of transduction efficiency was observed, that 
peaked at MOI 5E+4 gc/cell (Figure III.J.2 B, white bars). At this MOI, transduction of in vitro and in 
situ-exposed HUVEC were comparable. 
 
To rule out in vitro transduction by vector contamination carry-overs into cell culture and to further 
strengthen the proof for in situ transduction, the presence of vector genomes in HUVEC isolated 
immediately after exposure to AAV9-SLRSPPS (as before) was attempted. The number of isolated 
cells was determined (see Chapter II.F.7.2) and vector genome copies from purified total DNA 
were quantified by qRT-PCR yielding a total of 148.7±45.8 gc/cell (Figure III.J.2 B, black dot within 
grey bar). Similarly, presence of vector genome copies/cell was analysed in in vitro-exposed 
HUVEC at different MOIs, resulting in detection of more copies/cell from higher MOIs (Figure III.J.2 
B, black dots within white bars). A direct comparison of vector genome presence and transduction 
efficiency between in vitro and in situ-exposed HUVEC however can not be made, since in case of 
in vitro-exposed HUVEC the data was obtained from the same cell sample, while independent 
samples were used in case of in situ-exposed HUVEC. 
 
The experiments within this chapter revealed that in situ-exposure to AAV9-SLRSPPS but not to 
wtAAV9 lead to transduction of HUVEC embedded in their natural context of a blood vessel. This 
experimental setup represents therefore a good approximation of what the vector would enable in 
an in vivo attempt. However, EGFP-expression from in situ-exposed HUVEC was observed only 
after isolation and in vitro propagation of cells but not within vasculature-embedded cells. 
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Figure III.J.2: In situ and in vitro transduction of human umbilical vein endothelial cells (HUVEC). (A) HUVEC 
were isolated by dispase treatment from umbilical veins and were propagated in vitro for 4 d. Endothelial character was 
confirmed by flow cytometric analysis of >10.000 cells treated with a FITC-conjugated human PECAM-1 antibody (n = 3). 
The representative PI-versus-FITC dot plot shows an overlay of treated (green dots) versus non-treated cells (black 
dots). A subset of antibody-treated CD31– cells would appear as green dots among the subset of black dots. Only live 
cells gathered at 101 RFI in the PI-channel were analysed for CD31-presence. (B) In situ-exposure of HUVEC to wtAAV9 
or mutant AAV9 vectors displaying peptide SLRSPPS behind VP1 residue 589 occurred for 2 h at 4.3E+8 gc/cm umbilical 
vein. Both vectors packaged a CMV-EGFP expression cassette. After enzymatic isolation, cells were further propagated 
in vitro for 4 d. In another attempt, HUVEC were in vitro-exposed to AAV9-SLRSPPS only at various MOIs (X-axis) for 2 
h and were further incubated in presence of fresh medium ad 48 h to allow unfolding of EGFP-expression. In either case, 
transduction was monitored by FACS analysis and efficiencies are given in % EGFP-positive cells as means + SD (grey 
bars for in situ, white bars for in vitro, n = 3 each). To determine the intracelular presence of vector genomes, HUVEC 
exposed to AAV9-SLRSPPS in situ or in vitro were counted, total DNA was isolated and vector genomes were quantified 
by qRT-PCR. The amount of genome copies/cell is presented as means± SD (black dots, n = 3, right Y-axis). 
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III.K Supplementary material 
 
 
 
Figure S1: Peptide sequences obtained from sequencing of library clones. A total of 79 library plasmid clones (A) or 
70 unselected virus library clones (B) were sequenced to reveal the amino acid composition of the heptamers. 
Nucleotide sequences were translated into protein sequences using Geneious software and amino acids were 
highlighted in unique colours. Stop codons in (A) are represented by stars on black background. Within the plasmid 
library clones 30 stop codons were identified rendering 27/79 sequences unfeasible for AAV capsid formation. 
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Table S1: Occurrence of amino acids within 79 plasmid library (white background) or 70 virus library (grey background) heptamers 
AA1 Counts/amino acid position % occurrence  
 I II III IV V VI VII I II III IV V VI VII M2 TM3 
A 4 2 6 6 1 4 6 6 2 4 6 8 5 3 5.1 2.9 7.6 8.6 1.3 5.7 7.6 8.6 2.5 5.7 7.6 11.4 6.3 4.3 5.4 6.7 6.3 
C 5 0 4 0 3 0 5 2 5 0 7 0 3 1 6.3 0.0 5.1 0.0 3.8 0.0 6.3 2.9 6.3 0.0 8.9 0.0 3.8 1.4 5.8 0.6 3.1 
D 3 3 6 0 3 1 0 0 4 1 1 2 5 0 3.8 4.3 7.6 0.0 3.8 1.4 0.0 0.0 5.1 1.4 1.3 2.9 6.3 0.0 4.0 1.4 3.1 
E 0 0 0 0 3 2 3 0 2 0 1 1 0 2 0.0 0.0 0.0 0.0 3.8 2.9 3.8 0.0 2.5 0.0 1.3 1.4 0.0 0.0 1.6 1.0 3.1 
F 2 5 5 2 3 2 4 2 9 4 4 0 6 3 2.5 7.1 6.3 2.9 3.8 2.9 5.1 2.9 11.4 5.7 5.1 0.0 7.6 2.9 6.0 3.5 3.1 
G 6 7 3 5 3 4 3 6 4 5 3 1 3 8 7.6 10.0 3.8 7.1 3.8 5.7 3.8 8.6 5.1 7.1 3.8 1.4 3.8 11.4 4.5 7.3 6.3 
H 3 2 2 1 1 4 1 2 3 3 3 2 4 4 3.8 2.9 2.5 1.4 1.3 5.7 1.3 2.9 3.8 4.3 3.8 2.9 5.1 5.7 3.1 3.7 3.1 
I 1 1 1 3 5 5 4 3 5 5 1 1 1 2 1.3 1.4 1.3 4.3 6.3 7.1 5.1 4.3 6.3 7.1 1.3 1.4 1.3 2.9 3.3 4.1 3.1 
K 4 2 3 5 2 1 2 9 2 1 2 2 1 2 5.1 2.9 3.8 7.1 2.5 1.4 2.5 12.9 2.5 1.4 2.5 2.9 1.3 2.9 2.9 4.5 3.1 
L 9 7 6 6 4 5 7 4 10 5 8 10 9 6 11.4 10.0 7.6 8.6 5.1 7.1 8.9 5.7 12.7 7.1 10.1 14.3 11.4 8.6 9.6 8.8 9.4 
M 1 1 1 5 0 0 3 0 3 1 0 3 1 2 1.3 1.4 1.3 7.1 0.0 0.0 3.8 0.0 3.8 1.4 0.0 4.3 1.3 2.9 1.6 2.4 3.1 
N 2 18 3 3 2 1 1 3 3 1 0 4 2 4 2.5 25.7 3.8 4.3 2.5 1.4 1.3 4.2 3.8 1.4 0.0 5.7 2.5 5.7 2.4 6.9 3.1 
P 1 5 4 1 3 3 4 8 3 5 5 4 4 5 1.3 7.1 5.1 1.4 3.8 4.3 5.1 11.4 3.8 7.1 6.3 5.7 5.1 7.3 4.3 6.1 6.3 
Q 1 0 1 5 1 2 4 1 4 2 0 0 1 2 1.3 0.0 1.3 7.1 1.3 2.9 5.1 1.4 5.1 2.9 0.0 0.0 1.3 2.9 2.2 2.4 3.1 
R 5 5 8 7 9 9 7 10 3 6 8 9 4 6 6.3 7.1 10.1 10.0 11.4 12.9 8.9 14.3 3.8 8.6 10.1 12.9 5.1 8.6 8.0 10.6 9.4 
S 7 7 4 13 16 11 4 5 7 11 8 13 4 10 8.9 10.0 5.1 18.6 20.3 15.7 5.1 7.1 8.9 15.7 10.1 18.6 5.1 14.3 9.0 14.3 9.4 
T 3 1 3 1 4 5 8 3 2 2 6 3 1 3 3.8 1.4 3.8 1.4 5.1 7.1 10.1 4.3 2.5 2.9 7.6 4.3 1.3 4.3 4.9 3.7 6.3 
V 11 2 8 5 7 9 5 3 4 10 5 0 9 5 13.9 2.9 10.1 7.1 8.9 12.9 6.3 4.3 5.1 14.3 6.3 0.0 11.4 7.1 8.9 6.9 6.3 
W 4 1 3 1 1 1 2 0 2 2 1 5 1 0 5.1 1.4 3.8 1.4 1.3 1.4 2.5 0.0 2.5 2.9 1.3 7.1 1.3 0.0 2.5 2.0 3.1 
Y 5 1 7 1 3 0 2 2 1 2 0 1 9 3 6.3 1.4 8.9 1.4 3.8 0.0 2.5 2.9 1.3 2.9 0.0 1.4 11.4 4.3 4.9 2.0 3.1 
Stop4 2  1  5  5  2  9  5  2.5  1.3  6.3  6.3  2.5  11.4  6.3  5.2  3.1 
1amino acid (one letter code), 2mean, 3theoretical mean, 4stop codon (amber) 
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Table S2: Codon table for amino acids 
 T C A G  
T 
TTT Phe F TCT Ser S TAT Tyr Y TGT Cys C T 
TTC Phe F TCC Ser S TAC Tyr Y TGC Cys C C 
TTA Leu L TCA Ser S TAA Ochre Stop TGA Opal Stop A 
TTG Leu L TCG Ser S TAG Amber Stop TGG Trp W G 
C 
CTT Leu L CCT Pro P CAT His H CGT Arg R T 
CTC Leu L CCC Pro P CAC His H CGC Arg R C 
CTA Leu L CCA Pro P CAA Gln Q CGA Arg R A 
CTG Leu L CCG Pro P CAG Gln Q CGG Arg R G 
A 
ATT Ile I ACT Thr T AAT Asn N AGT Ser S T 
ATC Ile I ACC Thr T AAC Asn N AGC Ser S C 
ATA Ile I ACA Thr T AAA Lys K AGA Arg R A 
ATG Met M ACG Thr T AAG Lys K AGG Arg R G 
G 
GTT Val V GCT Ala A GAT Asp D GGT Gly G T 
GTC Val V GCC Ala A GAC Asp D GGC Gly G C 
GTA Val V GCA Ala A GAA Glu E GGA Gly G A 
GTG Val V GCG Ala A GAG Glu E GGG Gly G G 
 acidic  polar (uncharged)  non-polar  basic 
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IV. DISCUSSION 
 
 
IV.A Overview 
 
One of the major challenges in gene therapy is posed by the poor efficiency of gene transfer 
vectors. A good vector unifies tissue specificity, efficient transduction of targeted cells and low 
adverse immune effects. Recombinant Adeno-associated virus (AAV) vectors have become 
popular as gene therapy vectors due to their ability to deliver stable and efficient gene expression 
together with a good biological safety profile. Vectors based on AAV serotype 2 (AAV2), the most 
extensively investigated serotype, are to date the most widely used vectors due to their non-
existent pathogenicity, replication deficiency and low rate of integration into the host genome. 
However, a main drawback of AAV vectors is represented by their poor specificity, since a wide 
variety of cells and tissue are equally well transduced. This issue has been addressed by many 
studies that attempted to improve targeting by using alternative AAV serotypes or capsid 
modification. The most recent approaches involved insertion of receptor-targeting ligands or 
selection of capsid libraries and yielded targeting and transduction-optimized AAV vectors. 
Approaches employing directed evolution by error-prone PCR or DNA shuffling by fragmentation 
and re-assembly of AAV cap genes from different serotypes may complement the combinatoric 
peptide display system at exposed capsid sites involved in receptor binding and transduction. Each 
technique has advantages and disadvantages and the application decides which method will be 
preferred to select for targeted vectors. 
 
The potential of random peptide libraries displayed on AAV2 to select for AAV2 vectors with 
improved efficiency for endothelium-directed gene transfer has been demonstrated. However, 
AAV2 serotype vectors may not be ideal as backbones since there is a high prevalence of IgG 
against AAV2 in human serum. In contrast, AAV9 serotype vectors might represent a more suitable 
basis due to a lower susceptibility by neutralizing antibodies and a more efficient gene transfer 
after intravenous vector administration. Thus, the main focus of the present study was (I) to identify 
a suitable insertion site for targeting peptides within the AAV9 capsid surface, (II) to generate a 
random AAV9 peptide display library for selection of an AAV9-based targeting vector on 
endothelial cells, and (III) to compare vectors selected from AAV9 libraries with those from 
previous AAV2 libraries. 
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IV.B The display of foreign peptides on AAV9 capsids 
 
Insertion of foreign peptides on AAV capsids must be approached with caution. Disruption of 
functional capsid domains can impair host recognition, intracellular processing or in the worst case 
capsid assembly. The VP proteins of AAV1-9 share highly conserved regions as well as variable 
regions (VR I-VIII)100, which probably contribute to the different tropism of different AAV serotypes. 
Although the yet unknown AAV9 capsid structure disallows precise mutation design, modification 
of the variable regions, especially VR VIII that is a part of the 3-fold protrusion and harbours A589, 
should similarly to R588 of AAV2 exercise an influence on tropism. As a basis, it was assumed that 
display of foreign peptides behind AAV9 VP1 residue A589, analogously to peptide display behind 
R588 in AAV2, would yield similar targeting possibilities. Comparison of vectors displaying 
endothelium-targeted control peptide NDVRAVS behind R588 of AAV2 or A589 of AAV9 confirmed 
this assumption as the AAV9 mutant was able to transduce wtAAV-refractory HCAEC with 
significant higher efficiency than both wild type AAV2 or AAV9 (Chapter III.B.2.2). 
 
 
IV.C The AAV9 random peptide display library 
 
In order to develop an endothelial targeting vector with a peptide optimally displayed within the 
context of the AAV9 capsid, the evolutionary approach based on selection of a AAV9 random 
peptide display library was used. The AAV9 library was generated according to a multi-step 
procedure which has successfully been applied for generation of AAV2-based201,195 or capsid 
shuffled libraries213 and was characterized according to complexity, amino acid usage, functionality 
of virus particles and wtAAV9 contamination. 
 
 
IV.C.1 The library complexity 
 
The creation of a randomized peptide library demands an exhaustive complexity, i.e. an 
abundance of different peptide sequences matching theoretical expectations, that raises the 
probability of identifying a variant most adapted to the needs. The first attempt to estimate the 
complexity of the NNK-based peptide heptamer library was done after plasmid library synthesis by 
counting of bacterial colonies grown from a transformed aliquot. The quality of information obtained 
from the transformation efficiency is however poor, since calculation of transformation efficiency 
implements several dilution steps and therefore leaves room for statistical deviations. Additionally, 
it was assumed that the counted clones were unique and did not contain sequence repetitions. 
Therefore, the complexity of 6.02E+8 clones represents a maximal value which is further lowered 
by presence of stop codons within the peptide (discussed below) to a functional complexity of 
3.89E+8 clones (Chapter III.C.1.2). Nevertheless, the complexity can be regarded as sufficient 
when compared to theoretical 1.28E+9 and equals previously published AAV2 counterparts 
ranging from 1.2E+7 to 1.7E+8 clones201,213,207,202. 
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Complexity is further reduced due to losses during TSL production and purification as well as by 
intolerance of certain peptide motives that reduce the fitness of library variants. Both transfer 
shuttle libraries (TSL) using AAV2 or AAV9 helper plasmids (2-TSL, 9-TSL) yielded absolute 
infectious titres of 5E+7 IU at the same time representing the maximal complexity (Chapter 
III.C.3.1). Thus, the main limiting factor that defines the final virus library complexity is the 
replicative titre of TSL particles. 
 
 
IV.C.2 Amino acid usage of the library 
 
For a closer characterization, 79 or 70 independently assigned clones from plasmid and final virus 
library were sequenced, respectively. The aim was to reveal deviations from theoretical amino acid 
distribution (biases), since randomness is a central point of the library approach. The appearance 
of more than expected stop codons within the NNK-designed plasmid library (37.9% instead 
theoretical 35.4%, Supplementary Figure 1 A) could be explained by the low amount of sequenced 
clones. Analysis of additional clones would yield a more representative result, but as the functional 
complexity (Chapter III.C.1.2) was higher than the TSL complexity (Chapter III.C.3.1), no 
complications were expected from this point of view. 
 
Deviations of mean amino acid occurrences from theoretical values were judged without 
performing statistical calculations according to Figure III.C.1.3 and Supplementary Table 1. 
Basically, the presence of amino acids was regarded as above (over-represented), below (under-
represented) or similar to theoretical calculations. The plasmid library seemed to over-represent 
amino acids C, F, W and Y, but as no selective pressure acted upon its synthesis, it is difficult to 
estimate the importance of this finding. Increasing the amount of analysed clones probably would 
yield more representative results. In contrast, during the synthesis of the virus library a selective 
pressure potentially acts on the amino acid distribution, shifting their occurrence. Indeed, a 
noticeably decreased (C, D, E, T) or increased (N, S) mean occurrence of amino acids was seen 
within analysed clones from the virus library. A comparison to the plasmid library revealed that 
under-representation in case of E can be explained by a lowered presence in the plasmid library, 
but not in case of N, S and C (see Chapter III.C.3.2). Particularly N and S differences were 
detected in a residue-specific manner at positions 1 (N), 2 and 5-7 (all S). This outcome points 
indeed towards a selective allocation which may be explained by a varying tolerance of the capsid 
for certain amino acids at distinct residues. Similar observations were made for other AAV2 
libraries234,235,236,237, although other amino acids (and another serotype) were involved. Another 
plausible theory for this bias will be discussed in Chapters IV.C.3 and IV.D. Taken together, the 
concept of random peptide display developed for AAV2 by has also proven efficient for AAV9. 
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IV.C.3 The functional characterisation of library particles 
 
Insertion of foreign peptides on AAV capsid may have severe impacts on packaging, intracellular 
trafficking or uncoating of the genetic load. A low virus stability will not only reduce the final yield 
but also the complexity of the library particles. In this study, production of the AAV9 library from two 
different TSL sources was attempted (Chapter III.C.2). The mosaic TSL capsids consist of wild 
type and mutant VP monomers encoded by a wtAAV helper plasmid and several mutant cap genes 
from the plasmid library, respectively. In case of AAV2, a helper plasmid providing wtAAV2 VPs 
was used providing efficient and approximately equal re-infection efficiency to all library variants. 
Since on the one hand wtAAV9 does not transduce HEK293T very well and on the other hand 
efficient transcapsidation of AAV9 and AAV2 was not shown yet, both possibilities were considered 
for the production of the AAV9 TSL. 
 
Comparable genomic titres between 2-TSL and 9-TSL particles (Chapters III.C.2 and III.C.3.1) 
proved an efficient transcapsidation of AAV2 and AAV9. Interestingly, although not expected, the 
replicative titre of both TSLs was the same (5E+7 IU). Obviously, the 9-TSL did not suffer 
disadvantages to the 2-TSL although wtAAV2 infects HEK 293T much more efficient than wtAAV9. 
Due to the equal efficiency of both TSLs, comparable test-productions of final libraries were 
possible yielding absolute titres of 3E+9 gc. The factor that compensated helper VP-related 
differences of TSL particles may have acted during uptake and could be represented by the mutant 
VPs present in the TSL shells. Synergistic effects between mutant and wtAAV VPs are not 
inconceivable and offer an explanation for the bias of some amino acids within distinct residues of 
the library peptides (see also IV.C.2). This and a potentially improved intracellular processing of 
some TSL variants may have lead to a slight pre-selection of the library on HEK 293T. The final 
AAV9 library was produced using 2-TSL and yielded a genomic titre of 4.6E+11 gc translating into 
4.6E+3 gc/cell. This efficiency is comparable to AAV2 or AAV9 vector productions (Chapter III.E.1) 
and proves that insertion of peptides at capsid site A589 does not hamper genome packaging or 
capsid assembly. 
 
 
IV.C.4 Wild type contamination of the library 
 
A major challenge in generation of capsid libraries is given by the need to package the virus library 
genomes into corresponding capsids. A direct transfection of plasmid library into producer cells 
would provide many library plasmids per cell and create mosaic capsids as in the case of Perabo 
et al.194. To avoid this, the present AAV9 library was synthesized in a three-step procedure that 
employs intermediate-step transfer shuttle library (TSL) particles (see also Chapter I.C.3.1). The 
chimerical TSL shells enable an equal re-infection of producer cells via their wtAAV capsid 
domains but do not transfer wild type cap sequences upon re-infection of cells, since wtAAV helper 
plasmids used for TSL synthesis lack ITRs and can not be packaged. Thus, wild type-free final 
virus library particles with genomes corresponding to the capsids can be produced. 
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A library contamination with wild type viruses can only occur if the initial plasmid library contains 
wtAAV-encoding genomes or by a recombination effect between plasmid library and wtAAV helper 
plasmid sequences taking place during TSL production. Waterkamp et al.201, developed a codon-
modified wtAAV2 helper plasmid that impeded recombination events with library plasmids and 
generated a wild type-free library. 
 
The use of this modified wtAAV2 helper plasmid proved also efficient for the AAV9 library 
production but still wtAAV9 contaminations were detectable in library test-productions made from 
2-TSL or 9-TSL. A recursive PCR analysis revealed a wtAAV9 contamination within the plasmid 
library stock that persisted during virus library test-productions (Chapter III.C.2). Notably, the 
contamination of the 9-TSL was slightly higher than that of the 2-TSL. Consequently, the advanced 
contamination of 9-TSL lead to a stronger amplification of contaminating wtAAV9 viruses during 
production of the final virus library. It cannot be ruled out that a recombination event that took place 
between wtAAV9 but not wtAAV2 helper and library plasmid during TSL production creating an 
additional wtAAV9 contamination has added to the already present contamination from the library 
plasmid. 
 
Wild type-contaminations pose a potential drawback and could severely hamper the library 
selection process on cells that are wtAAV permissive. It is well imaginable that in contrast to 
wtAAV, a potentially efficient library clone does not efficiently enrich due to its considerably lower 
copy number. As well, the presence of ITR-positive wild type and library genomes in a cell during 
the first library selection round leads to the formation of chimerical capsids comparable to the TSL. 
While the lowered selection pressure on library clones in context of the TSL application is desired, 
wild type-contaminations led to a delayed selection of specific library variants during subsequent 
selection rounds. These difficulties are negligible in case wtAAV-refractory cells are used for 
selection as done in the case of this study (HCAEC). An in vivo selection of a wild type-
contaminated library however would re-initiate the synthesis of chimerical capsids from tissue that 
can be infected by both, wild type and library viruses. Due to the broad wtAAV9 tropism, 
subsequent application of the library in a new selection round would redirect library genome 
variants encapsidated in chimerical capsids to tissues prone to wtAAV9 infection, resulting in low 
specificity and a mislead readout. Therefore, considering the increased complexity level of an in 
vivo-selection attempt, only wild type-free AAV peptide libraries should be employed to facilitate 
evaluation of potential interesting library clones. 
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IV.D The library selection on HCAEC 
 
The in vitro selection represents a strongly accelerated capsid evolution resulting in variants better 
adapted to the host. The process affects the entire infection pathway of a virus comprising 
receptor-binding, endocytosis, intracellular processing and replication. Consecutive re-application 
of pre-selected libraries will further discriminate between leading mutants, finally establishing the 
most efficient of them. Selection of the AAV9 library on HCAEC led to a strong enrichment of 
distinct peptides after three or four rounds (Chapter III.D-2). Three different MOIs of 10, 100 and 
1000 gc/cell were applied each round to analyse the effect of an increased stringency. The amount 
of different peptides isolated from the MOI 10 approach was lower and more specific in comparison 
to other approaches with higher MOIs, although a comparable number of clones was analysed. 
Still, peptide RGDLRVS represented the most prominent peptide. This outcome would profit from 
analysis of more clones and/or widening the difference between applied MOIs but it still indicates 
that raising the stringency of the selection process by lowering the MOI (and therefore the 
complexity) of the library may lead to propagation of „positive“ mutants (i.e. mutants truly 
enhancing transduction efficiency) at the same time depleting „false positive“ mutants that are 
internalized and processed at low rates and thus only simulate high efficiency. Some of the 
selected peptides shared certain motifs (RGD, S/TL/IRS/APPS/A) and nearly all peptides show biased 
incorporations of certain amino acids. Amino acids P, R and L had a similar presence in both, 
unselected peptide and plasmid library. Their elevated presence within the selected peptides at 
certain residues can be ascribed to the selection process, as their presence conferred to AAV9 a 
selectional advantage. Amino acids N and S were distributed as expected within the plasmid library 
but had an elevated occurrence in the unselected peptide library as well as in selected clones. 
Remarkably, the residues occupied by these amino acids (1st for N, 2nd and 7th for S) were 
comparable to those from unselected peptide libraries (1st for N, 2nd and 5-7th for S) although also 
adjacent residues were affected (4th for S). In fact, their presence may arise from selection of the 
library on HCAEC but could also represent a pre-selection artefact of library production (see also 
IV.C.3). 
 
The tripeptide RGD as a cell binding mediator was initially shown for fibronectin238 with its receptor 
described as a 140kDa cell surface glycoprotein239 that later was named integrin240. Since peptides 
RGDLRVS and RGDFRVG both contain RGD, a retargeting of AAV9 towards integrins receptors is 
imaginable (see also Chapter IV.G).  
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Several enriched peptides contained basic arginine (R) residues at any but the second position 
within the heptamer. Arginine has the highest pKa (12.48, followed by K with 10.53 and H with 6.0) 
and has therefore the highest electrostatic interaction potential. In case of AAV2, capsid binding to 
heparin/HSPG was shown to be driven by electrostatic forces90, and it is imaginable that the 
elevated presence of arginine in peptides selected in this, as well as other AAV2 studies195,207,201,203 
are required for a certain net charge of the binding domain to allow AAV capsid/receptor 
interactions. 
 
An interesting finding was that selected peptides descended from the same DNA clone, 
independent of MOI or selection round. Peptide heptamers based on a NNK architecture can be 
encoded by 32 different oligonucleotide sequences. Most probably, not all of them will be 
represented in the initial construct, the oligonucleotide library. The entire library production process 
comprises many steps and leads to a secondary loss of complexity. Since enriched peptides were 
not detected in the unselected virus library, no obvious restriction of library complexity can be 
stated. Furthermore, the analysis of enriched peptides covers only a tiny part of the range of clones 
and is therefore not necessarily comprehensive. It is probable that analysis of more clones could 
reveal more than one DNA sequence encoding the same enriched peptide. Additionally, a 
preference of certain codon variants encoding a peptide is imaginable and thus a selective force 
would be applied also on the DNA sequence leading to the enrichment of distinct DNA sequences 
for a peptide. 
 
PCR-analysis for wtAAV9 contaminations within the selected library confirmed the assumption that 
wtAAV9-refractory HCAEC would “remove” the contamination (Chapter III.C.4). After selection 
round one, faint wild type DNA-bands were detectable which disappeared after round four. In 
addition, no wild type sequences were found within the 70 analysed virus library clones. This 
outcome is conform with the finding of Waterkamp et al.201 who showed a persistence of wtAAV2 
contaminations during selection of an AAV2 library only from cells that were wtAAV2-permissive. 
 
 
IV.E The efficiency of mutant AAV9 vectors 
 
IV.E.1 Production titres 
 
A trivial way of enhancing transgene expression to detectable (reporter genes) or biologically 
significant (therapeutic genes) levels in vitro or in vivo is posed by increasing the applied AAV 
vector dose. Easy-to-produce dose ranges of 1E+10 to 1E+12 gc used for in vivo-treatment of 
mice or rats yield sufficient levels of transgene expression50,241,242. While such low doses allow 
systemic application, in vivo exposure of larger animals or even humans via this route would 
require doses that exceed economical or technical prospects. More restricted intra-muscular, 
retinal or intracranial vector administrations performed in several human trials allowed lower doses 
ranging from 1E+11 to 6E+13 gc (reviewed by14). 
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The administration of elevated doses involves an efficient production of particles, which in case of 
AAV vector mutants that affect the packaging efficiency may be problematic. The titres obtained 
from novel AAV9 mutant vectors engineered in this study compared very well and in some cases 
even exceeded those of mutant AAV2 vectors (Chapter III.E.1) proving efficient packaging and the 
feasibility of the peptide insertion concept for AAV9. Of note, vectors displaying unselected 
(TEWDQPF) or scrambled (PSLPSRS from SLRSPPS) peptides yielded titres comparable to 
selected counterparts. Although the library selection process supports the notion of a synergistic 
effect of peptides and capsid apart from mere receptor targeting, production efficiencies of vectors 
displaying unselected peptides that parallel those of vectors displaying selected peptides may be 
coincidence. Indeed, another scrambled peptide, SDLRRGV (from RGDLRVS) yielded a vector 
titre one log step lower, supporting the synergistic effect of selection. 
 
 
IV.E.2 In vitro and in situ transduction of AAV9 vectors displaying selected peptides 
 
IV.E.2.1 In vitro transduction 
 
The selection of the AAV9 library on HCAEC yielded peptide SLRSPPS that outperformed 
transduction of HCAEC over wtAAV9 and, more important, AAV9-NDVRAVS at a low dose of 
1E+3 gc/cell (Chapter III.E.2), posing an improvement over the tenfold higher MOI previously 
applied to enable efficient transduction of endothelial cells (ECs)195,201. Such high efficiency with a 
low vector dose could also be advantageous for a future clinical use since a lower vector exposure 
might provoke a reduced immune response243 that complements the ability of this vector to escape 
neutralizing antibodies (Chapter III.H). Improvement of transduction does not arise from the mere 
insertion of a foreign peptide into an infection-relevant capsid site but is peptide sequence specific, 
since unselected control-peptide TEWDQPF abolished HCAEC transduction completely. 
Interestingly, the most abundant selected peptide RGDLRVS yielded a slightly lower transduction 
of HCAEC in contrast the less represented SLRSPPS. This was also observed for NDVRAVS 
selected in the context of an AAV2 library that outperformed most abundant NSSRDLG and 
NSVSSAS195 and can be explained by differential uptake and intracellular processing of the 
vectors. Enrichment of a peptide requires an efficient uptake leading to many genome copies/cell 
while vector transduction depends additionally on efficient downstream processing. SLRSPPS may 
have a more reduced uptake rate than RGDLRVS but its intracellular processing might be more 
efficient, leading to a (slightly) improved transduction of HCAEC. Obviously, there is no correlation 
between abundance of peptides and their efficiency and therefore criteria for the choice of peptides 
for further analyses should be rather their sequence than their abundance.  
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A key finding of this study is the fact that not only the peptide, but also the serotype backbone it is 
embedded in seems to influence the transduction efficiency. Clones derived from AAV2 libraries 
conferred lower efficiencies to AAV9 vectors than AAV9-derived peptides (Chapter III.G). This 
result underlines the need of a selection process in the context of the capsid on which the peptide 
is considered to be expressed and further confirms the assumption that peptide sequences 
selected from an library displayed on one serotype not necessarily work in the context of another 
serotype. Thus, it cannot be generalized from the performance of a peptide sequence from one 
serotype to another, justifying generation of an AAV9 library. 
 
So far, in vitro proof-of-concept for selection of targeted vectors from AAV peptide libraries has 
been shown for AAV2 and AAV9 random peptide libraries. However, the specificity towards the 
targeted cells still remains a matter of concern that must be solved in order to develop attractive 
vectors for gene transfer applications. The specificity of this study's most abundant peptide 
RGDLRVS and most potent peptide SLRSPPS was tested in vitro on primary (HCAEC, HCASMC) 
or immortalized cells (HeLa, 293T, 911, HepG2). At a low MOI of 2.5E+3 gc/cell AAV9-SLRSPPS 
was more specific than RGDLRVS although transduction of cells other than HCAEC was not 
completely abolished (Chapter III.F.1). The targeting of receptors commonly expressed by these 
cell types seems probable, explaining the general difficulty of increasing vector specificity by this 
method alone. The targeted receptor(s) must be likewise involved in uptake and it is less likely that 
each cell type has developed unique receptor sets that control the endocytosis process. Therefore, 
specific EC transgene expression was attempted in several studies by augmenting transductional 
with transcriptional targeting using human and murine endothelium specific promoters. Gory et 
al.233 successfully restricted transgene expression to bovine aortic ECs using the 313 bp fragment 
from murine VE-cadherin promoter. In the present study the combination of most potent vector 
AAV9-SLRSPPS and the 163/313 bp fragments from this promoter improved transcriptional 
targeting only moderately over the previously used CMV promoter (Chapter III.F.2). The CMV 
enhancer element was not removed before insertion of the VE-cadherin promoter and it is 
therefore likely that its influence has affected the EC-specificity. In combination with the efficient 
vector AAV9-SLRSPPS, however, a potent transgene delivery and expression system for in vitro 
studies involving human ECs could be created, since the advantageous size of the 163 bp 
fragment outperforms that of CMV (635 bp) enabling insertion of larger transgenes. 
 
IV.E.2.2 In situ transduction 
 
Efficient in vitro transduction from in vitro-selected vectors is not necessarily transferable to tissue 
that is embedded in its natural context in vivo. To assess the potential of this study's leading vector 
AAV9-SLRSPPS to transduce endothelium present in the context of blood vessels, gene transfer 
efficiency in murine mesenteric arteries and human umbilical veins was analysed. 
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Previously, transduction of H5V, a murine malignant hemangiosarcoma cell line derived from heart 
capillaries, using targeted AAV9 vectors (same vector stocks) was very low, probably due to a 
defective targeted receptor profile or a inefficient intracellular processing of vectors. A 48 h in situ 
or a 14 d in vivo exposure of mesenteric artery endothelium in mice to this vector at sufficiently 
high doses similarly did not lead to transduction (Chapter III.J.1). This surprising result opens 
several scenarios: (I) transduction of murine ECs does not occur due to the vector's specificity to 
ECs of human origin, (II) transduction takes place and missing EGFP-expression is explained by a 
very low intracellular processing rate of vector particles (e.g. due to the non-dividing state of ECs), 
(III) mesenteric endothelium was successfully transduced and missing EGFP fluorescence is due 
to a CMV promoter downregulation and (IV) the mesenteric artery ECs do not express the targeted 
receptor(s) at all. The data obtained so far does not allow a discrimination between these 
scenarios. The onset of transgene expression in mice from AAV mediated gene transfer is 
delayed244 but a 2 week exposure should be sufficient for detectable levels of transgene 
expression by fluorescence microscopy. Similarly, AAV is able to transduce dividing and non-
dividing cells in vitro 245 and in vivo in a variety of tissues246,247,248,249,250,251,252. Targeting the 
vascular endothelium with peptides selected in vitro implicit reliance on target receptor expression 
in vivo. Endothelial cells, however differ strongly in receptor profiles in vitro253 and in 
vivo254,255,256,257. Furthermore, the existence of complex endothelial zip codes in vivo render it 
heterogeneous. Thus, the AAV9-SLRSPPS vector may have been selected for receptors that 
redirect it to a certain type of endothelium which is not of mesenteric artery origin. 
 
Data obtained from successful and efficient in situ transduction of umbilical vein endothelium by 
AAV9-SLRSPPS but not by wtAAV9 (Chapter III.J.2) does not clarify the situation, as well. 
Quantification of genome copies from HUVEC exposed to AAV9-SLRSPPS in situ was performed 
to analyse whether vector uptake would occur during exposure or by contamination carry-overs in 
vitro. A substantial amount of vector genomes was found in HUVEC lysates that were prepared 
immediately after exposure and isolation. However, the experiment does not distinguish between 
endocytosed vectors or vectors that only have bound to receptors but were not internalized. The 
receptor(s) targeted by AAV9-SLRSPPS are unknown and it is unclear whether HUVEC isolation 
via dispase, a bacterial protease that cleaves leucine-phenylalanine bonds and digests fibronectin, 
collagen IV, and to a lesser extent collagen I, would also remove the targeted receptor(s) allowing 
only detection of intracellularly accumulated vector genomes. HUVEC exposed to the vector in 
vitro were collected with trypsin, a serine protease, which in fact removes HSPG258 but may as well 
not be able to remove the targeted receptor, leading to detection of bound but not internalized 
vectors. Therefore, none of the above mentioned scenarios (I)-(IV) can be excluded. Assuming an 
in situ-uptake of vectors and absence of technical limitations, the missing EGFP expression in 
cross-sectioned veins could be ascribed to a low intracellular processing of the vector from 
quiescent cells (scenario (II)). 
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Since intracellular vector processing varies between different vectors the testing of more enriched 
peptides using the umbilical vein model could yield vectors with an improved processing efficiency. 
The employment of EC-specific promoters may represent an alternative option to improve 
transgene expression in quiescent ECs. 
 
 
IV.F Escape from neutralization by pre-existing AAV antibodies 
 
Along with a good transduction efficiency and target specificity, the ability of a vector to evade 
neutralisation by pre-existing host antibodies determines the quality of a gene transfer vector. The 
selection of novel AAV vectors from combinatorial peptide libraries shared besides improvement of 
transduction efficiency another strategy: removal of antigenic epitopes from surface-exposed 
capsid domains. Neutralizing antibodies in general bind to capsid epitopes, thus preventing 
interaction of AAV with cellular surface receptor(s)172. For AAV2, several epitopes have been 
mapped within the loops of the threefold spike, the most prominent domain of the capsid173. 
Huttner et al.174 reported two AAV2 mutants carrying peptide insertions I-534 and I-573 with a 
reduced affinity for AAV antibodies in the majority of the analysed serum samples. These two 
insertions, especially I-573, are located in close proximity to R588, probably pointing to a 
relationship between capsid domains involved in tropism and domains serving as epitopes. This 
relationship is further sustained by the results obtained from the in vitro neutralization attempt in 
this study (Chapter III.H). The attempt analysed the ability of the novel AAV9 vector mutants 
displaying RGDLRVS and SLRSPPS to evade neutralization by IVIG, a pool of human antisera 
applicable for in vitro neutralization studies of AAV213,109 and ADK9, a monoclonal antibody raised 
in mice against wtAAV9 capsids. AAV9 mutants RGDLRVS and SLRSPPS improved in vitro 
escape from IVIG neutralization over wtAAV2, wtAAV9 and AAV2-NDVRAVS, underlining the 
suitability of AAV9 rather than AAV2 as a backbone for targeted peptide display. Still, IVIG dilutions 
below 1:160 completely neutralized transduction of the AAV9 mutants. However, the improved 
evasion (and the lowered MOI required for efficient transduction) lowers the vector dose required 
for gene transfer thereby reducing the dose-dependent immune response to vectors in treated 
subjects243. In contrast to an efficient recognition and neutralization by IVIG, ADK9-neutralization 
occurred only in case of wtAAV9. The epitope of monoclonal ADK9 seems to have been disrupted 
completely by insertion of peptides behind VP1 589, while the epitopes recognized by the pool of 
polyclonal AAV9 capsid antibodies present in IVIG were less affected. This outcome indicates that 
the capsid domain displaying peptides embraces a significant role in targeting and antibody 
recognition supporting the notion that epitope formation is more likely to occur at exposed capsid 
domains with good accessibility to the immune system (i.e. the threefold spikes). 
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IV.G Secondary characterisation of endothelium-targeted peptides 
 
Binding of AAV2 to HSPG receptors depends mainly on a subset of basic arginines (particularly 
R585/R588) that are absent in the corresponding region of AAV9. According to the heparin 
competition results, wtAAV2 vectors efficiently transduced HSPG-positive HepG2 cells in a 
heparin-dependent manner (Chapter III.I.2). Since augmentation of missing arginines can be 
achieved by displaying enriched heptamers like SLRSPPS and especially RGDLRVS, the effect of 
heparin on transduction efficiencies of AAV9 vectors displaying these peptides was analysed. For 
RGDLRVS, relevant (HCAEC) and notable (HepG2) transduction efficiencies were attained, which 
were slightly modulated by heparin. In case of SLRSPPS, only HCAEC was transduced at 
noteworthy levels and presence of heparin did not alter the transduction. Due to the minimal 
(unspecific) inhibitory effect heparin carries on RGDLRVS and the missing effect on SLRSPPS, a 
transduction that has been accidentally redirected to HSPG receptors can be excluded. 
 
The capsid competition experiments suggest that both peptides are capable of competing each 
other but not if the competing peptide is displayed in a scrambled manner (Chapter III.I.1). This 
indicates that (I) the peptides specifically modulate transduction patterns and (II) partly use a 
common transduction pathway. Since both vectors cannot be completely inhibited by each others 
(dose response experiments revealed that the inhibitory effect can be saturated), additional 
alternative receptors/post entry mechanisms might exist which also could explain different 
transduction patterns of cell lines and primary cells (Chapter III.F.1). It is known, that AAV2 utilizes 
co-receptors that enable endocytosis into the cell and that these receptors interact with different 
capsid sites. This could also be the case for AAV9 and the mutants. Both vectors might target the 
same primary receptor which explains the mutual competition, but different secondary receptors 
specifically targeted by each mutant may modulate transduction of different cell types and could 
impede a complete competitor-mediated inhibition of transduction. A vague indication is given by 
the motif RGD that is included in RGDLRVS but not SLRSPPS. The trimer is known to promote 
binding to a multitude of receptors from the integrin family (reviewed by259) and it has been 
demonstrated that integrins play an essential role as cellular entry receptors for AAV219 and 
AAV9125. Perabo et al.194 showed that the expression of RGD at position 587 enables AAV2 to 
efficiently infect cells via an integrin subtype and, importantly, those RGD-expressing vectors 
lacked cellular specificity which the authors ascribed to the wide-ranged expression profile of 
integrins on different tissues. 
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